Carbonate-Containing Lipid Compounds and Compositions for Intracellular Delivery of Therapeutic Agents - Patent application

Abstract

The application relates to empty or filled lipid nanoparticles (LNPs) comprising lipids of general formula (A), in which at least one of two side chains contains a carbonate functional group (M and / or M' is -0C(=0)0-), and such lipids as well as additional lipids, such as phospholipids, structural lipids, and PEG-lipids. Lipid nanoparticles further comprising a therapeutic and / or prophylactic agent, such as RNA, for modulating polypeptide, protein, or gene expression, are useful for delivering the therapeutic and / or prophylactic agent to mammalian cells or organs. [Case 1] JPEG2022549253000132.jpg33170

Description

[Technical field]

[0001] Related Applications This application claims priority to and the benefit of U.S. Provisional Application No. 62 / 902,929, filed September 19, 2019, the entire contents of which are incorporated herein by reference.

[0002] The present disclosure provides novel compounds, compositions comprising such compounds, and methods involving lipid nanoparticle compositions for delivering one or more therapeutic and / or prophylactic agents to mammalian cells or organs and / or producing polypeptides. In addition to the novel lipids, the disclosed lipid nanoparticle compositions may contain, in specific fractions, one or more cationic and / or ionic amino lipids, phospholipids including polyunsaturated lipids, PEG lipids, structured lipids, and / or therapeutic and / or prophylactic agents. [Background technology]

[0003] Effective targeted delivery of biologically active substances such as small molecule drugs, proteins, and nucleic acids represents a continuing medical challenge. In particular, delivery of nucleic acids to cells is made difficult by the relative instability and low cell permeability of such species. Thus, there is a need to develop methods and compositions that facilitate the delivery of therapeutic and / or prophylactic agents such as nucleic acids to cells.

[0004] Lipid-containing nanoparticle compositions, liposomes, and lipoplexes have been proven to be effective as vehicles for transporting biologically active substances, such as small molecule drugs, proteins, and nucleic acids, to cells and / or intracellular compartments. Such compositions generally contain one or more "cationic" and / or amino (ionic) lipids, phospholipids including polyunsaturated lipids, structural lipids (e.g., sterols), and / or lipids containing polyethylene glycol (PEG lipids). Cationic and / or ionic lipids include, for example, amine-containing lipids that can be easily protonated. Although various such lipid-containing nanoparticle compositions have been demonstrated, improvements in safety, efficacy, and specificity are still lacking. Summary of the Invention

[0005] The present disclosure provides novel compounds, compositions, and methods involving the same.

[0006] In some embodiments, the present disclosure provides a compound of formula (A): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein m is selected from 5, 6, 7, 8, and 9; R 2 and R 3 However, each independently, H, C 1-14 Alkyl, and C 2-14 alkenyl, R 4 But -(CH2) n OH, where n is selected from 1, 2, 3, 4, and 5; and [ka] (n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10); R 10 is -N(R)2, and each R is independently C 1-6 Alkyl, C 2-3 alkenyl, and H; M and M' are each independently selected from -OC(O)O- and -C(O)O-; At least one of M and M' is -OC(O)O-; R' a But, C 1-18 Alkyl or C 2-18 alkenyl, R” is a C3-C optionally substituted with OH 13 or an N-oxide thereof, or a salt or isomer thereof, wherein DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007] The present disclosure relates to novel lipids and lipid nanoparticles (e.g., empty or loaded LNPs) comprising the novel lipids. The disclosure also provides methods for delivering therapeutic and / or prophylactic agents to mammalian cells, methods for specifically delivering therapeutic and / or prophylactic agents to mammalian organs, methods for producing a polypeptide of interest in a mammalian cell, methods for improving the level of a protein produced in a mammalian cell compared to LNPs comprising other lipids, and methods for treating a disease or disorder in a mammal in need of such treatment. For example, a method for producing a polypeptide of interest in a cell involves contacting a nanoparticle comprising mRNA with a mammalian cell, whereby the mRNA can be translated to produce a polypeptide of interest. A method for delivering a therapeutic and / or prophylactic agent to a mammalian cell or organ can involve administering a nanoparticle composition comprising the therapeutic and / or prophylactic agent to a subject, whereby the administration involves contacting the cell or organ with the composition, whereby the therapeutic and / or prophylactic agent is delivered to the cell or organ. Such delivery methods can be in vitro or in vivo.

[0008] The present disclosure provides lipids comprising a central amine moiety and at least one biodegradable group. The lipids described herein can be advantageously used in lipid nanoparticle compositions to deliver therapeutic and / or prophylactic agents to mammalian cells or organs. For example, the lipids described herein have little or no immunogenicity. For example, the lipid compounds of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb) have low immunogenicity compared to reference lipids (e.g., MC3, KC2, or DLinDMA). For example, a formulation comprising a lipid disclosed herein and a therapeutic or prophylactic agent has an increased therapeutic index compared to a corresponding formulation comprising a reference lipid (e.g., MC3, KC2, or DLinDMA) and the same therapeutic or prophylactic agent.

[0009] In some embodiments, the disclosure provides a compound of formula (B): [ka] A compound of the formula: R 4 But -(CH2) n OH, where n is selected from 1, 2, 3, 4, and 5; and [ka] (n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10); R 10 is -N(R)2, and each R is independently C 1-6 Alkyl, C 2-3 alkenyl, and H; R aα , R aβ , and R aγ However, each independently, H, C 1-12 Alkyl, and C 2-12 alkenyl; R aα , R aβ , and R aγ At least one of the 1-12 Alkyl and C 2-12 alkenyl, R' is C 1-12 Alkyl or C 2-12 alkenyl.

[0010] In some embodiments, the disclosure provides a compound of formula (A1), (A2), or (A3): [ka] A compound of the formula: m is selected from 5, 6, 7, 8, and 9; R 2 and R 3 However, each independently, H, C 1-14 Alkyl, and C2-14 alkenyl, R 4 But -(CH2) n OH, where n is selected from 1, 2, 3, 4, and 5; and [ka] (n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10); R 10 is -N(R)2, and each R is independently C 1-6 Alkyl, C 2-3 alkenyl, and H; R' a but, [ka] and R aα , R aβ , and R aγ However, each independently, H, C 1-12 Alkyl, and C 2-12 alkenyl; R aα , R aβ , and R aγ At least one of the 1-12 Alkyl and C 2-12 alkenyl, R” is a C3-C optionally substituted with OH 13 is alkyl, R' is C 1-12 Alkyl or C 2-12 alkenyl.

[0011] In some embodiments, the disclosure provides a compound of formula (I): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1 But, C 5-30 Alkyl, C 5-20 alkenyl, -R*YR*", -YR*", and -R"M'R'; R 2 and R 3 However, independently, H, C 1-14 Alkyl, C 2-14 alkenyl, -R*YR*", -YR*", and -R*OR*", or R 2 and R 3 together with the atoms to which they are attached form a heterocyclic or carbocyclic ring, R 4 But -(CH2) n OH, where n is selected from 1, 2, 3, 4, and 5; and [ka] (n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10); R 10 is -N(R)2, and each R is independently C 1-6 Alkyl, C 2-3 alkenyl, and H; Each R 5 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R 6 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; M is -OC(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, SO-, -OS-, -S(R M )2O-, -OS(R M)2-, -S(O)O-, -OS(O)-, M" is a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; M' is -OC(O)O-, -C(O)O-, -OC(O)-, -OC(O)-M”-C(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -C(O)N(R M )-, -N(R M )C(O)-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR M )O-, -S(O)2-, -SS-, -SO-, -OS-, S(R M )2O-, -OS(R M )2-, -S(O)O-, -OS(O)-, an aryl group, and a heteroaryl group; M" is selected from a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; R 7 But, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R is independently C 1-6 Alkyl, C 1-3 Alkyl-aryl, C 2-3 alkenyl, and H; Each R' is independently C 1-18 Alkyl, C 2-18 Alkenyl, -R*YR*", -YR*", (CH2) qOR*, and H; each q is independently selected from 1, 2, and 3; Each R M However, independently, H, C 1-6 Alkyl, and C 2-6 alkenyl, Each R” is independently 3-15 Alkyl and C 3-15 alkenyl, Each R*” is C 1-15 Alkyl, and C 2-15 alkenyl, Each R* is independently 1-12 Alkyl and C 2-12 alkenyl, Each R** is independently H, OH, C 1-12 Alkyl, C 2-12 Alkenyl, (CH2) q OR*, and (CH2) q OH; Each Y is independently C 3-6 is a carbocyclic ring, The compound of formula (I) or an N-oxide thereof, or a salt or isomer thereof, wherein m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0012] In some embodiments, the disclosure provides a compound of formula (I'): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1 But, C 5-30 Alkyl, C 5-20 alkenyl, -R*YR*", -YR*", and -R"M'R'; R 2 and R 3 However, independently, H, C 1-14 Alkyl, C 2-14alkenyl, -R*YR*", -YR*", and -R*OR*", or R 2 and R 3 together with the atoms to which they are attached form a heterocyclic or carbocyclic ring, R 4 But -(CH2) n OH, where n is selected from 1, 2, 3, 4, and 5; and [ka] (n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10); R 10 is -N(R)2, and each R is independently C 1-6 Alkyl, C 2-3 alkenyl, and H; Each R 5 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R 6 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; M is -OC(O)O-, -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -C(O)N(R M )-, -N(R M )C(O)-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR M )O-, -S(O)2-, -SS-, -SO-, -OS-, S(R M )2O-, -OS(R M)2-, -S(O)O-, -OS(O)-, an aryl group, and a heteroaryl group; M" is selected from a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; M' is -OC(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, SO-, -OS-, -S(R M )2O-, -OS(R M )2-, -S(O)O-, -OS(O)-, M" is a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; R 7 But, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R' is independently C 1-18 Alkyl, C 2-18 Alkenyl, -R*YR*", -YR*", (CH2) q OR*, and H; each q is independently selected from 1, 2, and 3; Each R M However, independently, H, C 1-6 Alkyl, and C 2-6 alkenyl, Each R” is independently 3-15 Alkyl and C 3-15 alkenyl, Each R*” is C 1-15 Alkyl, and C2-15 alkenyl, Each R* is independently 1-12 Alkyl and C 2-12 alkenyl, Each R** is independently H, OH, C 1-12 Alkyl, C 2-12 Alkenyl, (CH2) q OR*, and (CH2) q OH; Each Y is independently 3-6 is a carbocyclic ring, The compound of formula (I') or an N-oxide thereof, or a salt or isomer thereof, wherein m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0013] In some embodiments, the disclosure provides a compound of formula (IX): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1 But, C 5-30 Alkyl, C 5-20 alkenyl, -R*YR*", -YR*", and -R"M'R'; R 2 and R 3 However, independently, H, C 1-14 Alkyl, C 2-14 alkenyl, -R*YR*", -YR*", and -R*OR*", or R 2 and R 3 together with the atoms to which they are attached form a heterocyclic or carbocyclic ring, R 4 But -(CH2) n OH, where n is selected from 1, 2, 3, 4, and 5; and [ka] (n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10); R 10 is -N(R)2, and each R is independently C 1-6 Alkyl, C 2-3 alkenyl, and H; Each R 5 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R 6 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; M' is -OC(O)O-, -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -C(O)N(R M )-, -N(R M )C(O)-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR M )O-, -S(O)2-, -SS-, -SO-, -OS-, S(R M )2O-, -OS(R M )2-, -S(O)O-, -OS(O)-, an aryl group, and a heteroaryl group; M" is selected from a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; Each R' is independently C 1-18 Alkyl, C 2-18 Alkenyl, -R*YR*", -YR*", (CH2) q OR*, and H; each q is independently selected from 1, 2, and 3; Each R M However, independently, H, C 1-6 Alkyl, and C 2-6 alkenyl, Each R” is independently 3-15 Alkyl and C 3-15 alkenyl, Each R*” is C 1-15 Alkyl, and C 2-15 alkenyl, Each R* is independently 1-12 Alkyl and C 2-12 alkenyl, Each R** is independently H, OH, C 1-12 Alkyl, C 2-12 Alkenyl, (CH2) q OR*, and (CH2) q OH; Each Y is independently C 3-6 is a carbocyclic ring, The compound of formula (IX), or an N-oxide thereof, or a salt or isomer thereof, wherein m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0014] In certain embodiments, a subset of compounds of formula (I) or (I') includes compounds of formula (IA): [ka] Things, or an N-oxide thereof, or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; and R 2 and R 3 However, independently, H, C 1-14 Alkyl, and C 2-14 alkenyl.

[0015] In certain embodiments, a subset of compounds of formula (I) or (I') includes compounds of formula (II): [ka] Things, or an N-oxide thereof, or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; R 2 and R 3 However, independently, H, C 1-14 Alkyl, and C 2-14 alkenyl.

[0016] In another embodiment, a subset of compounds of formula (II) includes compounds of formula (IIa): [ka] Things, or an N-oxide thereof, or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; M1 is M', Each R 2 and R 3 However, independently, H, C 1-14 Alkyl, and C 2-14 alkenyl.

[0017] In another embodiment, a subset of compounds of formula (II) includes compounds of formula (IIb): [ka] Things, or an N-oxide thereof, or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; M1 is M', Each R 2 and R 3 However, independently, H, C 1-14 Alkyl, and C2-14 alkenyl.

[0018] In another embodiment, a subset of compounds of formula (I) or (I') includes compounds of formula (Ia): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R″ is a linear or branched C3-C 13 alkyl, and m is selected from 5, 6, 7, 8, and 9.

[0019] In another embodiment, a subset of compounds of formula (I) or (I') includes compounds of formula (Ib): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R″ is a linear or branched C3-C 13 alkyl, and m is selected from 5, 6, 7, 8, and 9.

[0020] In another embodiment, a subset of compounds of formula (I) or (I') includes compounds of formula (Ic): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R″ is a linear or branched C3-C 13 alkyl, and m is selected from 5, 6, 7, 8, and 9.

[0021] In another embodiment, a subset of compounds of formula (I) or (I') includes compounds of formula (Id): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R″ is a linear or branched C3-C 13 alkyl, and m is selected from 5, 6, 7, 8, and 9.

[0022] In another embodiment, a subset of compounds of formula (I) or (I') includes compounds of formula (Ie): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R″ is a linear or branched C3-C 13 alkyl, and m is selected from 5, 6, 7, 8, and 9.

[0023] In another embodiment, a subset of compounds of formula (I) or (I') includes compounds of formula (If): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R″ is a linear or branched C3-C 13 alkyl, and m is selected from 5, 6, 7, 8, and 9.

[0024] In another embodiment, a subset of compounds of formula (I) or (I') includes compounds of formula (Ig): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R″ is a linear or branched C3-C 13 alkyl, and m is selected from 5, 6, 7, 8, and 9.

[0025] In some embodiments, the disclosure provides a compound of formula (IY): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1 But, C 5-30 Alkyl, C 5-20 alkenyl, -R*YR*", -YR*", and -R"M'R'; R 2 and R 3 However, independently, H, C 1-14 Alkyl, C 2-14 alkenyl, -R*YR*", -YR*", and -R*OR*", or R 2 and R 3 together with the atoms to which they are attached form a heterocyclic or carbocyclic ring, R 4 But -(CH2) n OH, where n is selected from 1, 2, 3, 4, and 5; and [ka] (n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10); R 10 is -N(R)2, and each R is independently C 1-6 Alkyl, C 2-3 alkenyl, and H; Each R 5 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R 6 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; M' is -OC(O)O-, -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -C(O)N(R M)-, -N(R M )C(O)-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR M )O-, -S(O)2-, -SS-, -SO-, -OS-, S(R M )2O-, -OS(R M )2-, -S(O)O-, -OS(O)-, an aryl group, and a heteroaryl group; M" is selected from a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; Each R' is independently C 1-18 Alkyl, C 2-18 Alkenyl, -R*YR*", -YR*", (CH2) q OR*, and H; each q is independently selected from 1, 2, and 3; Each R M However, independently, H, C 1-6 Alkyl, and C 2-6 alkenyl, Each R” is independently 3-15 Alkyl and C 3-15 alkenyl, Each R*” is C 1-15 Alkyl, and C 2-15 alkenyl, Each R* is independently 1-12 Alkyl and C 2-12 alkenyl, Each R** is independently H, OH, C 1-12 Alkyl, C 2-12 Alkenyl, (CH2) q OR*, and (CH2)q OH; Each Y is independently 3-6 is a carbocyclic ring, The compound of formula (IY), or an N-oxide thereof, or a salt or isomer thereof, wherein m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0026] In some embodiments, a subset of compounds of formula (IY) includes compounds of formula (I-Ya): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein each R" is independently H, OH, and C 1-6 alkyl; l is selected from 2, 3, 4, 5, and 6; and m is selected from 5, 6, 7, 8, and 9.

[0027] A compound of any one of formulas (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), if applicable, comprises one or more of the following features:

[0028] In some embodiments, R' a teeth, [ka] and [ka] indicates the attachment point, R aα , R aβ , and R aγ However, each independently, H, C 1-12 Alkyl, and C 2-12 alkenyl; Raα , R aβ , and R aγ At least one of the 1-12 Alkyl and C 2-12 alkenyl, R' is C 1-12 Alkyl or C 2-12 It is alkenyl.

[0029] In some embodiments, M and M' are each -OC(O)O-. In some embodiments, M is -C(O)O- and M' is -OC(O)O-. In some embodiments, M is -OC(O)O- and M' is -C(O)O-.

[0030] In some embodiments, l is 1, 3, or 5. In some embodiments, l is 1, 3, or 4. In some embodiments, l is 5.

[0031] In some embodiments, R 4 teeth, [ka] It is.

[0032] In some embodiments, R 4 is -(CH2)2OH.

[0033] In some embodiments, R 2 and R 3 is independently 3-14 Alkyl or C 3-14 It is alkenyl.

[0034] In some embodiments, R' a is C4 alkyl, C4 alkenyl, C5 alkyl, C5 alkenyl, C6 alkyl, C6 alkenyl, C7 alkyl, C7 alkenyl, C9 alkyl, C9 alkenyl, C 11 Alkyl, C 11 Alkenyl, C 17Alkyl, C 17 Alkenyl, C 18 Alkyl, and C 18 alkenyl, each of which is either linear or branched.

[0035] In some embodiments, R' is a C4 alkyl or C4 alkenyl. In some embodiments, R' is a C5 alkyl or C5 alkenyl. In some embodiments, R' is a C6 alkyl or C6 alkenyl. In some embodiments, R' is a C7 alkyl or C7 alkenyl. In some embodiments, R' is a C8 alkyl or C8 alkenyl. In some embodiments, R' is a C9 alkyl or C9 alkenyl. In some embodiments, R' is a C 10 Alkyl or C 10 In some embodiments, R' is C 11 Alkyl or C 11 It is alkenyl.

[0036] In certain embodiments, R' a is a branched C 1-18 For example, R' is an alkyl group. a teeth, [ka] It is.

[0037] In some embodiments, R″ is C 3-15 Alkyl and C 3-15 In some embodiments, R″ is selected from the group consisting of C alkyl, C alkyl, C alkyl, C alkyl, C alkyl, or C alkyl. In some embodiments, R″ is selected from the group consisting of C alkyl, C alkyl, C alkyl, C alkyl, C alkyl, or C alkyl. In some embodiments, R″ is selected from the group consisting of C alkyl, C alkyl, C alkyl, C alkyl, or C alkyl. 10 Alkyl, C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, or C 15 It is an alkyl.

[0038] In some embodiments, R 2 and R 3 is independently 5-14 Alkyl or C 5-14 It is alkenyl.

[0039] In some embodiments, R 2 and R 3 are the same. In some embodiments, R 2 and R 3 is C alkyl. In certain embodiments, R 2 and R 3 is C alkyl. In other embodiments, R 2 and R 3 is C alkyl. In some embodiments, R 2 and R 3 is C4 alkyl. In certain embodiments, R 2 and R 3 is C alkyl. In other embodiments, R 2 and R 3 is C alkyl. In some embodiments, R 2 and R 3 is a C7 alkyl.

[0040] In other embodiments, R 2 and R 3 are different. In certain embodiments, R 2 is C alkyl. In some embodiments, R 3 is C 1-7 (e.g., C1, C2, C3, C4, C5, C6, or C7 alkyl) or C9 alkyl.

[0041] In some embodiments, R 3 is C alkyl. In some embodiments, R 3 is C alkyl. In some embodiments, R 3 is C alkyl. In some embodiments, R 3 is C4 alkyl. In some embodiments, R3 is C alkyl. In some embodiments, R 3 is C alkyl. In some embodiments, R 3 is C alkyl. In some embodiments, R 3 is a C9 alkyl.

[0042] In some embodiments, m is 5, 6, 7, 8, or 9. In some embodiments, m is 5, 7, or 9. For example, in some embodiments, m is 5. For example, in some embodiments, m is 7. For example, in some embodiments, m is 9.

[0043] In some embodiments, n is 2, 3, or 4. In some embodiments, n is 2. In some embodiments, n is 4. In some embodiments, n is not 3.

[0044] In some embodiments, n2 is 2, 3, or 4. In some embodiments, n2 is 2. In some embodiments, n2 is 4. In some embodiments, n2 is not 3.

[0045] In some embodiments, the compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb) is selected from Table 1. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4]

[0046] The central amine moiety of lipids according to formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb) can be protonated at physiological pH. Thus, the lipids can have a positive or partial positive charge at physiological pH. Such lipids may be referred to as cationic or ionic (amino) lipids. The lipids may also be zwitterionic, i.e., neutral molecules that have both positive and negative charges.

[0047] definition As used herein, the term "alkyl" or "alkyl group" refers to a linear or branched saturated hydrocarbon containing one or more carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more carbon atoms), which is optionally substituted. 1-14 The term "alkyl" means an optionally substituted linear or branched saturated hydrocarbon containing 1 to 14 carbon atoms. Unless otherwise specified, alkyl groups as described herein refer to both unsubstituted and substituted alkyl groups.

[0048] As used herein, the term "alkenyl" or "alkenyl group" means a linear or branched hydrocarbon containing two or more carbon atoms (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more carbon atoms) and at least one optionally substituted double bond. 2-14 The term "alkenyl" refers to an optionally substituted linear or branched hydrocarbon containing 2 to 14 carbon atoms and at least one carbon-carbon double bond. Alkenyl groups can contain 1, 2, 3, 4, or more carbon-carbon double bonds. For example, C 18Alkenyl may contain one or more double bonds. 18 The alkenyl group can be a linoleyl group.Unless otherwise specified, the alkenyl groups described herein refer to both unsubstituted and substituted alkenyl groups.

[0049] As used herein, the term "alkynyl" or "alkynyl group" means a linear or branched hydrocarbon containing two or more carbon atoms (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more carbon atoms) and at least one optionally substituted carbon-carbon triple bond. 2-14 The term "alkynyl" refers to an optionally substituted linear or branched hydrocarbon containing 2 to 14 carbon atoms and at least one carbon-carbon triple bond. An alkynyl group may contain 1, 2, 3, 4, or more carbon-carbon triple bonds. For example, C 18 Alkynyl can include one or more carbon-carbon triple bonds.Unless otherwise specified, alkynyl groups described herein refer to both unsubstituted and substituted alkynyl groups.

[0050] As used herein, the term "carbocycle" or "carbocyclic group" means an optionally substituted monocyclic or polycyclic system containing one or more rings of carbon atoms. The rings can be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20-membered rings. 3-6The term "carbocycle" refers to a carbocycle containing a single ring having 3 to 6 carbon atoms. A carbocycle may contain one or more carbon-carbon double or triple bonds and may be non-aromatic or aromatic (e.g., a cycloalkyl or aryl group). Examples of carbocycles include cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and 1,2-dihydronaphthyl groups. The term "cycloalkyl" as used herein refers to a non-aromatic carbocycle, which may or may not contain double or triple bonds. Unless otherwise specified, carbocycles as described herein refer to both unsubstituted carbocyclic groups and substituted carbocyclic groups, i.e., optionally substituted carbocycles. In some embodiments, a carbocycle is a C 3-8 In some embodiments, the carbocycle is C 3-6 In some embodiments, the carbocycle is C 6-10 It is aryl.

[0051] "Aryl" includes groups having aromatic character, including "conjugated" or polycyclic systems having at least one aromatic ring and containing no heteroatoms in the ring structure. Examples include phenyl, benzyl, 1,2,3,4-tetrahydronaphthalenyl, and the like. In some embodiments, "aryl" includes C 6-10 A carbocyclic ring (e.g., "aryl" is C 6-10 (aryl).

[0052] As used herein, the term "heterocycle" or "heterocyclic group" refers to an optionally substituted monocyclic or polycyclic system containing one or more rings, with at least one ring containing at least one heteroatom. The heteroatom can be, for example, a nitrogen, oxygen, or sulfur atom. The ring can be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14-membered. The heterocycle can contain one or more double or triple bonds and can be non-aromatic or aromatic (e.g., a heterocycloalkyl or heteroaryl group). Examples of heterocycles include imidazolyl, imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl, pyrazolidinyl, pyrazolyl, isoxazolidinyl, isoxazolyl, isothiazolidinyl, isothiazolyl, morpholinyl, pyrrolyl, pyrrolidinyl, furyl, tetrahydrofuryl, thiophenyl, pyridinyl, piperidinyl, quinolyl, and isoquinolyl groups. As used herein, the term "heterocycloalkyl" refers to a non-aromatic heterocycle, which may or may not contain double or triple bonds. Unless otherwise specified, heterocycles described herein refer to both unsubstituted and substituted heterocyclic groups, i.e., optionally substituted heterocycles. In some embodiments, the heterocycle is a 4-12 membered heterocycloalkyl. In some embodiments, the heterocycle is a 5- or 6-membered heteroaryl.

[0053] A "heteroaryl" group is an aryl group as defined above, except that it has one to four heteroatoms in the ring structure, and may also be referred to as an "aryl heterocycle" or "heteroaromatic". As used herein, the term "heteroaryl" is intended to include a stable 5-, 6-, or 7-membered monocyclic, or 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic aromatic heterocyclic ring consisting of carbon atoms and one or more heteroatoms, e.g., 1, or 1-2, or 1-3, or 1-4, or 1-5, or 1-6 heteroatoms, or 1, 2, 3, 4, 5, or 6 heteroatoms, independently selected from the group consisting of nitrogen, oxygen, sulfur, and boron. The nitrogen atom may be substituted or unsubstituted (i.e., N, or NR, where R is H or other substituent as defined). The nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., N→O and S(O)). p where p=1 or 2. Note that the total number of S and O atoms in the aromatic heterocycle is not more than 1.

[0054] Examples of heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.

[0055] Additionally, the terms "aryl" and "heteroaryl" include polycyclic aryl and heteroaryl groups, e.g., tricyclic, bicyclic, such as naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzimidazole, benzothiophene, quinoline, isoquinoline, naphtholidine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.

[0056] As used herein, a "biodegradable group" is a group that can promote faster metabolism of lipids in a mammalian entity. The biodegradable group may be selected from the group consisting of, but is not limited to, -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)2-, an aryl group, and a heteroaryl group. As used herein, an "aryl group" is an optionally substituted carbocyclic group containing one or more aromatic rings. Examples of aryl groups include phenyl and naphthyl groups. As used herein, a "heteroaryl group" is an optionally substituted heterocyclic group containing one or more aromatic rings. Examples of heteroaryl groups include pyrrolyl, furyl, thiophenyl, imidazolyl, oxazolyl, and thiazolyl. Both aryl and heteroaryl groups can be optionally substituted. For example, M and M' can be selected from the non-limiting group consisting of optionally substituted phenyl, oxazole, and thiazole. In the formulas herein, M and M' can be independently selected from the list of biodegradable groups above. Unless otherwise specified, the aryl or heteroaryl groups described herein refer to both unsubstituted and substituted, i.e., optionally substituted, aryl or heteroaryl groups.

[0057] Alkyl, alkenyl, and cyclyl (eg, carbocyclyl and heterocyclyl) groups may be optionally substituted, unless otherwise specified. The optional substituents include, but are not limited to, halogen atoms (e.g., chloride, bromide, fluoride, or iodide groups), carboxylic acids (e.g., -C(O)OH), alcohols (e.g., hydroxyl, -OH), esters (e.g., -C(O)OR or -OC(O)R), aldehydes (e.g., -C(O)H), carbonyls (e.g., -C(O)R, alternatively represented by C=O), acyl halides (e.g., -C(O)X where X is a halide selected from bromide, fluoride, chloride, and iodide), carbonates (e.g., -OC(O)OR), alkoxy (e.g., -OR), acetals (e.g., -C(OR)R"") where each OR is an alkoxy group which may be the same or different and R"" is an alkyl or alkenyl group), phosphates (e.g., P(O)4 3- ), thiol (e.g., SH), sulfoxide (e.g., -S(O)R), sulfinic acid (e.g., -S(O)OH), sulfonic acid (e.g., -S(O)2OH), thial (e.g., -C(S)H), sulfate (e.g., S(O)4 2- ), sulfonyl (e.g., -S(O)2-), amide (e.g., -C(O)NR2, or In some embodiments, the aryl group may be selected from the group consisting of -N(R)C(O)R), azido (e.g., -N), nitro (e.g., -NO), cyano (e.g., -CN), isocyano (e.g., -NC), acyloxy (e.g., -OC(O)R), amino (e.g., -NR, -NRH, or -NH), carbamoyl (e.g., -OC(O)NR, -OC(O)NRH, or -OC(O)NH), sulfonamide (e.g., -S(O)NR, -S(O)NRH, -S(O)NH, -N(R)S(O)R, -N(H)S(O)R, -N(R)S(O)H, or -N(H)S(O)H), alkyl, alkenyl, and cyclyl (e.g., carbocyclyl or heterocyclyl) groups. In any of the foregoing, R is an alkyl or alkenyl group as defined herein. In some embodiments, the substituent itself may be further substituted, for example, with 1, 2, 3, 4, 5, or 6 substituents as defined herein. For example, C 1-6 Alkyl groups can be further substituted with 1, 2, 3, 4, 5, or 6 substituents described herein.

[0058] The disclosed compounds containing nitrogen can be converted to N-oxides by treatment with an oxidizing agent (e.g., 3-chloroperoxybenzoic acid (mCPBA) and / or hydrogen peroxide) to provide other disclosed compounds. Thus, all of the nitrogen-containing compounds shown and claimed can be converted to the N-oxide derivatives (N→O or N→O) of the shown compounds and their N-oxide derivatives, when permitted by valency and structure. + -O -(which may be designated as N-hydroxy or N-alkoxy). Additionally, in other cases, the nitrogen in the disclosed compounds may be converted to N-hydroxy or N-alkoxy compounds. For example, N-hydroxy compounds may be prepared by oxidation of the parent amine with an oxidizing agent such as m-CPBA. All nitrogen-containing compounds shown and claimed are also considered to encompass both the shown compound and its N-hydroxy (i.e., N-OH) and N-alkoxy (i.e., N-OR, where R is a substituted or unsubstituted C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, 3- to 14-membered carbocyclic, or 3- to 14-membered heterocyclic) derivatives, where permitted by valence and structure.

[0059] About, Approximately: As used herein, the terms "about" and "approximately" when applied to one or more values ​​of interest refer to a value similar to a stated reference value. In certain embodiments, the term "about" or "approximately" refers to a range of values ​​that falls within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction of the stated reference value (greater than or less than) unless otherwise stated or clear from the context (except where such numerical value exceeds 100% of possible values). For example, when used in the context of the amount of a given compound in the lipid component of a nanoparticle composition, "about" can mean + / - 10% of the recited value. For example, a nanoparticle composition that includes a lipid component having about 40% of a given compound may contain 30-50% of the compound.

[0060] As used herein, the term "compound" is meant to include all isomers and isotopes of the structure shown. "Isotopes" refer to atoms with the same atomic number but different mass numbers resulting from different numbers of neutrons in the nucleus. For example, isotopes of hydrogen include tritium and deuterium. Furthermore, the compounds, salts, or complexes of the present disclosure can be prepared in combination with solvents or water molecules by conventional methods to form solvates and hydrates.

[0061] As used herein, the term "contacting" refers to establishing a physical connection between two or more entities. For example, contacting a mammalian cell with a nanoparticle composition means that the mammalian cell and the nanoparticle are made to share a physical connection. Methods for contacting cells with external entities, both in vivo and ex vivo, are well known in the biological arts. For example, contacting a mammalian cell placed within a mammal with a nanoparticle composition can be performed by various routes of administration (e.g., intravenous, intramuscular, intradermal, and subcutaneous) and can involve various amounts of lipid nanoparticles (e.g., empty or loaded LNPs). Furthermore, two or more mammalian cells may be contacted with the nanoparticle composition.

[0062] As used herein, the term "delivering" means providing an entity to a destination. For example, delivering a therapeutic and / or prophylactic agent to a subject can involve administering to the subject (e.g., by intravenous, intramuscular, intradermal, or subcutaneous routes) a nanoparticle composition comprising the therapeutic and / or prophylactic agent. Administering a nanoparticle composition to a mammal or cells of a mammal can involve contacting one or more cells with the nanoparticle composition.

[0063] As used herein, the term "enhanced delivery" refers to greater (e.g., at least 1.5-fold greater, at least 2-fold greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater) delivery of a therapeutic and / or prophylactic agent by a nanoparticle to a target cell of interest (e.g., mammalian liver) compared to the level of delivery of a therapeutic and / or prophylactic agent by a control nanoparticle to a target cell of interest (e.g., MC3, KC2, or DLinDMA). The level of nanoparticle delivery to a particular tissue may be measured by comparing the amount of protein produced in the tissue to the weight of the tissue, comparing the amount of therapeutic and / or prophylactic agent in the tissue to the weight of the tissue, comparing the amount of protein produced in the tissue to the total amount of protein in the tissue, or comparing the amount of therapeutic and / or prophylactic agent in the tissue to the total amount of therapeutic and / or prophylactic agent in the tissue. It will be understood that the enhanced delivery of nanoparticles to target cells need not be determined in the subject being treated, but may be determined in a surrogate animal model (e.g., rat model), etc. In certain embodiments, nanoparticle compositions comprising a compound according to formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb) have substantially the same level of enhanced delivery, regardless of the route of administration. For example, certain compounds disclosed herein exhibit similar enhanced delivery when used to deliver therapeutic and / or prophylactic agents either intravenously or intramuscularly. In other embodiments, certain compounds disclosed herein exhibit higher levels of enhanced delivery when used to deliver therapeutic and / or prophylactic agents intramuscularly rather than intravenously.

[0064] As used herein, the terms "specific delivery," "specifically deliver," or "specifically delivering" refer to greater (e.g., at least 1.5-fold greater, at least 2-fold greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater) delivery of a therapeutic and / or prophylactic agent by a nanoparticle to a target tissue of interest (e.g., the liver of a mammal) compared to non-targeted cells (e.g., the spleen of a mammal). The level of nanoparticle delivery to a particular tissue may be measured by comparing the amount of protein produced in the tissue to the weight of the tissue, comparing the amount of therapeutic and / or prophylactic agent in the tissue to the weight of the tissue, comparing the amount of protein produced in the tissue to the total amount of protein in the tissue, or comparing the amount of therapeutic and / or prophylactic agent in the tissue to the total amount of therapeutic and / or prophylactic agent in the tissue. For example, renal vascular targeting provides a therapeutic and / or prophylactic agent specifically to the kidney of a mammal compared to the liver and spleen when 1.5, 2, 3, 5, 10, 15, or 20 times more therapeutic and / or prophylactic agent is delivered to the kidney per gram of tissue compared to that delivered to the liver or spleen following systemic administration of the therapeutic and / or prophylactic agent. It will be appreciated that the ability of nanoparticles to be specifically delivered to a target tissue need not be determined in the subject being treated, but may be determined in a surrogate such as an animal model (e.g., a rat model).

[0065] As used herein, "encapsulation efficiency" refers to the amount of therapeutic and / or prophylactic agent that becomes part of the nanoparticle composition relative to the initial total amount of therapeutic and / or prophylactic agent used to prepare the nanoparticle composition. For example, if 97 mg of therapeutic and / or prophylactic agent are encapsulated in the nanoparticle composition out of a total of 100 mg of therapeutic and / or prophylactic agent initially provided in the composition, the encapsulation efficiency may be 97%. As used herein, "encapsulation" may refer to complete, substantial, or partial sealing, confinement, surrounding, or encasement.

[0066] As used herein, "encapsulation," "enclosed," "loaded," and "associated" may refer to complete, substantial, or partial enclosure, confinement, surrounding, or encasement. As used herein, "encapsulation" or "association" may refer to the process of enclosing an individual nucleic acid molecule within a nanoparticle and / or the process of establishing a physiochemical relationship between an individual nucleic acid molecule and a nanoparticle. As used herein, "empty nanoparticle" may refer to a nanoparticle that is substantially free of a therapeutic or prophylactic agent. As used herein, "empty nanoparticle" or "empty lipid nanoparticle" may refer to a nanoparticle that is substantially free of a nucleic acid. As used herein, "empty nanoparticle" or "empty lipid nanoparticle" may refer to a nanoparticle that is substantially free of a nucleotide or polypeptide. As used herein, "empty nanoparticle" or "empty lipid nanoparticle" may refer to a nanoparticle that is substantially composed of only lipid components. As used herein, "loaded nanoparticle" or "loaded lipid nanoparticle" (also referred to as "complete nanoparticle" or "complete lipid nanoparticle") may refer to a nanoparticle that includes the components of an empty nanoparticle and a therapeutic or prophylactic agent. As used herein, "loaded nanoparticles" or "loaded lipid nanoparticles" (also referred to as "full nanoparticles" or "full lipid nanoparticles") may refer to nanoparticles that contain the components of an empty nanoparticle and a nucleotide or polypeptide. As used herein, "loaded nanoparticles" or "loaded lipid nanoparticles" (also referred to as "full nanoparticles" or "full lipid nanoparticles") may refer to nanoparticles that contain the components of an empty nanoparticle and a nucleic acid.

[0067] As used herein, "expression" of a nucleic acid sequence refers to translation of mRNA into a polypeptide or protein and / or post-translational modification of a polypeptide or protein.

[0068] As used herein, the term "in vitro" refers to events that take place not in a living organism (e.g., an animal, plant, or microorganism) but in an artificial environment, e.g., in a test tube or reaction vessel, in a cell culture, in a Petri dish, etc.

[0069] As used herein, the term "in vivo" refers to events that take place within an organism (e.g., an animal, plant, or microorganism, or cells or tissues thereof).

[0070] As used herein, the term "ex vivo" refers to an event that occurs outside of an organism (e.g., an animal, plant, or microorganism, or cells or tissues thereof). Ex vivo events can occur in an environment that is minimally altered from the natural (e.g., in vivo) environment.

[0071] As used herein, the term "isomer" refers to any geometric isomer, tautomer, zwitterion, stereoisomer, enantiomer, or diastereomer of a compound. A compound may contain one or more chiral centers and / or double bonds and therefore may exist as stereoisomers, such as double bond isomers (i.e., geometric E / Z isomers), or diastereomers (e.g., enantiomers (i.e., (+) or (-)), or cis / trans isomers). The present disclosure encompasses any and all isomers of the compounds described herein, including stereoisomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure), as well as mixtures of enantiomers and mixtures of stereoisomers, e.g., racemates. Mixtures of enantiomers and mixtures of stereoisomers of compounds, as well as means for resolving them into their enantiomeric or stereoisomeric components, are well known.

[0072] A "tautomer" is one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by the switching of adjacent conjugated double bonds. Tautomers exist as mixtures of tautomeric pairs in solution. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that are interconvertible by tautomerization is called tautomerism.

[0073] Of the various types of tautomerism possible, two are commonly observed: keto-enol tautomerism, in which a simultaneous shift of an electron and a hydrogen atom occurs; ring-chain tautomerism occurs as a result of an aldehyde group (-CHO) of a sugar molecule reacting with one of the hydroxyl groups (-OH) of the same molecule, resulting in the cyclic (ring-shaped) form assumed by glucose.

[0074] Common tautomeric pairs are ketone-enol, amide-nitrile, lactam-lactim, amide-imidic acid tautomers, imine-enamine, and enamine-enamine in heterocyclic rings (e.g., in nucleobases such as guanine, thymine, and cytosine). An example of tautomerism in a disubstituted guanidine is shown below. [ka]

[0075] It is understood that the disclosed compounds may be represented as different tautomeric forms, and it should be understood that where a compound has tautomeric forms, all tautomeric forms are intended to be included within the scope of the disclosure, and the naming of a compound does not exclude any tautomeric form.

[0076] As used herein, "lipid component" refers to that component of the nanoparticle composition that comprises one or more lipids.For example, lipid component can include one or more cationic / ionic lipids, PEGylated lipids, structural lipids, or other lipids such as phospholipids.

[0077] As used herein, a "linker" is a moiety that connects two moieties, such as the bond between two nucleosides of a capping species. The linker may include one or more groups, including, but not limited to, a phosphate group (e.g., phosphate, boranophosphate, thiophosphate, selenophosphate, and phosphonate), an alkyl group, an amidate, or glycerol. For example, the two nucleosides of a capping analog may be linked at their 5' positions by a triphosphate group or by a chain that includes two phosphate moieties and a boranophosphonate moiety.

[0078] As used herein, "administration method" can include intravenous, intramuscular, intradermal, subcutaneous, or other methods of delivering a composition to a subject. The administration method can be selected to target (e.g., specifically deliver) delivery to a particular area or system of the body.

[0079] As used herein, "modified" means non-natural. For example, RNA can be modified RNA. That is, RNA can contain one or more non-naturally occurring nucleobases, nucleosides, nucleotides, or linkers. "Modified" species can also be referred to herein as "altered" species. Species can be chemically, structurally, or functionally modified or altered. For example, modified nucleobase species can contain one or more substitutions that do not occur in nature.

[0080] As used herein, "N:P ratio" is the molar ratio of ionizable nitrogen atoms in RNA, e.g., in lipids, to phosphate groups (in the physiological pH range), in a nanoparticle composition comprising a lipid component and RNA.

[0081] As used herein, a "nanoparticle composition" is a composition that includes one or more lipids. Nanoparticle compositions are typically sized to about a few micrometers or less and may include a lipid bilayer. Nanoparticle compositions include lipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), and lipoplexes. For example, a nanoparticle composition may be a liposome with a lipid bilayer having a diameter of 500 nm or less.

[0082] As used herein, "naturally occurring" means existing in nature without artificial assistance.

[0083] As used herein, "patient" refers to a subject who may seek or require treatment, who is receiving treatment, who is undergoing treatment, or who is being treated by a trained professional for a particular disease or condition.

[0084] As used herein, "PEG lipid" or "PEGylated lipid" refers to a lipid that includes a polyethylene glycol moiety.

[0085] The phrase "pharmacologically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are suitable, within the scope of sound medical judgment, for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit / risk ratio.

[0086] The phrase "pharmaceutical acceptable excipient" as used herein refers to any component other than the compounds described herein (e.g., a vehicle capable of suspending, complexing, or dissolving active compounds), and has the properties of being substantially non-toxic and non-inflammatory in patients.Excipients can include, for example, anti-adhesive agents, antioxidants, binders, coating agents, compression aids, disintegrants, dyes (coloring agents), softeners, emulsifiers, fillers (diluents), film-forming agents or coating agents, flavors, flavoring agents, glidants (gliding agents), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, and hydration water. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, cross-linked polyvinylpyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, povidone, gelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E (alpha-tocopherol), vitamin C, xylitol, and other species disclosed herein.

[0087] In this specification, the structural formula of a compound may conveniently represent a certain isomer, but the present disclosure includes all isomers, such as geometric isomers, optical isomers based on asymmetric carbon, stereoisomers, tautomers, etc., and it is understood that not all isomers may have the same level of activity.In addition, the compound represented by the formula may have crystalline polymorphism.It should be noted that any crystalline form, crystalline form mixture, or their anhydride or hydrate are included in the scope of the present disclosure.

[0088] The term "crystalline polymorphism", "polymorphism", or "crystalline form" refers to crystal structures in which a compound (or a salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density hardness, crystal shape, optical and electrical properties, stability and solubility. Recrystallization solvent, crystallization rate, storage temperature, and other factors can result in the predominance of one crystalline form. Crystalline polymorphs of a compound can be prepared by crystallization under different conditions.

[0089] The composition may also include one or more salts of the compounds. The salt may be a pharma- ceutically acceptable salt. As used herein, "pharma- ceutically acceptable salt" refers to a derivative of the disclosed compound in which the parent compound is modified by converting an existing acid or base moiety into its salt form (e.g., by reacting a free base group with a suitable organic acid). Examples of pharma- ceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfonate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy- Salts include ethanesulfonate, lactobionate, lactate, laurate, sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, etc. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc., as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc. The pharma- ceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharma- ceutically acceptable salts of the present disclosure can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods.Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with an appropriate stoichiometric amount of base or acid in water or an organic solvent, or a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.

[0090] As used herein, a "phospholipid" is a lipid that includes a phosphate moiety and one or more carbon chains, such as an unsaturated fatty acid chain. A phospholipid may include one or more multiple (e.g., double or triple) bonds (e.g., one or more unsaturations). Certain phospholipids may facilitate fusion to a membrane. For example, a cationic phospholipid may interact with one or more negatively charged phospholipids of a membrane (e.g., a cell membrane or an intracellular membrane). By fusing a phospholipid to a membrane, one or more elements of a lipid-containing composition may pass through the membrane, for example, allowing delivery of one or more elements to a cell.

[0091] As used herein, "polydispersity index" or "PDI" is a ratio that describes the homogeneity of the particle size distribution of a system. A small value, e.g., less than 0.3, indicates a narrow particle size distribution.

[0092] As used herein, the term "polypeptide" or "polypeptide of interest" typically refers to a polymer of amino acid residues joined by peptide bonds that can be naturally (e.g., isolated or purified) or synthetically produced. The terms "polypeptide", "peptide", and "protein" are used interchangeably herein to refer to a polymer of amino acids of any length. A polymer can include modified amino acids. The term also encompasses amino acid polymers that are modified naturally or by intervention, e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included in the definition are, for example, polypeptides that contain one or more analogs of amino acids (including unnatural amino acids such as homocysteine, ornithine, p-acetylphenylalanine, D-amino acids, and creatine), as well as other modifications known in the art. As used herein, the term refers to proteins, polypeptides, and peptides of any size, structure, or function. Polypeptides include encoded polypeptide products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments, and other equivalents, variants, and analogs of the foregoing. Polypeptides can be monomers or multi-molecular complexes, such as dimers, trimers, or tetramers. They can also include single-chain or multi-chain polypeptides. Most commonly, disulfide bonds are found in multi-chain polypeptides. The term polypeptide can also apply to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids. In some embodiments, a "peptide" can be 50 amino acids or less in length, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids in length.

[0093] As used herein, "RNA" refers to ribonucleic acid, which may be natural or non-natural. For example, RNA may contain modifications and / or non-naturally occurring components, such as one or more nucleic acid bases, nucleosides, nucleotides, or linkers. RNA may contain cap structures, chain-terminating nucleosides, stem loops, polyA sequences, and / or polyadenylation signals. RNA may have a nucleotide sequence that encodes a polypeptide of interest.

[0094] As used herein, "DNA" refers to deoxyribonucleic acid that can occur naturally or non-naturally. For example, DNA can be a synthetic molecule, such as a synthetic DNA molecule that is generated in vitro. In some embodiments, the DNA molecule is a recombinant molecule. As used herein, "recombinant DNA molecule" refers to a DNA molecule that does not occur as a natural product, but is generated using molecular biology techniques.

[0095] As used herein, a "single unit dose" is a dose of any therapeutic agent administered in one dose / one time / single route / single point of contact, i.e., a single administration event.

[0096] As used herein, a "split dose" is the division of a single unit dose or total daily dose into two or more doses.

[0097] As used herein, a "total daily dose" is the amount given or prescribed in a 24-hour period. It may be administered as a single unit dose.

[0098] As used herein, "size" or "average size" in the context of lipid nanoparticles (e.g., empty LNPs or filled LNPs) refers to the average diameter of the nanoparticle composition.

[0099] As used herein, the term "subject" or "patient" refers to any organism to which a composition according to the disclosure can be administered, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and / or plants.

[0100] As used herein, "target cell" refers to any one or more cells of interest. The cells may be found in vitro, in vivo, in situ, or in a tissue or organ of an organism. The organism may be an animal, preferably a mammal, more preferably a human, and most preferably a patient.

[0101] As used herein, "target tissue" refers to any one or more tissue types of interest where delivery of a therapeutic and / or prophylactic agent will produce a desired biological and / or pharmacological effect. Examples of target tissues of interest include specific tissues, organs, and systems or groups thereof. In certain applications, the target tissue may be kidney, lung, spleen, vascular endothelium in blood vessels (e.g., coronary or femoral arteries), or tumor tissue (e.g., via intratumoral injection). "Non-target tissue" refers to any one or more tissue types where expression of the encoded protein does not produce a desired biological and / or pharmacological effect. In certain applications, non-target tissues may include liver and spleen.

[0102] The term "therapeutic agent" or "prophylactic agent" refers to any agent that has a therapeutic, diagnostic, and / or prophylactic effect and / or induces a desired biological and / or pharmacological effect when administered to a subject. Therapeutic agents are also referred to as "active agents" or "active agents." Such agents include, but are not limited to, cytotoxins, radioactive ions, chemotherapeutic agents, small molecule drugs, proteins, and nucleic acids.

[0103] As used herein, the term "therapeutically effective amount" means an amount of an agent (e.g., a nucleic acid, a drug, a composition, a therapeutic agent, a diagnostic agent, a prophylactic agent, etc.) delivered that, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and / or condition, is sufficient to treat the infection, disease, disorder, and / or condition, ameliorate the symptoms thereof, diagnose, prevent, and / or delay the onset thereof.

[0104] As used herein, "transfection" refers to the introduction of a seed (e.g., RNA) into a cell. Transfection can be performed, for example, in vitro, ex vivo, or in vivo.

[0105] As used herein, the term "treating" refers to partially or completely alleviating, ameliorating, ameliorating, mitigating, delaying the onset of, inhibiting progression, reducing the severity, and / or reducing the incidence of one or more symptoms or characteristics of a particular infection, disease, disorder, and / or condition. For example, "treating" cancer can refer to inhibiting tumor survival, growth, and / or spread. Treatment can be administered to subjects who do not exhibit symptoms of the disease, disorder, and / or condition and / or to subjects who exhibit only early signs of the disease, disorder, and / or condition for the purpose of reducing the risk of developing pathology associated with the disease, disorder, and / or condition.

[0106] As used herein, "zeta potential" is the electrokinetic potential of lipids, for example, in a particle composition.

[0107] Nanoparticle Composition The disclosure also features lipid nanoparticles comprising a compound according to (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb) described herein.

[0108] In some embodiments, the nanoparticle composition has a maximum dimension of 1 μm or less (e.g., 1 μm, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, 50 nm, or less), e.g., as measured by dynamic light scattering (DLS), transmission electron microscopy, scanning electron microscopy, or another method. Nanoparticle compositions include, for example, lipid nanoparticles (LNPs, e.g., empty or filled LNPs), liposomes, lipid vesicles, and lipoplexes. In some embodiments, the nanoparticle composition is a vesicle comprising one or more lipid bilayers. In certain embodiments, the nanoparticle composition comprises two or more concentric bilayers separated by an aqueous compartment. The lipid bilayers may be functionalized and / or crosslinked to one another. The lipid bilayers may comprise one or more ligands, proteins, or channels.

[0109] The nanoparticle composition includes a lipid component that includes at least one compound according to formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb). For example, the lipid component of the nanoparticle composition can include one or more of the compounds in Table 1. The nanoparticle composition can also include a variety of other components. For example, the lipid component of the nanoparticle composition can include, in addition to a lipid according to Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), one or more other lipids.

[0110] Cationic / Ionic Lipids The lipid nanoparticles (e.g., empty or filled LNPs) can include one or more cationic and / or ionic lipids (e.g., lipids that can bear a positive charge or a partial positive charge at physiological pH) in addition to lipids according to Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb). Cationic and / or ionic lipids include 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine (KL10), N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanamine (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane (KL25), 1,2-dilinoleyloxy-N,N-dimethyl ... DLin-DMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), Octatriacontan-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-MC3-DMA), 2,2-Dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 1,2-Dioleyl 2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA), (2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z , 12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA(2R)), and (2S)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA(2S)).In addition to these, the cationic lipids can also be lipids that contain a cyclic amine group.

[0111] structural lipids Lipid nanoparticles (e.g., empty or loaded LNPs) may include one or more structural lipids. The structural lipids may be selected from the group consisting of, but are not limited to, cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha-tocopherol, and mixtures thereof. In some embodiments, the structural lipid is cholesterol. In some embodiments, the structural lipid includes cholesterol and corticosteroids (such as prednisolone, dexamethasone, prednisone, and hydrocortisone), or combinations thereof. In some embodiments, the structural lipid is [ka] It is.

[0112] Phospholipids A lipid nanoparticle (e.g., empty or loaded LNP) may include one or more phospholipids, such as one or more (poly)unsaturated lipids. The phospholipids may be assembled into one or more lipid bilayers. In general, a phospholipid may include a phospholipid moiety and one or more fatty acid moieties. For example, a phospholipid may be represented by the formula (IV): [ka] wherein R p represents the phospholipid moiety, and R A and R Brepresents a fatty acid moiety with or without unsaturation, which may be the same or different. The phospholipid moiety may be selected from the non-limiting group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine, and sphingomyelin. The fatty acid moiety may be selected from the non-limiting group consisting of lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, phytanic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid. Non-natural species are also contemplated, including naturally occurring species with modifications and substitutions, including branching, oxidation, cyclization, and alkynes. For example, phospholipids can be functionalized or crosslinked with one or more alkynes (e.g., alkenyl groups in which one or more double bonds are replaced with triple bonds). Under appropriate reaction conditions, alkyne groups can undergo copper-catalyzed cycloaddition when exposed to azides. Such reactions can be useful for functionalizing the lipid bilayer of lipid nanoparticles (e.g., empty or filled LNPs) to facilitate membrane penetration or cell recognition, or for conjugating lipid nanoparticles (e.g., empty or filled LNPs) to useful components such as targeting or imaging moieties (e.g., dyes).

[0113] Phospholipids useful in the compositions and methods include 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2 cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphotidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), distearoyl-phosphatidyl-ethanolamine The lipid nanoparticles may be selected from the non-limiting group consisting of DSPC, dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE), and mixtures thereof. In some embodiments, the lipid nanoparticles (e.g., empty or loaded LNPs) comprise DSPC. In certain embodiments, the lipid nanoparticles (e.g., empty or loaded LNPs) comprise DOPE. In some embodiments, the lipid nanoparticles (e.g., empty or loaded LNPs) comprise both DSPC and DOPE.

[0114] PEGylated lipids Lipid nanoparticles (e.g., empty or loaded LNPs) may contain one or more PEG or PEG-modified lipids. Such species may alternatively be referred to as PEGylated lipids. PEG lipids are lipids modified with polyethylene glycol. The PEG lipids may be selected from the non-limiting group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide (PEG-CER), PEG-modified dialkylamine, PEG-modified diacylglycerol (PEG-DEG), PEG-modified dialkylglycerol, and mixtures thereof. For example, the PEG lipid may be a PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipid.

[0115] In certain embodiments, the PEG lipid is selected from the group consisting of PEG-modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified diacylglycerols, and PEG-modified dialkylglycerols.

[0116] In certain embodiments, the PEG lipid is selected from the group consisting of 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-distarylglycerol (PEG-DSG), PEG-dipalmetyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE), or PEG-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DMA). For example, in some embodiments, the PEG lipid is PEG-DMG.

[0117] In certain embodiments, the PEG lipid has the formula (PL-I): [ka] Compounds of or a salt thereof, wherein R 3PL1 But -OR OPL1 and R OPL1 is hydrogen, an optionally substituted alkyl, or an oxygen protecting group; r PL1 is an integer between 1 and 100 inclusive, L 1 But, with arbitrary substitutions C 1-10 alkylene, optionally substituted C 1-10 At least one methylene of the alkylene is independently selected from optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, O, N(R NPL1 ), S, C(O), C(O)N(R NPL1 ), N.R. NPL1 C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R NPL1 ), N.R. NPL1 C(O)O, or NR NPL1 C(O)N(R NPL1 ), D is a moiety obtained by click chemistry or a moiety cleavable under physiological conditions; m PL1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, A is of the formula: [ka] The L 2 each instance of 1-6 alkylene, optionally substituted C 1-6 One methylene unit of the alkylene is optionally O, N(R NPL1 ), S, C(O), C(O)N(R NPL1 ), N.R. NPL1C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R NPL1 ), N.R. NPL1 C(O)O, or NR NPL1 C(O)N(R NPL1 ), R 2SL Each instance of is independently 1-30 Alkyl, optionally substituted C 1-30 alkenyl, or optionally substituted C 1-30 alkynyl, and optionally R 2SL one or more methylene units of are independently selected from optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R NPL1 ), O, S, C(O), C(O)N(R NPL1 ), N.R. NPL1 C(O), NR NPL1 C(O)N(R NPL1 ), C(O)O, OC(O), OC(O)O, OC(O)N(R NPL1 ), N.R. NPL1 C(O)O, C(O)S, SC(O), C(=NR NPL1 ), C(=NR NPL1 )N(R NPL1 ), N.R. NPL1 C(=NR NPL1 ), N.R. NPL1 C(=NR NPL1 )N(R NPL1 ), C(S), C(S)N(R NPL1 ), N.R. NPL1 C(S), NR NPL1 C(S)N(R NPL1 ), S(O), OS(O), S(O)O, OS(O)O, OS(O)2, S(O)2O, OS(O)2O, N(R NPL1 )S(O), S(O)N(R NPL1 ), N(R NPL1 )S(O)N(R NPL1 ), OS(O)N(R NPL1 ), N(R NPL1 )S(O)O, S(O)2, N(R NPL1 )S(O)2, S(O)2N(R NPL1 ), N(R NPL1)S(O)2N(R NPL1 ), OS(O)2N(R NPL1 ), or N(R NPL1 )S(O)2O, R NPL1 each instance of is independently hydrogen, an optionally substituted alkyl, or a nitrogen protecting group; Ring B is an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl; p SL is 1 or 2.

[0118] In certain embodiments, the PEG lipid has the formula (PL-I-OH): [ka] or a salt thereof.

[0119] In certain embodiments, the PEG lipid has the formula (PL-II-OH): [ka] or a salt or isomer thereof, wherein R 3PEG But -OR O and R O But hydrogen, C 1-6 alkyl, or oxygen protecting group; r PEG is an integer from 1 to 100, R 5PEG But, C 10-40 Alkyl, C 10-40 Alkenyl, or C 10-40 alkynyl, and optionally R 5PEG one or more methylene groups are independently selected from the group consisting of C 3-10 Carbocyclylene, 4-10 membered heterocyclylene, C 6-10 Arylene, 4-10 membered heteroarylene, -N(R NPEG)-, -O-,-S-,-C(O)-, -C(O)N(R NPEG )-, -NR NPEG C(O)-, -NR NPEG C(O)N(R NPEG )-, -C(O)O-, -OC(O)-, -OC(O)O-, -OC(O)N(R NPEG )-, -NR NPEG C(O)O-, -C(O)S-,-SC(O)-, -C(=NR NPEG )-, -C(=NR NPEG )N(R NPEG )-, -NR NPEG C(=NR NPEG )-, -NR NPEG C(=NR NPEG )N(R NPEG )-, -C(S)-, -C(S)N(R NPEG )-, -NR NPEG C(S)-, -NR NPEG C(S)N(R NPEG )-, -S(O)-, -OS(O)-, -S(O)O-, -OS(O)O-, -OS(O)2-, -S(O)2O-, -OS(O)2O-, -N(R NPEG )S(O)-, -S(O)N(R NPEG )-, -N(R NPEG )S(O)N(R NPEG )-, -OS(O)N(R NPEG )-, -N(R NPEG )S(O)O-, -S(O)2-, -N(R NPEG )S(O)2-, -S(O)2N(R NPEG )-, -N(R NPEG )S(O)2N(R NPEG )-, -OS(O)2N(R NPEG )-, or -N(R NPEG )S(O)2O-, R NPEG Each instance of is independently hydrogen, C 1-6 alkyl, or a nitrogen protecting group.

[0120] In certain embodiments, in the PEG lipid of formula (PL-II-OH), r is an integer between 40 and 50. For example, r is selected from the group consisting of 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50. For example, r is 45.

[0121] In certain embodiments, in the PEG lipid of formula (PL-II-OH), R 5 is C 17 It is an alkyl.

[0122] In certain embodiments, the PEG lipid has the formula (PL-II): [ka] wherein r PEG is an integer between 1 and 100.

[0123] In certain embodiments, the PEG lipid has the formula (PEG-1): [ka] It is a compound of the formula:

[0124] In certain embodiments, the PEG lipid has the formula (PL-III): [ka] or a salt or isomer thereof, wherein PL1 is an integer between 1 and 100.

[0125] In certain embodiments, the PEG lipid has the following formula: [ka] It is a compound of the formula:

[0126] In certain embodiments, the formula (PL-I), (PL-I-OH), (PL-II), (PL-II-OH), (PL-III), PEG 2k Incorporation of one of the lipids, i.e., -DMG, or PEG-1, into a nanoparticle formulation may improve the pharmacokinetics and / or biodistribution of the lipid nanoparticle formulation. For example, incorporation of one of the lipids, i.e., (PL-II-OH), (PL-IIa-OH), (PL-II), or PEG-1, into a nanoparticle formulation may reduce the accelerated blood clearance (ABC) effect.

[0127] Adjuvants In some embodiments, lipid nanoparticles comprising one or more lipids described herein (e.g., empty LNPs or loaded LNPs) may further comprise one or more adjuvants, such as glucopyranosyl lipid adjuvant (GLA), CpG oligodeoxynucleotide (e.g., class A or B), poly(I:C), aluminum hydroxide, and Pam3CSK4.

[0128] Treatment The lipid nanoparticles (e.g., empty or loaded LNPs) can include one or more therapeutic and / or prophylactic agents. The disclosure features methods of delivering a therapeutic and / or prophylactic agent to a mammalian cell or organ, methods of producing a polypeptide of interest in a mammalian cell, and methods of treating a disease or disorder in a mammal in need of such treatment, comprising administering to the mammal lipid nanoparticles (e.g., empty or loaded LNPs) that include a therapeutic and / or prophylactic agent and / or contacting a mammalian cell with lipid nanoparticles (e.g., empty or loaded LNPs) that include a therapeutic and / or prophylactic agent.

[0129] Therapeutic and / or prophylactic agents include biologically active substances, alternatively referred to as "active agents." Therapeutic and / or prophylactic agents may be substances that, once delivered to a cell or organ, effect a desired change in the cell, organ, or other body tissue or system. Such species may be useful in the treatment of one or more diseases, disorders, or conditions. In some embodiments, therapeutic and / or prophylactic agents are small molecule drugs useful in the treatment of a particular disease, disorder, or condition.

[0130] In some embodiments, the therapeutic and / or prophylactic agent is a vaccine, a compound (e.g., a polynucleotide or nucleic acid molecule encoding a protein or polypeptide or peptide, or a protein or polypeptide or protein) that induces an immune response, and / or another therapeutic and / or prophylactic agent. Vaccines include compounds and preparations that are capable of providing immunity against one or more conditions associated with infectious diseases and may include mRNA encoding antigens and / or epitopes derived from infectious diseases. Vaccines also include compounds and preparations that induce an immune response against cancer cells and may include mRNA encoding antigens, epitopes, and / or neoepitopes derived from tumor cells. In some embodiments, vaccines and / or compounds capable of eliciting an immune response are administered intramuscularly via the disclosed compositions.

[0131] In other embodiments, the therapeutic and / or prophylactic agent is a protein, e.g., a protein required to enhance or replace a naturally occurring protein of interest. Such proteins or polypeptides can be naturally occurring or can be modified, e.g., to increase half-life, using methods known in the art. Exemplary proteins are intracellular, transmembrane, or secreted proteins.

[0132] Polynucleotides and Nucleic Acids In some embodiments, the therapeutic agent is an agent that enhances (i.e., increases, stimulates, upregulates) protein expression. Non-limiting examples of types of therapeutic agents that can be used to enhance protein expression include RNA, mRNA, dsRNA, CRISPR / Cas9 technology, ssDNA, and DNA (e.g., expression vectors). Agents that upregulate protein expression can upregulate the expression of naturally occurring or non-naturally occurring proteins (e.g., chimeric proteins modified to improve half-life, or those that contain desired amino acid changes). Exemplary proteins include intracellular, transmembrane, or secreted proteins, peptides, or polypeptides.

[0133] In some embodiments, the therapeutic agent is a DNA therapeutic agent.The DNA molecule can be double-stranded DNA, single-stranded DNA (ssDNA), or partially double-stranded DNA, i.e., a molecule having a part that is double-stranded and a part that is single-stranded.In some cases, the DNA molecule can be triple-stranded or partially triple-stranded, i.e., a part that is triple-stranded and a part that is double-stranded.The DNA molecule can be a circular DNA molecule or a linear DNA molecule.

[0134] A DNA therapeutic can be a DNA molecule capable of transcribing a gene into a cell, e.g., encoding and expressing a transcript. In other embodiments, the DNA molecule is a synthetic molecule, e.g., a synthetic DNA molecule generated in vitro. In some embodiments, the DNA molecule is a recombinant molecule. Non-limiting exemplary DNA therapeutics include plasmid expression vectors and viral expression vectors.

[0135] The DNA therapeutics described herein, such as DNA vectors, may include a variety of different features. The DNA therapeutics described herein, such as DNA vectors, may include non-coding DNA sequences. For example, the DNA sequence may include at least one regulatory element of a gene, such as a promoter, an enhancer, a termination element, a polyadenylation signal element, a splicing signal element, and the like. In some embodiments, the non-coding DNA sequence is an intron. In some embodiments, the non-coding DNA sequence is a transposon. In some embodiments, the DNA sequence described herein may have a non-coding DNA sequence operably linked to a gene that is transcriptionally active. In other embodiments, the DNA sequence described herein may have a non-coding DNA sequence that is not linked to a gene, i.e., the non-coding DNA does not regulate a gene on the DNA sequence.

[0136] In some embodiments, in the loaded LNPs of the disclosure, the one or more therapeutic and / or prophylactic agents are nucleic acids, hi some embodiments, the one or more therapeutic and / or prophylactic agents are selected from the group consisting of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA).

[0137] For example, in some embodiments, when the therapeutic and / or prophylactic agent is DNA, the DNA is selected from the group consisting of double-stranded DNA, single-stranded DNA (ssDNA), partially double-stranded DNA, triple-stranded DNA, and partially triple-stranded DNA. In some embodiments, the DNA is selected from the group consisting of circular DNA, linear DNA, and mixtures thereof.

[0138] In some embodiments, in the loaded LNPs of the disclosure, the one or more therapeutic and / or prophylactic agents are selected from the group consisting of a plasmid expression vector, a viral expression vector, and mixtures thereof.

[0139] For example, in some embodiments, when the therapeutic and / or prophylactic agent is RNA, the RNA is selected from the group consisting of single-stranded RNA, double-stranded RNA (dsRNA), partially double-stranded RNA, and mixtures thereof, hi some embodiments, the RNA is selected from the group consisting of circular RNA, linear RNA, and mixtures thereof.

[0140] For example, in some embodiments, when the therapeutic and / or prophylactic agent is RNA, the RNA is selected from the group consisting of short interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecules, microRNA (miRNA), antagomir, antisense RNA, ribozymes, dicer substrate RNA (dsRNA), small hairpin RNA (shRNA), messenger RNA (mRNA), locked nucleic acid (LNA), and CRISPR / Cas9 technology, and mixtures thereof.

[0141] For example, in some embodiments, when the therapeutic and / or prophylactic agent is RNA, the RNA is selected from the group consisting of small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), dicer substrate RNA (dsRNA), small hairpin RNA (shRNA), messenger RNA (mRNA), and mixtures thereof.

[0142] In some embodiments, the one or more therapeutic and / or prophylactic agents is an mRNA. In some embodiments, the one or more therapeutic and / or prophylactic agents is a modified mRNA (mmRNA).

[0143] In some embodiments, the one or more therapeutic and / or prophylactic agents are mRNAs that incorporate a microRNA binding site (miR binding site). Further, in some embodiments, the mRNAs include one or more of a stem loop, a chain terminating nucleoside, a polyA sequence, a polyadenylation signal, and / or a 5' cap structure.

[0144] mRNA can be naturally occurring or non-naturally occurring mRNA. mRNA can contain one or more modified nucleic acid bases, nucleosides, or nucleotides as described below, and can then be referred to as "modified mRNA" or "mmRNA". As described herein, a "nucleoside" is defined as a compound that contains a sugar molecule (e.g., pentose or ribose) or its derivative, combined with an organic base (e.g., purine or pyrimidine) or its derivative (also referred to herein as "nucleobase"). As described herein, a "nucleotide" is defined as a nucleoside that contains a phosphate group.

[0145] An mRNA can include a 5' untranslated region (5'-UTR), a 3' untranslated region (3'-UTR), and / or a coding region (e.g., an open reading frame). An mRNA can include any suitable number of base pairs, including tens (e.g., 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100), hundreds (e.g., 200, 300, 400, 500, 600, 700, 800, or 900), or thousands (e.g., 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10,000) of base pairs. Any number (e.g., all, some, or none) of the nucleic acid bases, nucleosides, or nucleotides can be canonical species, substituted, modified, or otherwise analogous to non-naturally occurring ones. In certain embodiments, all types of specific nucleic acid bases can be modified.In some embodiments, all uracil or uridine are modified.When all nucleic acid bases, nucleosides or nucleotides, for example, all uracil or uridine are modified, mRNA can be referred to as, for example, "fully modified" uracil or uridine.

[0146] In some embodiments, the mRNAs described herein may include a 5' cap structure, chain terminating nucleotides, optionally a Kozak sequence (also known as a Kozak consensus sequence), a stem loop, a polyA sequence, and / or a polyadenylation signal.

[0147] The 5' cap structure or cap species is a compound that includes two nucleoside moieties joined by a linker and can be selected from a naturally occurring cap, a non-naturally occurring cap or cap analog, or an inversion prevention cap analog (ARCA). The CAP species can include one or more modified nucleosides and / or linker moieties. For example, a natural mRNA cap can include a guanine nucleotide and a guanine (G) nucleotide methylated at the 7-position joined by a triphosphate bond at the 5'-position, such as m7G(5')ppp(5')G, commonly written as m7GpppG. The cap species can also be an inversion prevention cap analog. A non-limiting list of possible cap species includes m7GpppG, m7Gpppm7G, m73'dGpppG, m27,O3'GpppG, m27,O3'GppppG, m27,O2'GppppG, m7Gpppm7G, m73'dGpppG, m27,O3'GpppG, m27,O3'GppppG, and m27,O2'GppppG.

[0148] The mRNA may alternatively or additionally comprise chain-terminating nucleosides. For example, chain-terminating nucleosides may include nucleosides deoxygenated at the 2' and / or 3' positions of their sugar groups. Such species may include 3' deoxyadenosine (cordycepin), 3' deoxyuridine, 3' deoxycytosine, 3' deoxyguanosine, 3' deoxythymine, and 2',3' dideoxynucleosides such as 2',3' dideoxyadenosine, 2',3' dideoxyuridine, 2',3' dideoxycytosine, 2',3' dideoxyguanosine, and 2',3' dideoxythymine. In some embodiments, the incorporation of chain-terminating nucleotides into the mRNA, for example at the 3' end, may result in stabilization of the mRNA.

[0149] Alternatively or additionally, the mRNA may include a stem loop, such as a histone stem loop. The stem loop may include 2, 3, 4, 5, 6, 7, 8, or more nucleotide base pairs. For example, the stem loop may include 4, 5, 6, 7, or 8 nucleotide base pairs. The stem loop may be located in any region of the mRNA. For example, the stem loop may be located in, before, or after the untranslated region (5' untranslated region or 3' untranslated region), the coding region, or the polyA sequence, or the tail. In some embodiments, the stem loop may affect one or more functions (or functions) of the mRNA, such as translation initiation, translation efficiency, and / or transcription termination.

[0150] Alternatively or additionally, the mRNA may include a polyA sequence and / or a polyadenylation signal. The polyA sequence may be entirely or predominantly composed of adenine nucleotides or analogs or derivatives thereof. The polyA sequence may also include stabilizing nucleotides or analogs. For example, the polyA sequence may include deoxythymidine, e.g., inverted (or reverse-linked) deoxythymidine (dT), as the stabilizing nucleotide or analog. Details regarding the use of inverted dT and other stabilizing polyA sequence modifications can be found, for example, in WO2017 / 049275A2, the contents of which are incorporated herein by reference. The polyA sequence may be a tail located adjacent to the 3' untranslated region of the mRNA. In some embodiments, the polyA sequence may affect the nuclear export, translation, and / or stability of the mRNA.

[0151] Alternatively or additionally, the mRNA may contain a microRNA binding site. MicroRNA binding sites (or miR binding sites) can be used to regulate mRNA expression in various tissues or cell types. In an exemplary embodiment, miR binding sites are engineered into the 3'UTR sequence of an mRNA to regulate, e.g., enhance, the degradation of the mRNA in cells or tissues expressing the cognate miR. Such regulation is useful for regulating or controlling "off-target" expression of ir mRNA, i.e., in vivo expression in undesirable cells or tissues. Details regarding the use of mir binding sites can be found, for example, in WO2017 / 062513A2, the contents of which are incorporated herein by reference.

[0152] In some embodiments, the mRNA is a bicistronic mRNA that includes a first coding region and a second coding region, with an intervening sequence that includes an internal ribosome entry site (IRES) sequence that allows internal translation initiation between the first and second coding regions, or an intervening sequence that encodes a self-cleaving peptide, such as a 2A peptide. IRES sequences and 2A peptides are typically used to improve the expression of multiple proteins from the same vector. For example, various IRES sequences, including the encephalomyositis virus IRES, are known and available in the art and can be used.

[0153] In some embodiments, the disclosed mRNA comprises one or more modified nucleic acid bases, nucleosides, or nucleotides (referred to as "modified mRNA" or "mmRNA"). In some embodiments, the modified RNA may have useful properties compared to a reference unmodified mRNA, including improved stability, intracellular retention, improved translation, and / or lack of substantial induction of an innate immune response of a cell into which the mRNA is introduced. Thus, the use of modified mRNA may improve the efficiency of protein production, intracellular retention of nucleic acids, as well as have reduced immunogenicity.

[0154] In some embodiments, the mRNA comprises one or more (e.g., 1, 2, 3, or 4) different modified nucleobases, nucleosides, or nucleotides. In some embodiments, the mRNA comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more) different modified nucleobases, nucleosides, or nucleotides. In some embodiments, the modified mRNA can reduce degradation in cells into which the mRNA is introduced, compared to the corresponding unmodified mRNA.

[0155] In some embodiments, the modified nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having modified uracil include pseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s2U), 4-thio-uridine (s4U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho5U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridine or 5-bromo-uridine), 3-methyl-uridine (m3U), 5-Methoxy-uridine (mo5U), Uridine 5-oxyacetic acid (cmo5U), Uridine 5-oxyacetic acid methyl ester (mcmo5U), 5-carboxymethyl-uridine (cm5U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm5U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm5U), 5-methoxycarbonylmethyl-uridine (mcm5U), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U), 5-aminomethyl-2- Thio-uridine (nm5s2U), 5-methylaminomethyl-uridine (mnm5U), 5-methylaminomethyl-2-thio-uridine (mnm5s2U), 5-methylaminomethyl-2-seleno-uridine (mnm5se2U), 5-carbamoylmethyl-uridine (ncm5U), 5-carboxymethylaminomethyl-uridine (cmnm5U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm5s2U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (τm 5U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine (τm5s2U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uridine (m5U, i.e., with the nucleobase deoxythymine), 1-methyl-pseudouridine (m1ψ), 5-methyl-2-thio-uridine (m5s2U), 1-methyl-4-thio-pseudouridine (m1s4ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m3ψ), 2-thio-1-methyl-pseudouridine,1-Methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m5D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-meth 2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine (acp3U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp3ψ), 5-(isopentenylaminomethyl)uridine (inm5U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm5s2U), α-thio-uridine, 2 '-O-methyl-uridine (Um), 5,2'-O-dimethyl-uridine (m5Um), 2'-O-methyl-pseudouridine (ψm), 2-thio-2'-O-methyl-uridine (s2Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm5Um), 5-carbamoylmethyl-2'-O-methyl-uridine (ncm5Um), 5-carboxymethylaminomethyl-2'-O-methyl-uridine (ncm5Um), uridine (cmnm5Um), 3,2'-O-dimethyl-uridine (m3Um), and 5-(isopentenylaminomethyl)-2'-O-methyl-uridine (inm5Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH-ara-uridine, 5-(2-carbomethoxyvinyl)uridine, and 5-[3-(1-E-propenylamino)]uridine.

[0156] In some embodiments, the modified nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having modified cytosines include 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m3C), N4-acetyl-cytidine (ac4C), 5-formyl-cytidine (f5C), N4-methyl-cytidine (m4C), 5-methyl-cytidine (m5C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydro-cytidine (5-hydro-cytidine), 5-amino-cytidine (5-amino ... hydroxymethyl-cytidine (hm5C), 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s2C), 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine Zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, lysidine (k2C), α-thio-cytidine, 2'-O-methyl-cytidine (Cm), 5,2'-O-dimethyl- These include tyl-cytidine (m5Cm), N4-acetyl-2'-O-methyl-cytidine (ac4Cm), N4,2'-O-dimethyl-cytidine (m4Cm), 5-formyl-2'-O-methyl-cytidine (f5Cm), N4,N4,2'-O-trimethyl-cytidine (m42Cm), 1-thio-cytidine, 2'-F-ara-cytidine, 2'-F-cytidine, and 2'-OH-ara-cytidine.

[0157] In some embodiments, the modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having modified adenines include α-thio-adenosine, 2-amino-purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8- ... adenosine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), 2-methylthio-N6-methyl-adenosine (ms2m6A), N6-isopentenyl-adenosine (i6A), 2-methylthio-N6-isopentenyl-adenosine (ms2i6A), N6-(cis-hydroxyisopentenyl)adenosine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms2io6A), N6-glycinylcarbamoyl-adenosine (g6A), N6-threonylcarbamoyl-adenosine (t6A), N6-methyl-N6-threonylcarbamoyl-adenosine (m6t6A), 2-methylthio-N6-threonylcarbamoyl-adenosine (ms2g6A), N6,N6-dimethyl-adenosine (m62A), N6-hydroxynorba norvalylcarbamoyl-adenosine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms2hn6A), N6-acetyl-adenosine (ac6A), 7-methyl-adenine, 2-methylthio-adenosine, 2-methoxy-adenosine, α-thio-adenosine, 2'-O-methyl-adenosine (Am), N6,2'-O-dimethyl-adenosine (m6Am), N6,N6,2'-O-trimethyl-adenosine (m62Am), 1,2'-O-dimethyl-adenosine (m1Am), 2'-O-ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1-thio-adenosine, 8-azido-adenosine, 2'-F-ara-adenosine, 2'-F-adenosine, 2'-OH-ara-adenosine, and N6-(19-amino-pentaoxanonadecyl)-adenosine.

[0158] In some embodiments, the modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having modified guanine include α-thio-guanosine, inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wyosine (yW), peroxywyosine (o2yW), hydroxywyosine (OhyW), hypomodified hydroxywyosine (OhyW*), 7-deaza-guanosine, queosine (Q), epoxyqueosine (oQ), ga Lactosyl-queosine (galQ), mannosyl-queosine (manQ), 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), archaeosine (G+), 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m7G), 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl- Guanosine (m1G), N2-methyl-guanosine (m2G), N2,N2-dimethyl-guanosine (m22G), N2,7-dimethyl-guanosine (m2,7G), N2,N2,7-dimethyl-guanosine (m2,2,7G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thioguanosine, N2,N2-dimethyl-6-thioguanosine, α-thio-guanosine, 2'-O-methyl-guanosine (Gm), N2-methyl-2'-O-methyl 2'-O-methyl-guanosine (m2Gm), N2,N2-dimethyl-2'-O-methyl-guanosine (m22Gm), 1-methyl-2'-O-methyl-guanosine (m1Gm), N2,7-dimethyl-2'-O-methyl-guanosine (m2,7Gm), 2'-O-methyl-inosine (Im), 1,2'-O-dimethyl-inosine (m1Im), 2'-O-ribosylguanosine (phosphate) (Gr(p)), 1-thio-guanosine, O6-methyl-guanosine, 2'-F-ara-guanosine, and 2'-F-guanosine.

[0159] In some embodiments, the disclosed mRNA comprises a combination of one or more of the aforementioned modified nucleobases (eg, a combination of two, three, or four of the aforementioned modified nucleobases).

[0160] In some embodiments, the modified nucleobase is pseudouridine (ψ), N1-methylpseudouridine (m1ψ), 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, or 2'-O-methyluridine. In some embodiments, the disclosed mRNA comprises a combination of one or more of the foregoing modified nucleobases (e.g., a combination of two, three, or four of the foregoing modified nucleobases). In some embodiments, the modified nucleobase is N1-methylpseudouridine (m1ψ), and the disclosed mRNA is fully modified with N1-methylpseudouridine (m1ψ). In some embodiments, N1-methylpseudouridine (m1ψ) represents 75-100% of the uracils in the mRNA. In some embodiments, N1-methylpseudouridine (m1ψ) represents 100% of the uracils in the mRNA.

[0161] In some embodiments, the modified nucleobase is modified cytosine.Exemplary nucleobases and nucleosides with modified cytosine include N4-acetyl-cytidine (ac4C), 5-methyl-cytidine (m5C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methyl-pseudoisocytidine, 2-thio-cytidine (s2C), 2-thio-5-methyl-cytidine.In some embodiments, the disclosed mRNA comprises one or more combinations of the above modified nucleobases (e.g., a combination of two, three, or four of the above modified nucleobases).

[0162] In some embodiments, the modified nucleobase is modified adenine. Exemplary nucleobases and nucleosides with modified adenine include 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A). In some embodiments, the disclosed mRNA comprises one or more combinations of the above modified nucleobases (e.g., combinations of two, three, or four of the above modified nucleobases).

[0163] In some embodiments, the modified nucleobase is modified guanine. Exemplary nucleobases and nucleosides with modified guanine include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine. In some embodiments, the disclosed mRNA comprises one or more combinations of the above modified nucleobases (e.g., a combination of two, three, or four of the above modified nucleobases).

[0164] In some embodiments, the modified nucleobase is 1-methyl-pseudouridine (m1ψ), 5-methoxy-uridine (mo5U), 5-methyl-cytidine (m5C), pseudouridine (ψ), α-thio-guanosine, or α-thio-adenosine. In some embodiments, the disclosed mRNA comprises a combination of one or more of the foregoing modified nucleobases (e.g., a combination of two, three, or four of the foregoing modified nucleobases).

[0165] In some embodiments, the mRNA comprises pseudouridine (ψ). In some embodiments, the mRNA comprises pseudouridine (ψ) and 5-methyl-cytidine (m5C). In some embodiments, the mRNA comprises 1-methyl-pseudouridine (m1ψ). In some embodiments, the mRNA comprises 1-methyl-pseudouridine (m1ψ) and 5-methyl-cytidine (m5C). In some embodiments, the mRNA comprises 2-thiouridine (s2U). In some embodiments, the mRNA comprises 2-thiouridine and 5-methyl-cytidine (m5C). In some embodiments, the mRNA comprises 5-methoxy-uridine (mo5U). In some embodiments, the mRNA comprises 5-methoxy-uridine (mo5U) and 5-methyl-cytidine (m5C). In some embodiments, the mRNA comprises 2'-O-methyluridine. In some embodiments, the mRNA comprises 2'-O-methyluridine and 5-methyl-cytidine (m5C). In some embodiments, the mRNA comprises N6-methyl-adenosine (m6A). In some embodiments, the mRNA comprises N6-methyl-adenosine (m6A) and 5-methyl-cytidine (m5C).

[0166] In certain embodiments, the disclosed mRNA is uniformly modified for a particular modification (i.e., completely modified, modified throughout the entire sequence). For example, the mRNA can be uniformly modified with N1-methylpseudouridine (m1ψ) or 5-methyl-cytidine (m5C), which means that all uridine or all cytosine nucleosides in the mRNA sequence are replaced with N1-methylpseudouridine (m1ψ) or 5-methyl-cytidine (m5C). Similarly, the disclosed mRNA for any type of nucleoside residue present in the sequence can be uniformly modified by substitution with modified residues such as those described above.

[0167] In some embodiments, the disclosed mRNAs may be modified in the coding region (e.g., the open reading frame encoding a polypeptide). In other embodiments, the mRNAs may be modified in regions other than the coding region. For example, in some embodiments, a 5'-UTR and / or a 3'-UTR are provided, either or both of which may independently contain one or more different nucleoside modifications. In such embodiments, nucleoside modifications may also be present in the coding region.

[0168] The disclosed mmRNAs can include combinations of modifications to the sugar, nucleobase, and / or internucleoside linkages. These combinations can include any one or more of the modifications described herein.

[0169] When a single modification is listed, the listed nucleoside or nucleotide represents 100% of that A, U, G, or C nucleotide or nucleoside modified. When percentages are listed, they represent the percentage of that particular A, U, G, or C triphosphate nucleobase of the total amount of A, U, G, or C triphosphates present. For example, the combination: 25% 5-aminoallyl-CTP + 75% CTP / 25% 5-methoxy-UTP + 75% UTP refers to a polynucleotide in which 25% of the cytosine triphosphates are 5-aminoallyl-CTP and 75% of the cytosines are CTP, but 25% of the uracils are 5-methoxyUTP and 75% of the uracils are UTP. When no modified UTP is listed, naturally occurring ATP, UTP, GTP, and / or CTP are used at 100% of the sites of those nucleotides found in the polynucleotide. In this example, all of the GTP and ATP nucleotides remain unmodified.

[0170] The mRNA or region of the present disclosure can be codon-optimized. Codon optimization methods are known in the art and can be useful for a variety of purposes, including: matching codon frequency in host organisms to ensure proper folding; biasing G / C content to increase mRNA stability or reduce secondary structures; minimizing tandem repeat codons or stretches of bases that can impair gene assembly or expression; customizing transcriptional and translational control regions; inserting or removing protein transport sequences; removing / adding post-translational modification sites (e.g., glycosylation sites) in encoded proteins; adding, removing, or shuffling protein domains; inserting or deleting restriction sites; modifying ribosome binding sites and mRNA degradation sites; adjusting translation rates to allow various domains of proteins to fold properly; or reducing or eliminating problematic secondary structures in polynucleotides. Codon optimization tools, algorithms, and services are known in the art, and non-limiting examples include services and / or proprietary methods from GeneArt (Life Technologies), DNA2.0 (Menlo Park, Calif.). In some embodiments, mRNA sequences are optimized using optimization algorithms, for example, to optimize expression in mammalian cells or to improve mRNA stability.

[0171] In certain embodiments, the disclosure includes polynucleotides having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to any of the polynucleotide sequences set forth herein.

[0172] The mRNA of the present disclosure can be produced by means available in the art, including, but not limited to, in vitro transcription (IVT) and synthetic methods. Enzymatic (IVT), solid phase, liquid phase, combined synthetic methods, small region synthesis, and ligation methods can be utilized. In some embodiments, the mRNA is produced using IVT enzymatic synthetic methods. Thus, the present disclosure also includes polynucleotides, such as DNA, constructs, and vectors, that can be used to in vitro transcribe the mRNA described herein.

[0173] Non-natural modified nucleobases can be introduced into polynucleotides, such as mRNA, during or after synthesis.In certain embodiments, modifications can be present on internucleoside linkages, purine or pyrimidine bases, or sugars.In certain embodiments, modifications can be introduced into the ends of polynucleotide chains or anywhere else within polynucleotide chains using chemical synthesis or using polymerase enzymes.

[0174] Using either enzymatic or chemical ligation methods, polynucleotides or regions thereof can be conjugated with different functional moieties, such as targeting or delivery agents, fluorescent labels, liquids, nanoparticles, etc. Therapeutic Agents for Reducing Protein Expression

[0175] In some embodiments, the therapeutic agent is one that reduces (i.e., reduces, inhibits, downregulates) protein expression. Non-limiting examples of types of therapeutic agents that can be used to reduce protein expression include microRNA binding site(s) (miR binding sites), microRNAs (miRNAs), antagomirs, small (short) interfering RNAs (siRNAs) (including shortmers and dicer substrate RNAs), RNA interference (RNAi) molecules, antisense RNAs, ribozymes, small hairpin RNAs (shRNAs), locked nucleic acids (LNAs), and mRNAs incorporating CRISPR / Cas9 technology.

[0176] Peptide / Polypeptide Therapeutics In some embodiments, the therapeutic agent is a peptide therapeutic agent. In some embodiments, the therapeutic agent is a polypeptide therapeutic agent.

[0177] In some embodiments, the peptide or polypeptide is naturally occurring, e.g., isolated from a natural source. In other embodiments, the peptide or polypeptide is a synthetic molecule, e.g., a synthetic peptide or polypeptide generated in vitro. In some embodiments, the peptide or polypeptide is a recombinant molecule. In some embodiments, the peptide or polypeptide is a chimeric molecule. In some embodiments, the peptide or polypeptide is a fusion molecule. In some embodiments, the peptide or polypeptide therapeutic of the composition is a naturally occurring peptide or polypeptide. In some embodiments, the peptide or polypeptide therapeutic of the composition is a modified version of a naturally occurring peptide or polypeptide (e.g., containing fewer than 3, fewer than 5, fewer than 10, fewer than 15, fewer than 20, or fewer than 25 amino substitutions, deletions, or additions compared to its wild-type, naturally occurring peptide or polypeptide counterpart).

[0178] In some embodiments, in the loaded LNPs of the disclosure, the one or more therapeutic and / or prophylactic agents is a polynucleotide or a polypeptide.

[0179] Other components The lipid nanoparticles (e.g., empty or filled LNPs) may include one or more components in addition to those described in the preceding sections. For example, the lipid nanoparticles (e.g., empty or filled LNPs) may include one or more small hydrophobic molecules, such as vitamins (e.g., vitamin A or vitamin E) or sterols.

[0180] The lipid nanoparticles (e.g., empty or loaded LNPs) may also include one or more permeability enhancing molecules, carbohydrates, polymers, surface modifiers, or other moieties. Carbohydrates may include monosaccharides (e.g., glucose) and polysaccharides (e.g., glycogen and its derivatives and analogs).

[0181] A polymer may be included and / or used to encapsulate or partially encapsulate the nanoparticle composition. The polymer may be biodegradable and / or biocompatible. The polymer may be selected from, but is not limited to, polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyleneimines, polyisocyanates, polyacrylates, polyethacrylates, polyacrylonitriles, and polyarylates. For example, polymers include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic-glycolic acid) (PLGA), poly(L-lactic-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO ...L-lactide), polyalkyl cyanoacrylates, polyurethanes, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethylene glycol, poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol) (PEG), polyalkylene oxides (PEO), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohol (PVA), polyvinyl ethers, poly(vinyl acetate), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone (PVP), polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocellulose, hydroxypropyl cellulose, carboxymethyl cellulose, cellulose ethers, cellulose esters, cellulose ether ... cellulose, poly(methyl (meth)acrylate) (PMMA), poly(ethyl (meth)acrylate), poly(butyl (meth)acrylate), poly(isobutyl (meth)acrylate), poly(hexyl (meth)acrylate), poly(isodecyl (meth)acrylate), poly(lauryl (meth)acrylate), poly(phenyl (meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) and copolymers thereof, and Included may be mentioned are polymers of acrylic acid, such as mixtures thereof, polydioxanone and their copolymers, polyhydroxyalkanoates, polypropylene fumarates, polyoxymethylenes, poloxamers, poloxamines, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), trimethylene carbonate, poly(N-acryloylmorpholine) (PAcM), poly(2-methyl-2-oxazoline) (PMOX), poly(2-ethyl-2-oxazoline) (PEOZ), and polyglycols.

[0182] Surface-altering agents may include, but are not limited to, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as dimethyldioctadecyl-ammonium bromide), sugars or sugar derivatives (e.g., cyclodextrins), nucleic acids, polymers (e.g., heparin, polyethylene glycol, and poloxamers), mucolytic agents (e.g., acetylcysteine, mugwort, bromelan, papain, clerodendrum, bromexin, carbocysteine, eprazinone, mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, thioproline, gellin, thymosin, beta4, dornase, alpha, neltenexin, and erdosteine), and DNases (e.g., rhDNase). Surface-altering agents may be disposed (e.g., by coating, adsorption, covalent attachment, or other process) within the nanoparticle and / or on the surface of the lipid nanoparticle (e.g., empty or loaded LNP).

[0183] The lipid nanoparticles (e.g., empty or filled LNPs) may also include one or more functionalized lipids. For example, the lipids may be functionalized with alkyne groups that can undergo cycloaddition reactions when exposed to azides under suitable reaction conditions. In particular, lipid bilayers may be functionalized in this manner with one or more groups that are useful for facilitating membrane penetration, cell recognition, or imaging. The surface of the lipid nanoparticles (e.g., empty or filled LNPs) may also be conjugated with one or more useful antibodies. Functional groups and conjugates useful in target cell delivery, imaging, and membrane penetration are well known in the art.

[0184] In addition to these components, lipid nanoparticles (e.g., empty LNPs or filled LNPs) may contain any material useful in pharmaceutical compositions. For example, lipid nanoparticles (e.g., empty LNPs or filled LNPs) may contain one or more pharma- ceutically acceptable excipients or accessory ingredients, such as, but not limited to, one or more solvents, dispersion media, diluents, dispersion aids, suspension aids, granulation aids, disintegrants, fillers, fluids, liquid vehicles, binders, surfactants, isotonicity agents, thickening or emulsifying agents, buffers, lubricants, oils, preservatives, and other species. They may also contain excipients such as waxes, butters, colorants, coating agents, flavors, and fragrances.

[0185] Examples of diluents may include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and / or combinations thereof. The granulating and dispersing agents may be selected from the non-limiting list consisting of potato starch, corn starch, tapioca starch, sodium glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinylpyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium glycolate), carboxymethylcellulose, cross-linked sodium carboxymethylcellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, carboxymethylcellulose, magnesium aluminum silicate (VEEGUM®), sodium lauric sulfate, quaternary ammonium compounds, and / or combinations thereof.

[0186] Surfactants and / or emulsifiers include, but are not limited to, natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite [aluminum silicate] and VEEGUM® [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), sorbitan fatty acid esters, sorbitan ... (e.g., polyoxyethylene sorbitan monolaurate [TWEEN® 20], polyoxyethylene sorbitan [TWEEN® 60], polyoxyethylene sorbitan monooleate [TWEEN® 80], sorbitan monopalmitiate [SPAN® 40], sorbitan monostearate [SPAN® 60], sorbitan tristearate [SPAN® 65], glyceryl monooleate, sorbitan monooleate [SPAN® 80]), polyoxyethylene esters (e.g., polyoxyethylene monostearate [MYRJ® 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and SOLUTOL®), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., CREMOPHOR®), polyoxyethylene ethers (e.g., polyoxyethylene lauryl ether [BRIJ® 30]), poly(vinylpyrrolidone), diethylene glycol monolaurate, triethanolamine oleate,These may include sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, PLURONIC® F 68, POLOXAMER® 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and / or combinations thereof.

[0187] The binder may be starch (e.g., corn starch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol), natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinylpyrrolidone), magnesium aluminum silicate (VEEGUM® and larch arapinogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, and combinations thereof, or any suitable binder.

[0188] Examples of preservatives may include, but are not limited to, antioxidants, chelating agents, antibacterial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and / or other preservatives. Examples of antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl formate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and / or sodium sulfite. Examples of chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, phosphoric acid, sodium edetate, tartaric acid, and / or trisodium edetate. Examples of antibacterial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and / or thimerosal. Examples of antifungal agents include, but are not limited to, butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and / or sorbic acid. Examples of alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, benzyl alcohol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and / or phenylethyl alcohol. Examples of acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroascorbic acid, ascorbic acid, sorbic acid, and / or phytic acid.Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, distoxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT PLUS®, PHENONIP®, methylparaben, GERMALL® 115, GERMABEN® II, NEOLONE®, KATHON®, and / or EUXYL®.

[0189] Examples of buffering agents include, but are not limited to, citrate buffer, acetate buffer, phosphate buffer, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, d-gluconic acid, calcium glycerophosphate, calcium lactate, calcium lactobionate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixture, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixture, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixture, tromethamine, aminosulfonic acid buffer (e.g., HEPES), magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and / or combinations thereof. The lubricant may be selected from the non-limiting group consisting of magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and combinations thereof.

[0190] Examples of oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, linseed, geraniol, gourd, grapeseed, hazelnut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea Oils that may be used include, but are not limited to, cubeba, macadamia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savory, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, camellia, vetiver, walnut, and wheat germ oils, as well as butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, simethicone, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and / or combinations thereof.

[0191] formulation Lipid nanoparticles (e.g., empty or loaded LNPs) may include a lipid component and one or more additional components, such as a therapeutic agent and / or a prophylactic agent. Lipid nanoparticles (e.g., empty or loaded LNPs) may be designed for one or more specific applications or targets. The components of a lipid nanoparticle (e.g., empty or loaded LNPs) may be selected based on a particular application or target, and / or based on the efficacy, toxicity, cost, ease of use, availability, or other characteristics of one or more components. Similarly, a particular formulation of a nanoparticle composition may be selected for a particular application or target, for example, depending on the efficacy and toxicity of a particular combination of components.

[0192] The lipid component of the nanoparticle composition can include, for example, lipids according to formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), phospholipids (e.g., unsaturated lipids, such as DOPE or DSPC), PEG lipids, and structural lipids. The elements of the lipid component can be provided in specific fractions.

[0193] In some embodiments, the lipid component of the nanoparticle composition comprises a lipid according to formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a PEG lipid, and a structural lipid. In certain embodiments, the lipid component of the nanoparticle composition comprises about 30 mol% to about 60 mol% of a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), about 0 mol% to about 30 mol% of a phospholipid, about 18.5 mol% to about 48.5 mol% of a structural lipid, and about 0 mol% to about 10 mol% of a PEG lipid, provided that the total mol% does not exceed 100%. In some embodiments, the lipid component of the nanoparticle composition comprises about 35 mol% to about 55 mol% of a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), about 5 mol% to about 25 mol% of a phospholipid, about 30 mol% to about 40 mol% of a structural lipid, and about 0 mol% to about 10 mol% of a PEG lipid. In certain embodiments, the lipid component comprises about 50 mol% of the compound, about 10 mol% of a phospholipid, about 38.5 mol% of a structural lipid, and about 1.5 mol% of a PEG lipid. In another particular embodiment, the lipid component comprises about 40 mol% of the compound, about 20 mol% of a phospholipid, about 38.5 mol% of a structural lipid, and about 1.5 mol% of a PEG lipid. In some embodiments, the phospholipid can be DOPE or DSPC. In other embodiments, the PEG lipid can be PEG-1 or PEG. 2k -DMG and / or the structural lipid may be cholesterol.

[0194] In some embodiments, the empty lipid nanoparticle (empty LNP) comprises a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, and a PEG lipid.

[0195] In some embodiments, a loaded lipid nanoparticle (loaded LNP) comprises a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, a PEG lipid, and one or more therapeutic and / or prophylactic agents.

[0196] In some embodiments, empty or filled LNPs comprise a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb) in an amount of about 40% to about 60%.

[0197] In some embodiments, the empty or loaded LNPs comprise phospholipids in an amount of about 0% to about 20%. For example, in some embodiments, the empty or loaded LNPs comprise DSPC in an amount of about 0% to about 20%.

[0198] In some embodiments, the empty or loaded LNPs comprise structural lipids in an amount of about 30% to about 50%. For example, in some embodiments, the empty or loaded LNPs comprise cholesterol in an amount of about 30% to about 50%.

[0199] In some embodiments, the empty or loaded LNPs contain PEG lipids in an amount of about 0% to about 5%. For example, in some embodiments, the empty or loaded LNPs contain PEG-1 or PEG lipids in an amount of about 0% to about 5%. 2k -Contains about 0% to about 5% DMG.

[0200] In some embodiments, empty or loaded LNPs comprise about 40 mol% to about 60 mol% of a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), about 0 mol% to about 20 mol% of a phospholipid, about 30 mol% to about 50 mol% of a structural lipid, and about 0 mol% to about 5 mol% of a PEG lipid.

[0201] In some embodiments, empty or loaded LNPs contain about 40 mol% to about 60 mol% of a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), about 0 mol% to about 20 mol% DSPC, about 30 mol% to about 50 mol% cholesterol, and about 0 mol% to about 5 mol% PEG. 2k In some embodiments, the empty or loaded LNPs comprise about 40 mol% to about 60 mol% of a compound in Table 1, about 0 mol% to about 20 mol% DSPC, about 30 mol% to about 50 mol% cholesterol, and about 0 mol% to about 5 mol% PEG. 2k -DMG, including

[0202] In some embodiments, empty or loaded LNPs comprise about 40 mol% to about 60 mol% of a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), about 0 mol% to about 20 mol% DSPC, about 30 mol% to about 50 mol% cholesterol, and about 0 mol% to about 5 mol% PEG-1. In some embodiments, empty or loaded LNPs comprise about 40 mol% to about 60 mol% of a compound in Table 1, about 0 mol% to about 20 mol% DSPC, about 30 mol% to about 50 mol% cholesterol, and about 0 mol% to about 5 mol% PEG-1.

[0203] In some embodiments, the empty or filled LNPs comprise a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, and a PEG lipid, where the phospholipid is DSPC and the structural lipid is cholesterol. In some embodiments, the empty or filled LNPs comprise a compound of Table 1, a phospholipid, a structural lipid, and a PEG lipid, where the phospholipid is DSPC and the structural lipid is cholesterol.

[0204] In some embodiments, the empty or filled LNPs comprise a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, and a PEG lipid, wherein the structural lipid is cholesterol and the PEG lipid is PEG. 2kIn some embodiments, the empty or filled LNPs comprise a compound of Table 1, a phospholipid, a structural lipid, and a PEG lipid, wherein the structural lipid is cholesterol and the PEG lipid is PEG -DMG. 2k -DMG.

[0205] In some embodiments, the empty or filled LNPs comprise a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, and a PEG lipid, wherein the structural lipid is cholesterol and the PEG lipid is PEG-1. In some embodiments, the empty or filled LNPs comprise a compound of Table 1, a phospholipid, a structural lipid, and a PEG lipid, wherein the structural lipid is cholesterol and the PEG lipid is PEG-1.

[0206] In some embodiments, the empty or filled LNPs comprise a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC and the PEG lipid is PEG. 2k In some embodiments, the empty or filled LNPs comprise a compound of Table 1, a phospholipid, a structural lipid, and a PEG lipid, wherein the structural lipid is DSPC and the PEG lipid is PEG -DMG. 2k -DMG.

[0207] In some embodiments, the empty or filled LNPs comprise a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC and the PEG lipid is PEG-1. In some embodiments, the empty or filled LNPs comprise a compound of Table 1, a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC and the PEG lipid is PEG-1.

[0208] In some embodiments, the empty or filled LNPs comprise a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC, the structural lipid is cholesterol, and the PEG lipid is PEG. 2k In some embodiments, the empty or filled LNPs comprise a compound of Table 1, a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC, the structural lipid is cholesterol, and the PEG lipid is PEG. 2k -DMG.

[0209] In some embodiments, the empty or filled LNPs comprise a compound of formula (A), a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC, the structural lipid is cholesterol, and the PEG lipid is PEG. 2k In some embodiments, the empty or filled LNPs comprise a compound of Table 1, a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC, the structural lipid is cholesterol, and the PEG lipid is PEG. 2k -DMG.

[0210] In some embodiments, the empty or filled LNPs comprise a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC, the structural lipid is cholesterol, and the PEG lipid is PEG-1.

[0211] In some embodiments, the empty or filled LNPs comprise a compound of formula (A), a phospholipid, a structural lipid, and a PEG lipid, where the phospholipid is DSPC, the structural lipid is cholesterol, and the PEG lipid is PEG-1. In some embodiments, the empty or filled LNPs comprise a compound of Table 1, a phospholipid, a structural lipid, and a PEG lipid, where the phospholipid is DSPC, the structural lipid is cholesterol, and the PEG lipid is PEG-1.

[0212] Lipid nanoparticles (e.g., empty or loaded LNPs) may be designed for one or more specific applications or targets. For example, nanoparticle compositions may be designed to deliver therapeutic and / or prophylactic agents, such as RNA, to specific cells, tissues, organs, or systems or groups thereof in the mammalian body. The physicochemical properties of the lipid nanoparticles (e.g., empty or loaded LNPs) may be altered to increase selectivity for specific body targets. For example, particle size may be adjusted based on the pore size of different organs. The therapeutic and / or prophylactic agents included in the nanoparticle composition may also be selected based on the desired delivery target or targets. For example, the therapeutic and / or prophylactic agents may be selected for a specific indication, condition, disease, or disorder, and / or for delivery to specific cells, tissues, organs, or systems or groups thereof (e.g., localized or specific delivery). In certain embodiments, the nanoparticle composition may include an mRNA encoding a polypeptide of interest that is capable of being translated in a cell to produce the polypeptide of interest. Such compositions may be designed to be specifically delivered to a specific organ. In some embodiments, the compositions may be designed to be specifically delivered to the liver of a mammal.

[0213] The amount of therapeutic and / or prophylactic agent in the nanoparticle composition can depend on the size, composition, desired target and / or use, or other properties of the nanoparticle composition, as well as the properties of the therapeutic and / or prophylactic agent. For example, the amount of RNA useful in a nanoparticle composition can depend on the size, sequence, and other characteristics of the RNA. The relative amounts of therapeutic and / or prophylactic agent and other components (e.g., lipids) in the nanoparticle composition can also vary. In some embodiments, the weight / weight ratio of lipid component to therapeutic and / or prophylactic agent in the nanoparticle composition can be about 5:1 to about 60:1, such as 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, and 60:1. For example, the weight / weight ratio of lipid component to therapeutic and / or prophylactic agent can be from about 10:1 to about 40:1. In certain embodiments, the weight / weight ratio is about 20:1.

[0214] The amount of therapeutic and / or prophylactic agent in the nanoparticle composition can be measured using, for example, absorption spectroscopy (eg, UV-visible spectroscopy).

[0215] In some embodiments, the nanoparticle composition includes one or more RNAs, one or more RNAs, and lipids, the amounts of which can be selected to provide a particular N:P ratio. The N:P ratio of a composition refers to the molar ratio of nitrogen atoms in one or more lipids to the number of phosphate groups in the RNA. In general, lower N:P ratios are preferred. The one or more RNAs, lipids, and the amounts thereof can be selected to provide an N:P ratio of about 2:1 to about 30:1, such as 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 12:1, 14:1, 16:1, 18:1, 20:1, 22:1, 24:1, 26:1, 28:1, or 30:1. In certain embodiments, the N:P ratio can be about 2:1 to about 8:1. In other embodiments, the N:P ratio is about 5:1 to about 8:1. For example, the N:P ratio can be about 5.0:1, about 5.5:1, about 5.67:1, about 6.0:1, about 6.5:1, or about 7.0:1. For example, the N:P ratio can be about 5.67:1.

[0216] physical properties The characteristics of lipid nanoparticles (e.g., empty LNPs or filled LNPs) may depend on their components. For example, lipid nanoparticles (e.g., empty LNPs or filled LNPs) that contain cholesterol as a structural lipid may have different characteristics from lipid nanoparticles (e.g., empty LNPs or filled LNPs) that contain different structural lipids. Similarly, the characteristics of lipid nanoparticles (e.g., empty LNPs or filled LNPs) may depend on the absolute or relative amounts of their components. For example, lipid nanoparticles (e.g., empty LNPs or filled LNPs) that contain a higher molar fraction of phospholipids may have different characteristics from lipid nanoparticles (e.g., empty LNPs or filled LNPs) that contain a lower molar fraction of phospholipids. The characteristics may also vary depending on the preparation method and conditions of the nanoparticle composition.

[0217] Lipid nanoparticles (e.g., empty or loaded LNPs) can be characterized by various methods. For example, microscopy (e.g., transmission electron microscopy or scanning electron microscopy) can be used to examine the morphology and size distribution of the nanoparticle composition. Dynamic light scattering or potentiometry (e.g., potentiometric titration) can be used to measure the zeta potential. Dynamic light scattering can also be used to determine particle size. Instruments such as the Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK) can also be used to measure several properties of the nanoparticle composition, such as particle size, polydispersity index, and zeta potential.

[0218] The average size of lipid nanoparticles (e.g., empty or loaded LNPs) can be tens of nm to hundreds of nm, e.g., as measured by dynamic light scattering (DLS). For example, the average size can be about 40 nm to about 150 nm, e.g., about 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm. In some embodiments, the average size of the lipid nanoparticles (e.g., empty LNPs or filled LNPs) can be about 50 nm to about 100 nm, about 50 nm to about 90 nm, about 50 nm to about 80 nm, about 50 nm to about 70 nm, about 50 nm to about 60 nm, about 60 nm to about 100 nm, about 60 nm to about 90 nm, about 60 nm to about 80 nm, about 60 nm to about 70 nm, about 70 nm to about 150 nm, about 70 nm to about 130 nm, about 70 nm to about 100 nm, about 70 nm to about 90 nm, about 70 nm to about 80 nm, about 80 nm to about 150 nm, about 80 nm to about 130 nm, about 80 nm to about 100 nm, about 80 nm to about 90 nm, about 90 nm to about 150 nm, about 90 nm to about 130 nm, or about 90 nm to about 100 nm. In certain embodiments, the average size of the lipid nanoparticles (e.g., empty or loaded LNPs) may be about 70 nm to about 130 nm, or about 70 nm to about 100 nm. In certain embodiments, the average size may be about 80 nm. In other embodiments, the average size may be about 100 nm. In other embodiments, the average size may be about 120 nm.

[0219] The lipid nanoparticles (e.g., empty LNPs or filled LNPs) can be relatively homogeneous. The polydispersity index can be used to indicate the homogeneity of the nanoparticle composition, e.g., the particle size distribution of the lipid nanoparticles (e.g., empty LNPs or filled LNPs). A small (e.g., less than 0.3) polydispersity index generally indicates a narrow particle size distribution. The lipid nanoparticles (e.g., empty LNPs or filled LNPs) can have a polydispersity index of about 0 to about 0.25, such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, or 0.25. In some embodiments, the polydispersity index of the lipid nanoparticles (e.g., empty LNPs or filled LNPs) can be from about 0.10 to about 0.20.

[0220] The zeta potential of lipid nanoparticles (e.g., empty or filled LNPs) can be used to indicate the electrokinetic potential of the composition. For example, the zeta potential can describe the surface charge of a nanoparticle composition. Lipid nanoparticles (e.g., empty or filled LNPs) with a relatively low charge, positive or negative, are generally desirable, since more highly charged species may have undesirable interactions with cells, tissues, and other elements in the body. In some embodiments, the zeta potential of lipid nanoparticles (e.g., empty or filled LNPs) can be between about -10 mV and about +20 mV, between about -10 mV and about +15 mV, between about -10 mV and about +10 mV, between about -10 mV and about +5 mV, between about -10 mV and about 0 mV, between about -10 mV and about -5 mV, between about -5 mV and about +20 mV, between about It can be -5mV to about +15mV, about -5mV to about +10mV, about -5mV to about +5mV, about -5mV to about 0mV, about 0mV to about +20mV, about 0mV to about +15mV, about 0mV to about +10mV, about 0mV to about +5mV, about +5mV to about +20mV, about +5mV to about +15mV, or about +5mV to about +10mV.

[0221] The efficiency of encapsulation of a therapeutic and / or prophylactic agent describes the amount of therapeutic and / or prophylactic agent that is encapsulated or associated with lipid nanoparticles (e.g., empty or loaded LNPs) after preparation, compared to the initial amount provided. The encapsulation efficiency is desirably high (e.g., close to 100%). The encapsulation efficiency can be measured, for example, by comparing the amount of therapeutic and / or prophylactic agent in a solution containing lipid nanoparticles (e.g., empty or loaded LNPs) with one or more organic solvents or detergents before and after the lipid nanoparticles (e.g., empty or loaded LNPs) are degraded. Fluorescence may also be used to measure the amount of free therapeutic and / or prophylactic agent (e.g., RNA) in the solution. In the lipid nanoparticles described herein (e.g., empty LNPs or loaded LNPs), the encapsulation efficiency of the therapeutic and / or prophylactic agent can be at least 50%, e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the encapsulation efficiency can be at least 80%. In certain embodiments, the encapsulation efficiency can be at least 90%. In some embodiments, the encapsulation efficiency of the therapeutic and / or prophylactic agent is between 80% and 100%.

[0222] Pharmaceutical Compositions Lipid nanoparticles (e.g., empty or filled LNPs) may be formulated in whole or in part as a pharmaceutical composition. A pharmaceutical composition may include one or more lipid nanoparticles (e.g., empty or filled LNPs). In one embodiment, a pharmaceutical composition includes a population of lipid nanoparticles (e.g., empty or filled LNPs). For example, a pharmaceutical composition may include one or more lipid nanoparticles (e.g., empty or filled LNPs) that include one or more different therapeutic and / or prophylactic agents. A pharmaceutical composition may further include one or more pharma- ceutical acceptable excipients or accessory ingredients, such as those described herein. General guidelines for the formulation and manufacture of pharmaceutical compositions and medicaments can be found, for example, in Remington's The Science and Practice of Pharmacy, 21 st Edition, AR Gennaro; Lippincott, Williams & Wilkins, Baltimore, MD, 2006. Conventional excipients and accessory ingredients can be used in any pharmaceutical composition, except insofar as any conventional excipient or accessory ingredient may be incompatible with one or more of the ingredients of the nanoparticle composition. An excipient or accessory ingredient may be incompatible with a component of a nanoparticle (e.g., empty or loaded LNP) if its combination with the ingredient may produce any undesirable biological or other deleterious effect.

[0223] In some embodiments, one or more excipients or accessory ingredients may comprise more than 50% of the total mass or volume of a pharmaceutical composition comprising a nanoparticle composition. For example, one or more excipients or accessory ingredients may comprise 50%, 60%, 70%, 80%, 90%, or more of pharmaceutical regulations. In some embodiments, a pharma- ceutically acceptable excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, the excipient is approved for human and veterinary use. In some embodiments, the excipient is approved by the U.S. Food and Drug Administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments, the excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or the International Pharmacopoeia.

[0224] The relative amounts of one or more lipid nanoparticles according to the present disclosure (e.g., empty or filled LNPs), one or more pharma- ceutically acceptable excipients, and / or any additional components in a pharmaceutical composition will vary depending on the identity, size, and / or condition of the subject being treated, as well as the route by which the composition is administered. By way of example, a pharmaceutical composition may contain 0.1%-100% (weight / weight) of one or more lipid nanoparticles (e.g., empty or filled LNPs).

[0225] In certain embodiments, the disclosed lipid nanoparticles (e.g., empty LNPs or filled LNPs) and / or pharmaceutical compositions are refrigerated or frozen for storage and / or shipping (e.g., at a temperature below 4° C., at a temperature of about −150° C. to about 0° C., or at a temperature of about −80° C. to about −20° C. (e.g., at about −5° C., −10° C., −15° C., −20° C., −25° C., −30° C., −40° C., −50° C., −60° C., −70° C., −80° C., −90° C., −130° C., or −15° C.). For example, a pharmaceutical composition comprising a compound of any of Formulas (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya), (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb) may be refrigerated for storage and / or shipping, e.g., at about -20°C, -30°C, -40°C, -50°C, -60°C, -70°C, or -80°C. In certain embodiments, the disclosure also provides methods for preparing lipid nanoparticles (e.g., empty or filled LNPs) and / or pharmaceutical compositions by storing the lipid nanoparticles (e.g., empty or filled LNPs) and / or pharmaceutical compositions at a temperature of about -150°C to about 0°C or about -80°C to about -20°C, e.g., at or below 4°C, such as at about -5°C, -10°C, -15°C, -20°C, -25°C, -30°C, -40°C, -50°C, -60°C, -70°C, -80°C, -90°C, -130°C, or -150°C). The present invention relates to a method for increasing the stability of a pharmaceutical composition comprising a compound of any of formulas (1-1), (2-1), (Ia), (A), (B), (A-1), (A-2), (A-3), (IA), (IB), (B-1), (B-2), (B-3), (Aa), (A-a1), (A-a2), (A-a3), (Ab), (A-b1), (A-b2), (A-b3), (Ac), and (Bc).For example, the lipid nanoparticles (e.g., empty or loaded LNPs) and / or pharmaceutical compositions disclosed herein are stable at temperatures below 4° C. (e.g., about 4° C. to −20° C.) for at least about 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 1 month, at least 2 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 14 months, at least 16 months, at least 18 months, at least 20 months, at least 22 months, or at least 24 months. In some embodiments, the formulation is stabilized at about 4° C. for at least 4 weeks. In certain embodiments, the disclosed pharmaceutical compositions comprise the lipid nanoparticles (e.g., empty or loaded LNPs) disclosed herein and a pharma- ceutically acceptable carrier selected from one or more of Tris, acetate (e.g., sodium acetate), citrate (e.g., sodium citrate), saline, PBS, and sucrose. In certain embodiments, the disclosed pharmaceutical compositions have a pH value of about 7-8 (e.g., 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0, or 7.5-8, or 7-7.8). For example, the disclosed pharmaceutical compositions include lipid nanoparticles disclosed herein (e.g., empty or filled LNPs), Tris, saline, and sucrose, and have a pH of about 7.5-8, e.g., suitable for storage and / or shipping at about -20°C. For example, the disclosed pharmaceutical compositions include lipid nanoparticles disclosed herein (e.g., empty or filled LNPs), and PBS, and have a pH of about 7-7.8, e.g., suitable for storage and / or shipping at about 4°C or below. "Stability," "stabilized," and "stable," in the context of this disclosure, refer to the resistance of the lipid nanoparticles (e.g., empty or filled LNPs) and / or pharmaceutical compositions disclosed herein to chemical or physical changes (e.g., degradation, particle size change, aggregation, change in encapsulation, etc.) under given conditions of manufacture, preparation, transportation, storage, and / or use, e.g., when stressed by shear forces, freeze / thaw stress, etc.

[0226] In some embodiments, the disclosed pharmaceutical compositions comprise empty or filled LNPs, a cryoprotectant, a buffer, or a combination thereof.

[0227] In some embodiments, the cryoprotectant comprises one or more cryoprotectants, each of which may be independently selected from the group consisting of a polyol (e.g., a diol or triol, such as propylene glycol (i.e., 1,2-propanediol), 1,3-propanediol, glycerol, (+ / -)-2-methyl-2,4-pentanediol, 1,6-hexanediol, 1,2-butanediol, 2,3-butanediol, ethylene glycol, or diethylene glycol), a non-detergent sulfobetaine (e.g., NDSB-201 (3-(1-pyridino)-1-propanesulfonate)), an osmolyte (e.g., L-proline or trimethylamine N-oxide dihydrate), a polymer (e.g., polyethylene glycol 200 (PEG200), PEG400, PEG600, PEG1000, PEG2000, PEG3000, PEG400, PEG500, PEG600, PEG700, PEG800, PEG900, PEG1000, PEG1000, PEG1000, PEG1000, PEG1000, PEG2 ... 2k-DMG, PEG3350, PEG4000, PEG8000, PEG10000, PEG20000, polyethylene glycol monomethyl ether 550 (mPEG550), mPEG600, mPEG2000, mPEG3350, mPEG4000, mPEG5000, polyvinylpyrrolidone (e.g., polyvinylpyrrolidone K15), pentaerythritol propoxylate, or polypropylene glycol P400), organic solvent (e.g., dimethyl sulfoxide (DMSO) or ethanol), sugar (e.g., D-(+)-sucrose, D- In some embodiments, the cryoprotectant comprises sucrose. In some embodiments, the cryoprotectant and / or excipient is sucrose. In some embodiments, the cryoprotectant comprises sodium acetate. In some embodiments, the cryoprotectant and / or excipient is sodium acetate. In some embodiments, the cryoprotectant comprises sucrose. In some embodiments, the cryoprotectant and / or excipient is sodium acetate. In some embodiments, the cryoprotectant comprises sucrose and sodium acetate. In some embodiments, the cryoprotectant and / or excipient is sodium acetate. In some embodiments, the cryoprotectant comprises sucrose and sodium acetate.

[0228] In some embodiments, the buffer is selected from the group consisting of acetate buffer, citrate buffer, phosphate buffer, Tris buffer, and combinations thereof.

[0229] Lipid nanoparticles (e.g., empty or loaded LNPs) and / or pharmaceutical compositions comprising one or more lipid nanoparticles (e.g., empty or loaded LNPs) may be administered to any patient or subject, including patients or subjects who may benefit from a therapeutic effect provided by delivery of a therapeutic and / or prophylactic agent to one or more specific cells, tissues, organs, or systems or groups thereof. The description provided herein of lipid nanoparticles (e.g., empty or loaded LNPs) and pharmaceutical compositions comprising lipid nanoparticles (e.g., empty or loaded LNPs) is directed primarily to compositions suitable for administration to humans, although it will be understood by those skilled in the art that such compositions are generally suitable for administration to any other mammal. Modifications of compositions suitable for administration to humans to generate compositions suitable for administration to a variety of animals are well understood, and such modifications can be designed and / or performed by a veterinary pharmacologist of ordinary skill with no more than routine experimentation (if any). Subjects to which the compositions are contemplated for administration include, but are not limited to, humans, other primates, and other mammals, such as commercially relevant mammals, such as cows, pigs, horses, sheep, cats, dogs, mice, and / or rats. The subject lipid nanoparticles can also be used for in vitro and ex vivo uses.

[0230] Pharmaceutical compositions containing one or more lipid nanoparticles (e.g., empty or filled LNPs) may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such methods of preparation include bringing into association the active ingredient with an excipient and / or one or more other accessory ingredients and then, if desired or necessary, dividing, shaping, and / or packaging the product into the desired single or multiple dosage units.

[0231] Pharmaceutical compositions according to the present disclosure may be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as multiple unit doses.As used herein, a "unit dose" is a discrete amount of pharmaceutical composition that contains a predetermined amount of active ingredient (e.g., lipid nanoparticles).The amount of active ingredient is generally equal to the dosage of active ingredient administered to a subject and / or a convenient fraction of such a dosage, such as one-half or one-third of such a dosage.

[0232] Pharmaceutical compositions can be prepared in various forms suitable for various routes and methods of administration. For example, pharmaceutical compositions can be prepared in liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and elixirs), injectable dosage forms, solid dosage forms (e.g., capsules, tablets, pills, powders, and granules), dosage forms for topical and / or transdermal administration (e.g., ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and patches), suspensions, powders, and other forms.

[0233] Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharma- ceutically acceptable emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and / or elixirs.In addition to the active ingredient, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed, peanut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, and mixtures thereof.Besides inert diluents, oral compositions may contain additional agents, such as additional therapeutic and / or prophylactic agents, wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents, and / or aromatic agents. In certain embodiments for parenteral administration, the composition is mixed with a solubilizing agent, such as Cremophor®, alcohol, oil, modified oil, glycol, polysorbate, cyclodextrin, polymer, and / or combinations thereof.

[0234] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to known techniques using suitable dispersing agents, wetting agents, and / or suspending agents. Sterile injectable preparations can be sterile injectable solutions, suspensions, and / or emulsions in non-toxic parenterally acceptable diluents and / or solvents, for example, as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution, USP, and isotonic sodium chloride solution. Sterile fixed oils are conventionally used as solvents or suspending media. For this purpose, any bland fixed oil can be used, including synthetic mono- or diglycerides. Fatty acids, such as oleic acid, can be used in the preparation of injectables.

[0235] The injectable preparations may be sterilized, for example, by filtration through a bacterial-retaining filter, and / or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0236] In order to prolong the effect of an active ingredient, it is often desirable to slow the absorption of the active ingredient from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends on its rate of dissolution, which in turn may depend on crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer and the nature of the particular polymer used, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.

[0237] Compositions for rectal or vaginal administration can typically be prepared by mixing the composition with a suitable non-irritating excipient, such as cocoa butter, polyethylene glycol, or a suppository wax, which is solid at ambient temperature, but liquid at body temperature, and thus will melt in the rectum or vaginal cavity and release the active ingredient.

[0238] Oral solid dosage forms include capsules, tablets, pills, films, powders, and granules. The active ingredient of such solid dosage forms is mixed with at least one inert pharma- ceutically acceptable excipient, such as sodium citrate or dicalcium phosphate, and / or a filler or extender (e.g., starch, lactose, sucrose, glucose, mannitol, and silicic acid), a binder (e.g., carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidinone, sucrose, and acacia), a humectant (e.g., glycerol), a disintegrant (e.g., agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate), solution retarders (e.g., paraffin), absorption enhancers (e.g., quaternary ammonium compounds), wetting agents (e.g., cetyl alcohol and glycerol monostearate), absorbents (e.g., kaolin and bentonite clay, silicates), and lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium laurate sulfate), and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may contain buffering agents.

[0239] Similar types of solid compositions can be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose or milk sugar, as well as high molecular weight polyethylene glycols. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They can optionally contain opacifying agents, and can be of a composition that releases the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Similar types of solid compositions can be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose or milk sugar, as well as high molecular weight polyethylene glycols.

[0240] Dosage forms for topical and / or transdermal administration of the composition may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and / or patches. In general, the active ingredient is mixed under sterile conditions with a pharma- ceutically acceptable excipient and / or any necessary preservatives and / or buffers, as necessary. In addition, the present disclosure often contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms may be prepared, for example, by dissolving and / or dispensing the compound in a suitable medium. Alternatively or additionally, the rate may be controlled by either providing a rate-controlling membrane and / or dispersing the compound in a polymer matrix and / or gel.

[0241] Suitable devices for use in intradermal delivery of the pharmaceutical compositions described herein include short needle devices. Intradermal compositions can be administered by devices that limit the effective penetration length of the needle into the skin. Jet injection devices are suitable that deliver liquid compositions to the dermis via a liquid jet injector and / or via a needle that creates a jet that penetrates the stratum corneum and reaches the dermis. Ballistic delivery powder / particle delivery devices are suitable that use compressed gas to accelerate the vaccine in powder form through the outer layer of the skin to the dermis. Alternatively or additionally, conventional syringes can be used in the classical Mantoux method of intradermal administration.

[0242] Formulations suitable for topical administration include liquid and / or semi-liquid preparations, such as, but not limited to, liniments, lotions, oil-in-water and / or water-in-oil emulsions (e.g., creams, ointments and / or pastes), and / or solutions and / or suspensions. Topically administrable formulations may contain, for example, about 1% to about 10% (w / w) of active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further include one or more of the additional ingredients described herein.

[0243] The pharmaceutical composition may be prepared, packaged, and / or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles containing the active ingredient. Such a composition is conveniently in the form of a dry powder for administration using a device comprising a dry powder reservoir to which a stream of propellant can be directed to disperse the powder, and / or using a self-propelling solvent / powder dispensing container, such as a device comprising the active ingredient dissolved and / or suspended in a low-boiling propellant in a sealed container. Dry powder compositions may comprise a solid fine powder diluent, such as sugar, and are conveniently provided in a unit dose form.

[0244] Low boiling propellants generally include liquid propellants having a boiling point below 65° F. at atmospheric pressure. Generally, the propellant may comprise 50%-99.9% (w / w) of the composition, and the active ingredient may comprise 0.1%-20% (w / w) of the composition. The propellant may further include additional ingredients such as liquid nonionic and / or solid anionic surfactants and / or solid diluents (which may have a particle size on the same order as the particles containing the active ingredient).

[0245] Pharmaceutical compositions formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and / or suspension. Such formulations may be prepared, packaged, and / or sold as, optionally sterile, aqueous and / or dilute alcoholic solutions and / or suspensions containing the active ingredient, and may be conveniently administered using any nebulizer and / or nebulizer device. Such formulations may further comprise one or more additional ingredients, including, but not limited to, flavoring agents such as sodium saccharin, volatile oils, buffers, surfactants, and / or preservatives such as methyl hydroxybenzoate. The droplets provided by this route of administration may have an average diameter in the range of about 1 nm to about 200 nm.

[0246] The formulations described herein as useful for pulmonary delivery are useful for intranasal delivery of pharmaceutical compositions. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle size of about 0.2 μm to 500 μm. Such a formulation is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passages from a container of powder held close to the nose.

[0247] Formulations suitable for nasal administration may contain, for example, between about 0.1% (w / w) and about 100% (w / w) of the active ingredient, and may include one or more of the additional ingredients described herein. Pharmaceutical compositions may be prepared, packaged, and / or sold in a formulation suitable for buccal administration. Such formulations may be, for example, in the form of tablets and / or lozenges made using conventional methods and may be, for example, 0.1 to 20% (w / w) of the active ingredient, the remainder comprising an orally dissolvable and / or degradable composition, and optionally one or more of the additional ingredients described herein. Alternatively, formulations suitable for buccal administration may comprise a powder and / or an aerosolized and / or atomized solution and / or suspension comprising the active ingredient. Such powdered, aerosolized, and / or aerosolized formulations, when dispersed, may have an average particle and / or droplet size in the range of about 0.1 nm to about 200 nm, and may further comprise one or more of any of the additional ingredients described herein.

[0248] A pharmaceutical composition may be prepared, packaged, and / or sold in a formulation suitable for ophthalmic administration. Such a formulation may be in the form of, for example, eye drops comprising a 0.1 / 1.0% (w / w) solution and / or suspension of the active ingredient in an aqueous or oily liquid vehicle. Such eye drops may further comprise one or more other ingredients, such as buffering agents, salts, and / or any additional ingredients described herein. Other ophthalmically administrable formulations that are useful include those comprising the active ingredient in microcrystalline form and / or in a liposomal preparation. Ear drops and / or eye drops are contemplated as being within the scope of this disclosure.

[0249] mRNA therapy mRNA as a drug modality has the potential to deliver secreted proteins, as well as intracellular and transmembrane proteins. mRNA as a drug modality has the potential to deliver proteins, i.e., targets that are inaccessible to standard biological agents due to their inability to cross the cell membrane when delivered in protein form, across the membrane and into the cell. One major challenge to realizing mRNA-based therapy is the identification of an optimal delivery vehicle. Due to the size, chemical instability, and potential immunogenicity of the vehicle, mRNA requires a delivery vehicle that can provide protection from endonucleases and exonucleases, as well as shielding the cargo from immune sentinels. Lipid nanoparticles (LNPs) have been identified as an advanced option in this regard.

[0250] The key performance criteria for lipid nanoparticle delivery systems are to maximize cellular uptake and allow efficient release of mRNA from endosomes. In one embodiment, the subject LNPs containing the novel lipids disclosed herein show improvements in at least one of cellular uptake and endosomal release. At the same time, the LNPs should provide a stable drug product and be able to be safely administered at therapeutically relevant levels. LNPs are typically multi-component systems consisting of amino lipids, phospholipids, cholesterol, and PEG lipids. Each component is necessary for the efficient delivery of nucleic acid cargo and aspects of particle stability. The key component believed to drive cellular uptake, endosomal escape, and tolerability is the amino lipid. While cholesterol and PEG lipids contribute to the stability of the drug product both in vivo and during storage, the phospholipids provide additional fusogenicity to the LNPs, thus helping to drive endosomal escape and making the nucleic acid bioavailable in the cytoplasm of cells.

[0251] For oligonucleotide delivery, several aminolipid series, including the aminolipid MC3 (DLin-MC3-DMA), have been developed over the past decades. MC3-based LNPs have been shown to be effective for the delivery of mRNA. When delivered intravenously, this class of LNPs is rapidly opsonized by apolipoprotein E (ApoE), which allows cellular uptake by the low-density lipoprotein receptor (LDLr). However, concerns remain that the long tissue half-life of MC3 may contribute to undesirable side effects that preclude its use for long-term therapy. In addition, extensive literature evidence suggests that long-term administration of lipid nanoparticles may result in several toxic side effects, including complement activation-associated pseudoallergy (CARPA) and liver damage. Thus, to release the limitations of the potential of mRNA and other nucleic acid, nucleopeptide or peptide-based therapies for humans, a class of LNPs with increased delivery efficiency along with metabolic and toxicity profiles that would enable long-term administration in humans is needed.

[0252] The ability to treat a wide range of diseases requires the flexibility to administer safely over the long term at varying dose levels. Through systematic optimization of amino lipid structures, the disclosed compounds were identified as compounds with a good balance of chemical stability, improved efficiency of delivery due to improved endosomal escape, rapid in vivo metabolism, and clean toxicity profile. The combination of these features provides a drug candidate that can be administered over the long term without activating the immune system. Initial rodent screening led to the identification of advanced lipids with good delivery efficiency and pharmacokinetics. The advanced LNPs were further profiled in non-human primates for delivery efficiency after single and repeated administration. Finally, the optimized LNPs were evaluated in a one-month repeated dose toxicity study in rats and non-human primates. Without wishing to be bound by theory, the novel ionic lipids of the present disclosure have improved cellular delivery, improved protein expression, and improved biodegradability properties, and may result in a 2-fold, 5-fold, 10-fold, 15-fold, or greater than 20-fold increase in mRNA expression in cells compared to LNPs lacking the inventive lipid. In another embodiment, LNPs containing the lipids of the invention may result in specific (e.g., preferential) delivery to a particular cell type or types compared to other cell types, thereby resulting in a 2-fold, 5-fold, 10-fold, 15-fold, or greater than 20-fold increase in mRNA expression in a particular cell or tissue compared to LNPs lacking the lipids of the invention. These improvements over the prior art enable the safe and effective use of mRNA-based therapies in acute and chronic diseases.

[0253] method In some aspects, the disclosure provides a method of delivering a therapeutic and / or prophylactic agent to a cell (e.g., a mammalian cell). The method includes contacting the cell with a loaded LNP or pharmaceutical composition of the disclosure, whereby the therapeutic and / or prophylactic agent is delivered to the cell. In some embodiments, the cell is in a subject, and the contacting includes administering the cell to the subject. In some embodiments, the method includes administering to the subject a lipid nanoparticle comprising a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, a PEG lipid, and one or more therapeutic and / or prophylactic agents, whereby the therapeutic and / or prophylactic agent is delivered to the cell.

[0254] In some embodiments, disclosure provides a method of delivering a therapeutic and / or prophylactic agent to a cell in a subject, the method comprising: a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb); DSPC; cholesterol; and PEG. 2k The present invention provides a method of delivering a therapeutic and / or prophylactic agent to a subject, the method comprising administering to the subject lipid nanoparticles comprising -DMG and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA). For example, in some embodiments, the disclosure provides a method of delivering a therapeutic and / or prophylactic agent to a cell in a subject, the method comprising administering to the subject lipid nanoparticles comprising a compound of formula (A), DSPC, cholesterol, and PEG. 2k -A method is provided that includes administering to a subject lipid nanoparticles comprising DMG and one or more therapeutic and / or prophylactic agents selected from nucleotides, polypeptides, and nucleic acids (e.g., RNA).

[0255] In some embodiments, the disclosure provides a method of delivering a therapeutic and / or prophylactic agent to a cell in a subject, the method comprising administering to the subject lipid nanoparticles comprising a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA). For example, in some embodiments, the disclosure provides a method of delivering a therapeutic and / or prophylactic agent to a cell in a subject, the method comprising administering to the subject lipid nanoparticles comprising a compound of Formula (A), DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA).

[0256] In some aspects, the disclosure provides a method of delivering (e.g., specifically delivering) a therapeutic and / or prophylactic agent to a mammalian organ or tissue (e.g., liver, kidney, spleen, or lung). The method includes contacting a cell with a loaded LNP or pharmaceutical composition of the disclosure, thereby delivering the therapeutic and / or prophylactic agent to the target organ or tissue. In some embodiments, the method includes administering to a subject lipid nanoparticles comprising a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, a PEG lipid, and one or more therapeutic and / or prophylactic agents, thereby delivering the therapeutic and / or prophylactic agent to the target organ or tissue.

[0257] In some embodiments, disclosure provides a method for specifically delivering a therapeutic and / or prophylactic agent to an organ of a target, the method comprising: a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb); DSPC; cholesterol; and PEG. 2k The present invention provides a method of delivering a therapeutic and / or prophylactic agent to a subject comprising administering to the subject lipid nanoparticles comprising -DMG and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA). For example, in some embodiments, the disclosure provides a method of specifically delivering a therapeutic and / or prophylactic agent to an organ of a subject, the method comprising administering to the subject lipid nanoparticles comprising a compound of formula (A), DSPC, cholesterol, and PEG. 2k -A method is provided that includes administering to a subject lipid nanoparticles comprising DMG and one or more therapeutic and / or prophylactic agents selected from nucleotides, polypeptides, and nucleic acids (e.g., RNA).

[0258] In some embodiments, the disclosure provides a method of specifically delivering a therapeutic and / or prophylactic agent to an organ of a subject, the method comprising administering to a subject lipid nanoparticles comprising a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA). For example, in some embodiments, the disclosure provides a method for specifically delivering a therapeutic and / or prophylactic agent to an organ of a subject, the method comprising administering to a subject lipid nanoparticles comprising a compound of formula (A), DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA).

[0259] In some aspects, the disclosure features a method for enhanced delivery of a therapeutic and / or prophylactic agent (e.g., mRNA) to a target tissue (e.g., liver, spleen, or lung). The method includes contacting a cell with a loaded LNP or pharmaceutical composition of the disclosure, whereby the therapeutic and / or prophylactic agent is delivered to the target tissue (e.g., liver, kidney, spleen, or lung). In some embodiments, the method includes administering to a subject lipid nanoparticles comprising a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, a PEG lipid, and one or more therapeutic and / or prophylactic agents, thereby delivering the therapeutic and / or prophylactic agents to the target tissue (e.g., liver, kidney, spleen, or lung).

[0260] In some embodiments, disclosure provides a method for enhanced delivery of a therapeutic and / or prophylactic agent to a target tissue, the method comprising: a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb); DSPC; cholesterol; and PEG. 2k The present invention provides a method for improving the delivery of a therapeutic and / or prophylactic agent to a target tissue, the method comprising administering to a subject lipid nanoparticles comprising -DMG and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA). For example, in some embodiments, the disclosure provides a method for improved delivery of a therapeutic and / or prophylactic agent to a target tissue, the method comprising administering to a subject lipid nanoparticles comprising a compound of formula (A), DSPC, cholesterol, and PEG. 2k -A method is provided that includes administering to a subject lipid nanoparticles comprising DMG and one or more therapeutic and / or prophylactic agents selected from nucleotides, polypeptides, and nucleic acids (e.g., RNA).

[0261] In some embodiments, the disclosure provides a method for enhanced delivery of a therapeutic and / or prophylactic agent to a target tissue, the method comprising administering to a subject lipid nanoparticles comprising a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA). For example, in some embodiments, the disclosure provides a method for enhanced delivery of therapeutic and / or prophylactic agents to a target tissue, the method comprising administering to a subject lipid nanoparticles comprising a compound of formula (A), DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA).

[0262] In some aspects, the disclosure provides a method of producing a polypeptide of interest in a cell (e.g., a mammalian cell). The method includes contacting the cell with a loaded LNP or pharmaceutical composition of the disclosure, where the loaded LNP or pharmaceutical composition includes an mRNA, whereby the mRNA can be translated in the cell to produce the polypeptide. In some embodiments, the cell is in a subject, and the contacting includes administering the cell to the subject. In some embodiments, the method includes administering to the subject a lipid nanoparticle that includes a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, a PEG lipid, and an mRNA, whereby the mRNA can be translated in the cell to produce the polypeptide.

[0263] In some embodiments, the disclosure provides a method of producing a polypeptide of interest in a cell, the method comprising: combining a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), DSPC, cholesterol, and PEG. 2k The method includes administering to a subject lipid nanoparticles comprising -DMG and mRNA. For example, in some embodiments, the disclosure provides a method for producing a polypeptide of interest in a cell, the method comprising administering to a subject lipid nanoparticles comprising a compound of Table 1, DSPC, cholesterol, PEG, DMG, and mRNA. 2k The method includes administering to a subject lipid nanoparticles comprising -DMG and mRNA. For example, in some embodiments, the disclosure provides a method for producing a polypeptide of interest in a cell, the method comprising administering to a subject lipid nanoparticles comprising a compound of formula (A), DSPC, cholesterol, and PEG. 2k The present invention provides a method comprising administering to a subject lipid nanoparticles comprising -DMG and mRNA.

[0264] In some embodiments, the disclosure provides a method of producing a polypeptide of interest in a cell, the method comprising administering to a subject a lipid nanoparticle comprising a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), DSPC, cholesterol, PEG-1, and mRNA. For example, in some embodiments, the disclosure provides a method of producing a polypeptide of interest in a cell, the method comprising administering to a subject a lipid nanoparticle comprising a compound of formula (A), DSPC, cholesterol, PEG-1, and mRNA. For example, in some embodiments, the disclosure provides a method of producing a polypeptide of interest in a cell, the method comprising administering to a subject lipid nanoparticles comprising a compound of Table 1, DSPC, cholesterol, PEG-1, and mRNA.

[0265] In some aspects, the disclosure provides a method of treating a disease or disorder in a mammal (e.g., a human) in need of such treatment. The method comprises administering a therapeutically effective amount of the disclosed loaded LNP or pharmaceutical composition to the mammal. In some embodiments, the method comprises administering to the subject lipid nanoparticles comprising a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), a phospholipid, a structural lipid, a PEG lipid, and one or more therapeutic and / or prophylactic agents, thereby delivering the therapeutic and / or prophylactic agent to the cell. In some embodiments, the disease or disorder is characterized by a dysfunction or aberrant protein or polypeptide activity. For example, the disease or disorder is selected from the group consisting of rare diseases, infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardio- and renal vascular diseases, and metabolic diseases.

[0266] In some embodiments, the disclosure provides a method of treating a disease or disorder in a subject, the method comprising combining a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), DSPC, cholesterol, and PEG. 2k The present invention provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject lipid nanoparticles comprising -DMG and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA). For example, in some embodiments, the disclosure provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject lipid nanoparticles comprising a compound of formula (A), DSPC, cholesterol, and PEG. 2k The method includes administering to a subject lipid nanoparticles comprising -DMG and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA). For example, in some embodiments, the disclosure provides a method of treating a disease or disorder in a subject, the method comprising administering to a subject lipid nanoparticles comprising a compound of Table 1, DSPC, cholesterol, and PEG. 2k -A method is provided that includes administering to a subject lipid nanoparticles comprising DMG and one or more therapeutic and / or prophylactic agents selected from nucleotides, polypeptides, and nucleic acids (e.g., RNA).

[0267] In some embodiments, the disclosure provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject a lipid nanoparticle comprising a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from nucleotides, polypeptides, and nucleic acids (e.g., RNA). For example, in some embodiments, the disclosure provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject a lipid nanoparticle comprising a compound of formula (A), DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from nucleotides, polypeptides, and nucleic acids (e.g., RNA). For example, in some embodiments, the disclosure provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject lipid nanoparticles comprising a compound of Table 1, DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA).

[0268] In yet another aspect, the disclosure features a method of reducing immunogenicity comprising introducing a disclosed loaded LNP or pharmaceutical composition into a cell, wherein the loaded LNP or pharmaceutical composition reduces induction of a cellular immune response in the cell to the loaded LNP or pharmaceutical composition compared to induction of a cellular immune response in the cell induced by a reference composition. In some embodiments, the cell is in a subject and the contacting comprises administering the cell to the subject. In some embodiments, the method includes administering to a subject lipid nanoparticles comprising a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), and one or more therapeutic and / or prophylactic agents selected from phospholipids, structural lipids, PEG-lipids, and nucleotides, polypeptides, and nucleic acids (e.g., RNA), wherein the lipid nanoparticles are selected from the group consisting of a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya), (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb). The lipid nanoparticles comprising a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb) reduce the induction of a cellular immune response in cells to lipid nanoparticles comprising a compound of formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb) compared to the induction of a cellular immune response in cells induced by a reference composition. For example, the cellular immune response is an innate immune response, an adaptive immune response, or both.

[0269] In some embodiments, the disclosure provides a method of reducing immunogenicity in a subject, the method comprising combining a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), DSPC, cholesterol, and PEG.2k The present invention provides a method of reducing immunogenicity in a subject, the method comprising administering to the subject lipid nanoparticles comprising -DMG and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA). For example, in some embodiments, the disclosure provides a method of reducing immunogenicity in a subject, the method comprising administering to the subject lipid nanoparticles comprising a compound of formula (A), DSPC, cholesterol, and PEG. 2k The method includes administering to a subject lipid nanoparticles comprising -DMG and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA). For example, in some embodiments, the disclosure provides a method of reducing immunogenicity in a subject, the method comprising administering to a subject lipid nanoparticles comprising a compound of Table 1, DSPC, cholesterol, and PEG. 2k -A method is provided that includes administering to a subject lipid nanoparticles comprising DMG and one or more therapeutic and / or prophylactic agents selected from nucleotides, polypeptides, and nucleic acids (e.g., RNA).

[0270] In some embodiments, the disclosure provides a method of reducing immunogenicity in a subject, the method comprising administering to the subject a lipid nanoparticle comprising a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from nucleotides, polypeptides, and nucleic acids (e.g., RNA). For example, in some embodiments, the disclosure provides a method of reducing immunogenicity in a subject, the method comprising administering to the subject a lipid nanoparticle comprising a compound of Formula (A), DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from nucleotides, polypeptides, and nucleic acids (e.g., RNA). For example, in some embodiments, the disclosure provides a method of reducing immunogenicity in a subject, the method comprising administering to the subject lipid nanoparticles comprising a compound of Table 1, DSPC, cholesterol, PEG-1, and one or more therapeutic and / or prophylactic agents selected from a nucleotide, a polypeptide, and a nucleic acid (e.g., RNA).

[0271] The disclosure also includes methods of synthesizing a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), and methods of making lipid nanoparticles (e.g., empty LNPs or filled LNPs) that include a lipid component that comprises a compound of Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb).

[0272] Methods for Producing Polypeptides in Cells The present disclosure provides a method for producing a polypeptide of interest in mammalian cells. The method for producing the polypeptide involves contacting cells with lipid nanoparticles (e.g., empty LNPs or loaded LNPs) that contain mRNA encoding the polypeptide of interest. When the nanoparticle composition is contacted with cells, the mRNA can be taken up into the cells and translated to produce the polypeptide of interest.

[0273] Generally, the step of contacting mammalian cells with lipid nanoparticles (e.g., empty or loaded LNPs) containing mRNA encoding a polypeptide of interest can be performed in vivo, ex vivo, in culture, or in vitro. The amount of lipid nanoparticles (e.g., empty or loaded LNPs) contacted with the cells, and / or the amount of mRNA therein, can depend on the type of cell or tissue to be contacted, the means of administration, the physiochemical characteristics (e.g., size, charge, and chemical composition) of the lipid nanoparticles (e.g., empty or loaded LNPs) and the mRNA therein, as well as other factors. In general, an effective amount of lipid nanoparticles (e.g., empty or loaded LNPs) will allow efficient polypeptide production in the cells. Metrics for efficiency can include polypeptide translation (indicated by polypeptide expression), mRNA degradation levels, and immune response indicators.

[0274] The step of contacting a lipid nanoparticle (e.g., empty or loaded LNP) containing mRNA with a cell may involve or cause transfection. The phospholipids contained in the lipid component of the lipid nanoparticle (e.g., empty or loaded LNP) may facilitate transfection and / or increase transfection efficiency, for example, by interacting with and / or fusing with the cell membrane or intracellular membrane. Transfection may allow translation of the mRNA in the cell.

[0275] In some embodiments, the lipid nanoparticles described herein (e.g., empty or loaded LNPs) may be used therapeutically. For example, the mRNA contained in the lipid nanoparticles (e.g., empty or loaded LNPs) may encode a therapeutic polypeptide (e.g., in a translatable region) and produce the therapeutic polypeptide upon contacting and / or entering (e.g., transfection with) a cell. In other embodiments, the mRNA contained in the lipid nanoparticles (e.g., empty or loaded LNPs) may encode a polypeptide that may improve or increase immunity in a subject. For example, the mRNA may encode granulocyte colony stimulating factor or trastuzumab.

[0276] In certain embodiments, the mRNA contained in the lipid nanoparticle (e.g., empty or loaded LNP) may encode a recombinant polypeptide that may replace one or more polypeptides that may be substantially absent in the contacted cell with the nanoparticle composition. The one or more substantially absent polypeptides may be absent due to genetic mutations in the encoding gene or its regulatory pathway. Alternatively, the recombinant polypeptide produced by translation of the mRNA may antagonize the activity of an endogenous protein present within the cell, on the cell surface, or secreted from the cell. An antagonistic recombinant polypeptide may be desirable to counteract adverse effects caused by the activity of an endogenous protein, such as altered activity or localization caused by mutation. In another alternative, the recombinant polypeptide produced by translation of the mRNA may indirectly or directly antagonize the activity of a biological moiety present within the cell, on the cell surface, or secreted from the cell. The antagonized biological moiety may include, but is not limited to, lipids (e.g., cholesterol), lipoproteins (e.g., low density lipoprotein), nucleic acids, carbohydrates, and small molecule toxins. Recombinant polypeptides produced by translation of mRNA can be engineered for localization within the cell, such as within a specific compartment, such as the nucleus, or can be engineered for secretion from the cell or for translocation to the plasma membrane of the cell.

[0277] In some embodiments, contacting cells with lipid nanoparticles (e.g., empty or loaded LNPs) containing mRNA may reduce the cells' innate immune response to the exogenous nucleic acid. The cells may be contacted with a first lipid nanoparticle (e.g., empty or loaded LNPs) containing a first amount of a first exogenous mRNA, including a translatable region, and the level of the cells' innate immune response to the first exogenous mRNA may be determined. The cells may then be contacted with a second composition containing a second amount of the first exogenous mRNA, the second amount being a lower amount of the first exogenous mRNA compared to the first amount. Alternatively, the second composition may contain a first amount of a second exogenous mRNA that is different from the first exogenous mRNA. The step of contacting the cells with the first and second compositions may be repeated one or more times. In addition, the efficiency of intracellular polypeptide production (e.g., translation) may optionally be determined, and the cells may be repeatedly re-contacted with the first and / or second compositions until a target protein production efficiency is achieved.

[0278] Methods for delivering therapeutic agents to cells and organs The present disclosure provides a method for delivering a therapeutic and / or prophylactic agent to a mammalian cell or organ. Delivering a therapeutic and / or prophylactic agent to a cell involves administering lipid nanoparticles (e.g., empty or loaded LNPs) containing the therapeutic and / or prophylactic agent to a subject, and administering the composition involves contacting the composition with the cell. For example, a protein, a cytotoxic agent, a radioactive ion, a chemotherapeutic agent, or a nucleic acid (such as RNA, e.g., mRNA) can be delivered to a cell or organ. When the therapeutic and / or prophylactic agent is an mRNA, contacting the cell with the nanoparticle composition can result in translation of the translatable mRNA within the cell to produce a polypeptide of interest. However, substantially non-translatable mRNA can also be delivered to a cell. Substantially non-translatable mRNA can be useful as a vaccine and / or can sequester the translational components of the cell to reduce expression of other species within the cell.

[0279] In some embodiments, lipid nanoparticles (e.g., empty or loaded LNPs) may target a particular type or class of cells (e.g., cells of a particular organ or system thereof). For example, lipid nanoparticles (e.g., empty or loaded LNPs) containing a therapeutic and / or prophylactic agent of interest may be specifically delivered to the liver, kidney, spleen, or lungs of a mammal. Specific delivery to a particular class of cells, organ, or system or group thereof means that a higher percentage of lipid nanoparticles (e.g., loaded LNPs) containing a therapeutic and / or prophylactic agent are delivered to the destination of interest (e.g., tissue) compared to other destinations. In some embodiments, specific delivery of loaded LNPs containing mRNA may result in a 2-fold, 5-fold, 10-fold, 15-fold, or greater than 20-fold increase in mRNA expression in cells of the target destination (e.g., tissue of interest such as liver) compared to cells of another destination (e.g., spleen). In some embodiments, the tissue of interest is selected from the group consisting of liver, kidney, lung, spleen, and tumor tissue (e.g., via intratumoral injection).

[0280] In some embodiments, specific delivery of mRNA contained in a disclosed loaded LNP (i.e., lipid nanoparticles formulated with a disclosed compound) may result in a 2-fold, 5-fold, 10-fold, 15-fold, or greater than 20-fold increase in mRNA expression compared to delivery of mRNA contained in an LNP formulated with another lipid (i.e., not including any of the lipids of formulas (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb)).

[0281] As another example of targeted or specific delivery, mRNA encoding a protein binding partner (e.g., an antibody or functional fragment thereof, a scaffolding protein, or a peptide) or a receptor on the cell surface can be included in the nanoparticle composition. The mRNA can additionally or alternatively be used to induce the synthesis and extracellular localization of lipids, carbohydrates, or other biological moieties. Alternatively, other therapeutic and / or prophylactic agents or elements (e.g., lipids or ligands) of the lipid nanoparticles (e.g., empty or loaded LNPs) can be selected based on their affinity for a particular receptor (e.g., low density lipoprotein receptor) so that the lipid nanoparticles (e.g., empty or loaded LNPs) can more easily interact with a target cell population that contains the receptor. For example, ligands may include, but are not limited to, members of specific binding pairs, antibodies, monoclonal antibodies, Fv fragments, single chain Fv (scFv) fragments, Fab' fragments, F(ab')2 fragments, single domain antibodies, camelized antibodies and fragments thereof, humanized antibodies and fragments thereof, and multivalent versions thereof; multivalent binding reagents including mono- or bispecific antibodies such as disulfide-stabilized Fv fragments, scFv tandems, diabodies, tribodies, or tetrabodies; as well as aptamers, receptors, and fusion proteins.

[0282] In some embodiments, the ligand may be a surface-bound antibody, which may allow tuning of cell targeting specificity. This is particularly useful, since highly specific antibodies may be raised against epitopes of interest at the desired targeting site. In some embodiments, multiple antibodies may be expressed on the surface of a cell, each with different specificity for a desired target. Such an approach may increase the affinity and specificity of the targeting interaction.

[0283] Ligands can be selected, for example, by one of ordinary skill in the biological arts based on the desired localization or function of a cell.

[0284] Target cells may include, but are not limited to, hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, lung cells, bone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiac myocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes, and tumor cells.

[0285] In some embodiments, lipid nanoparticles (e.g., empty or loaded LNPs) can target hepatocytes. Apolipoproteins such as apolipoprotein E (apoE) have been shown to associate with lipid nanoparticles (e.g., empty or loaded LNPs) containing neutral or nearly neutral lipids in the body, and are known to associate with receptors such as low-density lipoprotein receptors (LDLRs) found on the surface of hepatocytes. Thus, lipid nanoparticles (e.g., empty or loaded LNPs) containing lipid components with neutral or nearly neutral charges administered to a subject can acquire apoE in the subject's body, and then deliver therapeutic and / or prophylactic agents (e.g., RNA) to hepatocytes containing LDLR in a targeted manner.

[0286] Methods of Treating Diseases and Disorders The lipid nanoparticles (e.g., empty or loaded LNPs) may be useful for treating diseases, disorders, or conditions. In particular, such compositions may be useful for treating diseases, disorders, or conditions characterized by missing or abnormal protein or polypeptide activity. For example, lipid nanoparticles (e.g., empty or loaded LNPs) containing mRNA encoding a missing or abnormal polypeptide may be administered or delivered to cells. Subsequent translation of the mRNA may produce the polypeptide, thereby reducing or eliminating problems caused by the absence of the polypeptide or the abnormal activity it causes. Because translation may occur rapidly, the methods and compositions may be useful for treating acute diseases, disorders, or conditions, such as sepsis, stroke, and myocardial infarction. Therapeutic and / or prophylactic agents contained in the lipid nanoparticles (e.g., empty or loaded LNPs) may also be capable of altering the transcription rate of a given species, thereby affecting gene expression.

[0287] Diseases, disorders, and / or conditions characterized by dysfunctional or abnormal protein or polypeptide activity for which the compositions may be administered include, but are not limited to, rare diseases, infectious diseases (both as vaccines and therapeutics), cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardio- and renal vascular diseases, and metabolic diseases. Several diseases, disorders, and / or conditions may be characterized by a lack of protein activity (or a substantial decrease such that proper protein function does not occur). Such proteins may be absent or essentially non-functional. The present disclosure provides methods for treating such diseases, disorders and / or conditions in a subject by administering lipid nanoparticles (e.g., empty or loaded LNPs) comprising RNA and lipid components including lipids according to Formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya)(IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), phospholipids (optionally unsaturated), PEG-lipids, and structural lipids, where the RNA can be an mRNA encoding a polypeptide that antagonizes or overcomes aberrant protein activity present in the subject's cells.

[0288] The disclosure provides methods involving administering lipid nanoparticles (e.g., empty or loaded LNPs) containing one or more therapeutic and / or prophylactic agents, as well as pharmaceutical compositions comprising the same. The terms therapeutic and prophylactic agents may be used interchangeably herein with respect to features and embodiments of the present disclosure. Therapeutic compositions, or imaging, diagnostic, or prophylactic compositions thereof, may be administered to a subject using any reasonable amount and any route of administration effective to prevent, treat, diagnose, or image a disease, disorder, and / or condition, and / or any other purpose. The specific amount administered to a given subject may vary depending on the species, age, and general condition of the subject, the purpose of administration, the particular composition, the mode of administration, and the like. Compositions according to the present disclosure may be formulated in unit dosage form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present disclosure will be determined by the attending physician within the scope of sound medical judgment. The particular therapeutically effective, prophylactically effective, or otherwise appropriate (e.g., for imaging) dose level for any particular patient will depend upon a variety of factors, including the severity and identity of the disorder being treated (if any); the one or more therapeutic and / or prophylactic agents used; the particular composition used; the age, weight, general health, sex, and diet of the patient; the time of administration, route of administration, and excretion rate of the particular pharmaceutical composition used; the duration of treatment; drugs used in combination or concomitantly with the particular pharmaceutical composition used; and similar factors well known in the medical arts.

[0289] The loaded LNPs may be administered by any route. In some embodiments, compositions including prophylactic, diagnostic, or imaging compositions comprising one or more loaded LNPs described herein are administered by one or more of a variety of routes, including oral, intravenous, intramuscular, intraarterial, subcutaneous, transdermal or intradermal, interdermal, intraperitoneal, mucosal, nasal, intratumoral, intranasal; inhalation; as an oral spray and / or powder, nasal spray, and / or aerosol, and / or through a portal vein catheter. In some embodiments, the compositions may be administered intravenously, intramuscularly, intradermal, intraarterial, intratumoral, subcutaneous, or any other parenteral route of administration, or by inhalation. However, the present disclosure encompasses delivery or administration of the compositions described herein by any suitable route, taking into account possible advances in the science of drug delivery. In general, the most appropriate route of administration will depend on a variety of factors, including the nature of the loaded LNPs containing one or more therapeutic and / or prophylactic agents (e.g., their stability in various bodily environments, such as the bloodstream and gastrointestinal tract), the condition of the patient (e.g., whether the patient is able to tolerate a particular route of administration), and the like.

[0290] In certain embodiments, compositions according to the present disclosure provide a therapeutically effective amount of 5 mg / kg to about 10 mg / kg, about 0.0001 mg / kg to about 10 mg / kg, about 0.001 mg / kg to about 10 mg / kg, about 0.005 mg / kg to about 10 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.05 mg / kg to about 10 mg / kg, about 0.1 mg / kg to about 10 mg / kg, about 1 mg / kg to about 10 mg / kg, about 2 mg / kg to about 10 mg / kg, about 5 mg / kg to about 10 mg / kg, about 0.0001 mg / kg ~5mg / kg, approximately 0.001mg / kg~5mg / kg, approximately 0.005mg / kg~5mg / kg, approximately 0.01mg / kg~5mg / kg, approximately 0.05mg / kg~5mg / kg, approximately 0.1mg / kg~5mg / kg, approximately 1m g / kg~about 5mg / kg, about 2mg / kg~about 5mg / kg, about 0.0001mg / kg~about 2.5mg / kg, about 0.001mg / kg~about 2.5mg / kg, about 0.005mg / kg~about 2.5mg / kg, about 0.01mg / kg~about 2 .5mg / kg, about 0.05mg / kg to about 2.5mg / kg, about 0.1mg / kg to about 2.5mg / kg, about 1mg / kg to about 2.5mg / kg, about 2mg / kg to about 2.5mg / kg, about 0.0001mg / kg to about 1mg / kg, about 0 .001mg / kg~about 1mg / kg, about 0.005mg / kg~about 1mg / kg, about 0.01mg / kg~about 1mg / kg, about 0.05mg / kg~about 1mg / kg, about 0.1mg / kg~about 1mg / kg, about 0.0001mg / kg~about The therapeutic and / or prophylactic agent may be administered at a dosage level sufficient to deliver 0.25 mg / kg, about 0.001 mg / kg to about 0.25 mg / kg, about 0.005 mg / kg to about 0.25 mg / kg, about 0.01 mg / kg to about 0.25 mg / kg, about 0.05 mg / kg to about 0.25 mg / kg, or about 0.1 mg / kg to about 0.25 mg / kg of therapeutic and / or prophylactic agent (e.g., mRNA), with a dose of 1 mg / kg (mpk) providing 1 mg of therapeutic and / or prophylactic agent per kg of subject body weight. In some embodiments, a dose of about 0.001 mg / kg to about 10 mg / kg of loaded LNP may be administered. In other embodiments, a dose of about 0.005 mg / kg to about 2.5 mg / kg of therapeutic and / or prophylactic agent may be administered.In certain embodiments, a dose of about 0.1 mg / kg to about 1 mg / kg may be administered. In other embodiments, a dose of about 0.05 mg / kg to about 0.25 mg / kg may be administered. The dose may be administered one or more times per day in the same or different amounts to obtain a desired level of mRNA expression and / or therapeutic, diagnostic, prophylactic, or imaging effect. The desired dosage may be delivered, for example, three times per day, twice per day, once per day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage may be delivered using multiple administrations (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more administrations). In some embodiments, a single dose may be administered, for example, before or after a surgical procedure or in the case of an acute disease, disorder, or condition.

[0291] Lipid nanoparticles (e.g., empty or loaded LNPs) containing one or more therapeutic and / or prophylactic agents may be used in combination with one or more other therapeutic, prophylactic, diagnostic, or imaging agents. By "combined with," it is not intended to imply that the agents must be administered simultaneously and / or formulated together for delivery, although these delivery methods are within the scope of the present disclosure. For example, one or more lipid nanoparticles (e.g., empty or loaded LNPs) containing one or more different therapeutic and / or prophylactic agents may be administered in combination. The composition may be administered simultaneously with, prior to, or after one or more other desired therapeutic agents or medical procedures. Generally, each agent is administered at a dose and / or time schedule determined for that agent. In some embodiments, the present disclosure encompasses the delivery of the composition, or imaging, diagnostic, or prophylactic compositions thereof, in combination with agents that improve bioavailability, reduce and / or alter metabolism, inhibit excretion, and / or alter distribution in the body.

[0292] It will be further understood that therapeutic, prophylactic, diagnostic, or imaging active agents utilized in combination can be administered together in a single composition or can be administered separately in different compositions. In general, it is expected that agents utilized in combination will be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination may be lower than the levels utilized individually.

[0293] The particular combination of therapies (therapeutic agents or procedures) to use in a combination regimen will take into account the compatibility of the desired therapeutic agents and / or procedures with the desired therapeutic effect to be achieved. It will also be understood that the therapies used may achieve a desired effect for the same disorder (e.g., a composition useful for treating cancer may be administered simultaneously with a chemotherapeutic agent) or they may achieve a different effect (e.g., control of any adverse effects such as infusion-related reactions).

[0294] The lipid nanoparticles (e.g., empty or loaded LNPs) may be used in combination with a drug to increase the efficacy and / or therapeutic time frame of the composition. Such drugs may be, for example, anti-inflammatory compounds, steroids (e.g., corticosteroids), statins, estradiol, BTK inhibitors, S1P1 agonists, glucocorticoid receptor modulators (GRMs), or antihistamines. In some embodiments, the lipid nanoparticles (e.g., empty or loaded LNPs) may be used in combination with dexamethasone, methotrexate, acetaminophen, H1 receptor blockers, or H2 receptor blockers. In some embodiments, the methods of treating a subject in need of treatment for a disease or disorder or delivering therapeutic and / or prophylactic agents to a subject (e.g., a mammal) may involve pre-treating the subject with one or more drugs prior to administering the nanoparticle composition. For example, the subject may be pre-treated with a useful amount (e.g., 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any other useful amount) of dexamethasone, methotrexate, acetaminophen, an H1 receptor blocker, or an H2 receptor blocker. The pre-treatment may be administered 24 hours or less (e.g., 24 hours, 20 hours, 16 hours, 12 hours, 8 hours, 4 hours, 2 hours, 1 hour, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or 10 minutes) prior to administration of the lipid nanoparticles (e.g., empty or loaded LNPs), and may be administered once, twice, or more times, e.g., in increasing dosages.

[0295] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments in accordance with the present disclosure described herein. The scope of the present disclosure is not intended to be limited to the above detailed description, but is intended to be set forth in the appended claims.

[0296] In the claims, articles such as "a," "an," and "the" may mean one or more, unless indicated to the contrary or clear from the context. A claim or description containing "or" between one or more members of a group is deemed to be satisfied if one, more than one, or all of the members of the group are present in, employed in, or otherwise associated with a given product or process, unless indicated to the contrary or clear from the context. The disclosure includes embodiments in which exactly one member of a group is present in, employed in, or otherwise associated with a given product or process. The disclosure includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise associated with a given product or process. As used herein, phrases such as "one or more of A, B, or C," "one or more of A, B, or C," "one or more of A, B, and C," "one or more of A, B, and C," "selected from A, B, and C," "selected from the group consisting of A, B, and C," and the like are used synonymously and all refer to selection from the group consisting of A, B, and / or C, i.e., one or more A, one or more B, one or more C, or any combination thereof, unless otherwise specified.

[0297] It should also be noted that the term "comprising" is intended to be open-ended, permitting but not requiring the inclusion of additional elements or steps. Thus, when the term "comprising" is used herein, the terms "consisting essentially of" and "consisting of" are also included and disclosed. Throughout this specification, when a composition is described as having, including, or comprising specific components, it is contemplated that the composition also consists essentially of or consists of the recited components. Similarly, when a method or process is described as having, including, or comprising specific process steps, the process also consists essentially of or consists of the recited processing steps. Furthermore, it should be understood that the order or sequence of steps for performing a particular act is not important so long as the invention remains operable. Moreover, two or more steps or acts can be performed simultaneously.

[0298] Where ranges are given, the endpoints are included. Additionally, unless otherwise indicated or clear from the context and the understanding of one of ordinary skill in the art, values ​​expressed as ranges are to be understood as envisaging any particular value or subrange within the range set forth in different embodiments of the disclosure to one tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

[0299] The disclosed synthetic processes can tolerate a wide variety of functional groups, and thus variously substituted starting materials can be used. Although the processes generally provide the desired final compound at or near the completion of the entire process, in certain cases it may be desirable to further convert the compound to its pharma-ceutically acceptable salt.

[0300] The compounds of the present disclosure can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates by using standard synthetic methods and procedures that are known to those of skill in the art or will be apparent to those of skill in the art in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or standard textbooks in the field. Examples of such methods and procedures include, but are not limited to, any one or several sources, such as Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5, incorporated herein by reference. th edition, John Wiley & Sons: New York, 2001, Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) are useful and recognized reference texts of organic synthesis known to those skilled in the art. The following description of synthetic methods is designed to illustrate, but not limit, the general procedures for the preparation of the compounds of the present disclosure.

[0301] Compounds of the present disclosure having any of the formulas described herein can be prepared from commercially available starting materials or starting materials that can be prepared using literature procedures according to the procedures shown in Schemes 1, 2, and 3 below. 1 , R 2 , and R 3 etc. are as defined herein.) Those skilled in the art will note that the order of certain steps, such as the introduction and removal of protecting groups, may be varied in the reaction sequences and synthetic schemes described herein.

[0302] Those skilled in the art will recognize that certain groups may require protection from reaction conditions through the use of protecting groups. Protecting groups can also be used to modify similar functional groups within a molecule. Lists of protecting groups, as well as methods for introducing and removing these groups, can be found in Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons: New York, 1999.

[0303] Preferred protecting groups include, but are not limited to, the following: For the hydroxyl moiety, TBS, benzyl, THP, Ac; Carboxylic acids include benzyl esters, methyl esters, ethyl esters, and allyl esters; Amines include Fmoc, Cbz, BOC, DMB, Ac, Bn, Tr, Ts, trifluoroacetyl, phthalimide, benzylideneamine; For diols, Ac(x2)TBS(x2) or when combined with acetonide; For thiols, AC, Benzimidazoles include SEM, benzil, PMB, and DMB; For aldehydes, di-alkyl acetals such as dimethoxy acetal or diethyl acetyl.

[0304] In the reaction scheme described herein, multiple stereoisomers can be produced.When no specific stereoisomer is shown, it is understood to mean all possible stereoisomers that can be produced from the reaction.Those skilled in the art will recognize that the reaction can be optimized to give one isomer preferentially, or new schemes can be devised to produce a single isomer.When a mixture is produced, techniques such as preparative thin layer chromatography, preparative HPLC, preparative chiral HPLC, or preparative SFC can be used to separate isomers. [ka]

[0305] As shown in Scheme 1 above, 8-bromooctanoic acid is reacted with an alcohol a1 (e.g., heptadecan-9-ol) to give an ester b1 (e.g., heptadecan-9-yl 8-bromooctanoate). Step 1 can be carried out, for example, in the presence of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, N,N-diisopropylethylamine, and DMAP in an organic solvent (e.g., dichloromethane). Step 1 can be carried out at room temperature for 18 hours. Ester b1 is then reacted with 2-aminoethan-1-ol to give amine c1 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate). Step 2 can be carried out, for example, in ethanol at a temperature of about 60°C. Amine c1 is then reacted with a bromoalkyl R 1 -Br (e.g., 1-bromotetradecane) to give compound d1 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)(tetradecyl)amino)octanoate). Step 3 can be carried out in ethanol in the presence of N,N-diisopropylethylamine. [ka]

[0306] As shown in Scheme 2 above, acid a2 (x 3is an integer from 1 to 7, for example, 8-bromooctanoic acid) is reacted with alcohol b2 (for example, nonan-1-ol) to give ester c2 (for example, nonyl-8-bromooctanoate). Step 1 can be carried out, for example, in the presence of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, N,N-diisopropylethylamine, and DMAP in an organic solvent (for example, dichloromethane). Alcohol e2 (for example, heptadecan-9-ol) can be reacted with aldehyde d2 (for example, nonanol) via step 2 using a Grignard reagent R 3 -MgX (e.g., n-CH 17 MgBr). 8-Bromooctanoic acid can then be reacted with alcohol e2 (e.g., heptadecan-9-ol) to give ester f2 (e.g., heptadecan-9-yl 8-bromooctanoate). Step 3 can be carried out, for example, in the presence of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, N,N-diisopropylethylamine, and DMAP in an organic solvent (e.g., dichloromethane). Ester f2 can then be reacted with 2-aminoethan-1-ol to give amine g2 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate). Step 4 can be carried out in ethanol in the presence of i-Pr2EtN. Amine g2 is then reacted with ester c2 (e.g., nonyl-8-bromooctanoate) to give compound h2 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate). Step 5 can be carried out, for example, at elevated temperature (such as about 70-90° C., e.g., about 80° C.) in the presence of a base (such as an inorganic base (e.g., K2CO3) or a non-nucleophilic organic base (e.g., i-Pr2EtN)), and a catalyst (e.g., an iodide such as KI or NaI) in an organic solvent (e.g., a mixture of CPME and MeCN). [ka]

[0307] As shown in Scheme 3 above, a haloalkanol (x 3 is an integer from 1 to 12, for example, 6-bromohexan-1-ol) is used as the starting material a3 (x 2 is an integer from 1 to 6, for example, 4-(hexyloxy)-4-oxobutanoic acid) to obtain a halogenated diester b3 (for example, 6-bromohexylhexyl succinate). Compound a3 can be obtained by reacting an alcohol (for example, hexane-1-ol) with an acid anhydride (for example, succinic anhydride, dihydro-2H-pyran-2,6(3H)-dione, 3-(tert-butoxy)-3-oxopropanoic acid, 4-(tert-butoxy)-3-methyl-4-oxobutanoic acid, or 4-(tert-butoxy)-2-methyl-4-oxobutanoic acid). Step 1 can be carried out, for example, in the presence of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, N,N-diisopropylethylamine, and DMAP in an organic solvent (for example, dichloromethane). Next, the halogenated diester b3 is reacted with the amine c3 (x 4 is an integer between 5 and 13, and x 5 is an integer from 1 to 5, for example, heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate) to give product d3. Step 2 can be carried out at elevated temperature (e.g., about 90° C.) in the presence of a base (an inorganic base (e.g., K2CO3), and a catalyst (e.g., an iodide such as KI), and an ether solvent (e.g., cyclopentyl methyl ether), and in an organic solvent (e.g., a mixture of CPME and MeCN).

[0308] Those skilled in the art will recognize that the order of certain steps in the above schemes may be interchangeable.

[0309] In certain aspects, the disclosure also includes methods of synthesizing compounds of any of formulas (1-1), (2-1), (Ia), (A), (B), (A-1), (A-2), (A-3), (IA), (IB), (B-1), (B-2), (B-3), (Aa), (A-a1), (A-a2), (A-a3), (Ab), (A-b1), (A-b2), (A-b3), (Ac), and (Bc), as well as intermediate(s) for synthesizing the compounds.

[0310] In some embodiments, the method of synthesizing the disclosed compounds comprises the step of synthesizing a compound of formula (X2): [ka] Compound R 1 -Br to obtain the disclosed compounds, wherein each variable is as defined herein. For example, m is 5, 6, 7, 8, or 9, preferably 5, 7, or 9. For example, R 5 , R 6 , and R 7 Each of is H. For example, M is -C(O)O- or -OC(O)-. For example, R 4 is unsubstituted C 1-3 Alkyl or -(CH2) n Q, n is 2, 3, or 4, and Q is OH, -NHC(S)N(R), -NHC(O)N(R), -N(R)C(O)R, or -N(R)S(O)R. For example, a compound of formula (X2) and R 1 The reaction with -Br is carried out in the presence of a base, such as an inorganic base (e.g., K2CO3) or a non-nucleophilic organic base (e.g., i-Pr2EtN). For example, the reaction is carried out in the presence of an inorganic base (e.g., K2CO3) and a catalyst (e.g., an iodide such as KI or NaI). For example, the reaction is carried out at elevated temperatures, such as about 50-100°C, 70-90°C, or about 80°C).

[0311] The method also includes the step of: [ka] Compound R 4 with NH2 to obtain a compound of formula (X2), wherein each variable is as defined herein.

[0312] In some embodiments, the intermediate(s) have the formulas (X1) and (X2): [ka] and wherein each variable is as defined herein. For example, intermediates include heptadecan-9-yl 8-bromooctanoate, and heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate, and structural forms (e.g., crystalline forms) thereof.

[0313] In addition, it is to be understood that any particular embodiment of the present disclosure that falls within the prior art may be expressly excluded from any one or more of the claims. Such embodiments may be excluded even if the exclusion is not expressly set forth herein because they are deemed to be known to those of ordinary skill in the art.

[0314] All cited documents, e.g., references, publications, databases, database entries, and arts cited herein, are incorporated by reference into this application, even if not expressly stated in the cited documents. In the event of a conflict between the statements of the cited documents and this application, the statements of this application shall take precedence. EXAMPLES

[0315] Example 1: Synthesis of Compounds in Table 1 A. General considerations All solvents and reagents used were commercially available and used as received unless otherwise stated. 1 H NMR spectra were recorded in CDCl3 using a Bruker Ultrashield 300 MHz instrument at 300 K. Chemical shifts are 1Reported as parts per million (ppm) relative to TMS (0.00) in H. Silica gel chromatography was performed on an ISCO CombiFlash Rf+Lumen Instruments using ISCO RediSep Rf Gold Flash Cartridges (particle size: 20-40 microns). Reverse phase chromatography was performed on an ISCO CombiFlash Rf+Lumen Instruments using RediSep Rf Gold C18 High Performance columns. All final compounds were determined to be >85% pure via analysis by reverse phase UPLC-MS (retention time, RT, in minutes) using a Waters Acquity UPLC instrument equipped with a DAD and ELSD, and a ZORBAX Rapid Resolution High Definition (RRHD) SB-C18 LC column, 2.1 mm, 50 mm, 1.8 μm, and a gradient of 65-100% acetonitrile in water with 0.1% TFA over 5 min at 1.2 mL / min. The injection volume was 5 μL and the column temperature was 80° C. Detection was based on electrospray ionization (ESI) in positive mode using a Waters SQD mass spectrometer (Milford, MA, USA) and an evaporative light scattering detector.

[0316] The procedures described below are useful for the synthesis of the compounds in Table 1.

[0317] The following abbreviations are used herein: THF: tetrahydrofuran MeCN: Acetonitrile LAH: Lithium aluminum hydride DCM: dichloromethane DMAP: 4-dimethylaminopyridine LDA: Lithium diisopropylamide rt: room temperature DME: 1,2-dimethoxyethane n-BuLi: n-butyl lithium CPME: Cyclopentyl methyl ether i-Pr2EtN: N,N-diisopropylethylamine AA. Compound 6: Heptadecan-9-yl 8-((2-hydroxyethyl)(6-(((nonyloxy)carbonyl)oxy)hexyl)amino)octanoate [ka]

[0318] UPLC / ELSD: RT=3.12min, MS(ES):m / z(MH + ) C 43 H 85 713.191 for NO6 1 H NMR(300MHz,CDCl3)δ:ppm4.89(p,1H);4.17(t,4H);3.56(bm,2H);2.75-2.36(m,6H);2.30(t,2H);1.77-1.20(m,61H);0.90(m,9H). AB. Compound 25: Heptadecane-9-yl 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(6-(((nonyloxy)carbonyl)oxy)hexyl)amino)octanoate 6-Bromohexyl(4-nitrophenyl)carbonate [ka]

[0319] To a solution of 6-bromo-1-hexanol (7 g, 38.658 mmol) in DCM (100 mL) in a round bottom flask charged with a magnetic stir bar at room temperature, 4-nitrophenyl chloroformate (9.35 g, 46.39 mmol) was added in one portion. The reaction was kept under N2 and pyridine (4.69 mL, 57.988 mmol) was added dropwise over 10 min, then stirring was continued at room temperature for 16 h. The reaction was diluted with water and DCM. The organic layer was separated and the aqueous layer was washed with DCM. The combined organics were washed with brine, dried over Na2SO4, and evaporated under vacuum. The residue was purified by silica gel chromatography (0-100% ethyl acetate in hexanes) to give 6-bromohexyl(4-nitrophenyl)carbonate (10.3 g, 38.7 mmol, 77%). 1 H NMR(300MHz,CDCl3)δ:ppm8.29(d,2H);7.43(d,2H);4.33(t,2H);3.43(t,2H);2.02-1.69(m,4H);1.53(m,4H). 6-Bromohexylnonyl carbonate [ka]

[0320] To a solution of 6-bromohexyl 4-nitrophenyl carbonate (5 g, 14.443 mmol) in DCM (15 mL) in a round bottom flask filled with a magnetic stir bar at room temperature under N2, nonan-1-ol (8.334 g, 57.774 mmol) was added dropwise. The reaction was kept under N2 and pyridine (1.46 mL, 18.054 mmol) was added dropwise over 10 min, followed by 4-dimethylaminopyridine (0.353 g, 2.889 mmol) in one portion. The reaction was stirred at room temperature for 16 h and then diluted with water and DCM. The organic layer was separated and the aqueous layer was washed with DCM. The combined organics were washed with brine, dried over Na2SO4 and evaporated in vacuo. The residue was purified by silica gel chromatography (0-100% ethyl acetate in hexanes) to give 6-bromohexylnonyl carbonate (1.3 g, 3.7 mmol, 26%). 1H NMR(300MHz,CDCl3)δ:ppm4.15(m,4H);3.43(t,2H);1.89(m,2H);1.71(m,4H);1.58-1.18(m,16H);0.90(m,3H). Heptadecan-9-yl 8-((3-((tert-butoxycarbonyl)amino)propyl)amino)octanoate [ka]

[0321] A solution of heptadecan-9-yl 8-bromooctanoate (69.2 g, 0.15 mol) and tert-butyl (3-aminopropyl)carbamate (130.6 g, 0.75 mol) in 500 mL of ethanol was heated to 65° C. overnight. The reaction mixture was concentrated and the crude was purified by flash column chromatography (SiO2: methanol / dichloromethane 0-20%) to give heptadecan-9-yl 8-((3-((tert-butoxycarbonyl)amino)propyl)amino)octanoate (62 g, 74%) as a pale yellow oil. MS (CI): m / z (MH + ) C 33 H 66 555.5 for N2O4 1 H NMR(300MHz,CDCl3):δppm5.15(bs,1H);4.85(quartet,1H,J=6.0Hz);3.17(m,2H);2.65(t,2H,J=6.6Hz);2.56(t,2H,J =6.8Hz);2.26(t,2H,J=7.6Hz);1.68-1.56(m,6H);1.46(m,5H);1.43(s,9H);1.24(m,30H);0.86(t,6H,J=6.6Hz). Heptadecan-9-yl 8-((3-((tert-butoxycarbonyl)amino)propyl)(6-(((nonyloxy)carbonyl)oxy)hexyl)amino)octanoate [ka]

[0322] To a solution of 6-bromohexylnonyl carbonate (0.633 g, 1.802 mmol) and heptadecan-9-yl 8-((3-((tert-butoxycarbonyl)amino)propyl)amino)octanoate (1 g, 1.802 mmol) in 40 mL of a 1:1 mixture of cyclopentyl methyl ether and acetonitrile was added potassium carbonate (0.996 g, 7.208 mmol) and potassium iodide (0.329 g, 1.982 mmol). The reaction was heated to 77° C. and stirred for 16 h. The reaction was cooled, filtered, and the volatiles were evaporated under vacuum. The residue was purified by silica gel chromatography (0-100% (20% MeOH, 80% DCM, 1% NH4OH) in DCM) to give heptadecan-9-yl 8-((3-((-butoxycarbonyl)amino)propyl)(6-(((nonyloxy)carbonyl)oxy)hexyl)amino)octanoate (0.32 g, 0.39 mmol, 22%). UPLC / ELSD: RT=3.02 min, MS(ES): m / z (MH + ) C 49 H 96 826.300 for N2O7 1 H NMR(300MHz,CDCl3)δ:ppm5.65(bm,1H);4.88(m,1H);4.14(t,4H);3.19(bm,2H);3.00(bm,1H);2.52-2.22(m,7H);1.76-1.17(m,71H);0.90(m,9H). Heptadecane-9-yl 8-((3-aminopropyl)(6-(((nonyloxy)carbonyl)oxy)hexyl)amino)octanoate [ka]

[0323] To a solution of heptadecan-9-yl 8-((3-((tert-butoxycarbonyl)amino)propyl)(6-(((nonyloxy)carbonyl)oxy)hexyl)amino)octanoate (320 mg, 0.39 mmol) in 3 mL of DCM was added trifluoroacetic acid (0.6 mL, 7.8 mmol) and the solution was stirred at room temperature for 16 h. The reaction was quenched by adding saturated sodium bicarbonate solution at 0° C. The organic layer was washed with saturated sodium bicarbonate solution and brine. After drying over anhydrous sodium sulfate, the solvent was removed under vacuum to give heptadecan-9-yl 8-((3-aminopropyl)(6-(((nonyloxy)carbonyl)oxy)hexyl)amino)octanoate (283 mg, quantitative). UPLC / ELSD: RT=2.39 min, MS(ES): m / z(MH + ) C 44 H 88 726.142 for N2O5 1 H NMR(300MHz,CDCl3)δ:ppm4.87(m,1H);4.14(m,4H);3.21-2.97(m,4H);2.78(m,4H);2.30(m,2H);2.04(m,2H);1.80-1.17(m,60H);0.90(m,9H). 3-Methoxy-4-(methylamino)cyclobutene-1,2-dione [ka]

[0324] To a solution of 3,4-dimethoxy-3-cyclobutene-1,2-dione (1 g, 7 mmol) in 100 mL of diethyl ether was added a 2 M solution of methylamine in THF (3.8 mL, 7.6 mmol) and the ppt formed almost immediately. The mixture was stirred at room temperature for 24 hours, then filtered, the filtered solid washed with diethyl ether and air dried. The filtered solid was dissolved in hot EtOAc, filtered, the filtrate allowed to cool to room temperature and then cooled to 0° C. to give the ppt, which was isolated by filtration, washed with cold EtOAc, air dried and then dried under vacuum to give 3-methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione (0.70 g, 5 mmol, 73%) as a white solid. 1 H NMR(300MHz,DMSO-d6)δ:ppm8.50(br.d,1H,J=69Hz);4.27(s,3H);3.02(sdd,3H,J=42Hz,4.5Hz). Heptadecane-9-yl 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(6-(((nonyloxy)carbonyl)oxy)hexyl)amino)octanoate [ka]

[0325] To a solution of heptadecan-9-yl 8-((3-aminopropyl)(6-(((nonyloxy)carbonyl)oxy)hexyl)amino)octanoate (0.2 g, 0.28 mmol) in THF (2 mL) and water (0.4 mL) was added 3-methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione (0.06 g, 0.41 mmol) and the reaction was heated to 67° C. and stirred for 20 h. The reaction was cooled to room temperature during which time the clear solution became a cloudy mixture. Anhydrous MgSO4 was added, the reaction was filtered, and the filtrate was concentrated. The residue was purified by silica gel chromatography (0-100% (20% MeOH, 80% DCM, 1% NH4OH) in DCM) to give heptadecan-9-yl 8-((3-((2-methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(6-(((nonyloxy)carbonyl)oxy)hexyl)amino)octanoate (120 mg, 0.14 mmol, 50%). UPLC / ELSD: RT=2.81 min, MS(ES): m / z (MH + ) C 49 H 91 835.058 for N3O7 1 H NMR(300MHz,CDCl3)δ:ppm4.88(p,1H);4.14(m,4H);3.74(m,2H);3.40-2.90(m,9H);2.31(m,2H);2.12(m,2H);1.80-1.20(m,62H);0.90(m,9H). AC. Compound 64: Heptadecane-9-yl 8-((2-hydroxyethyl)(6-((((3-pentyloctyl)oxy)carbonyl)oxy)hexyl)amino)octanoate [ka]

[0326] UPLC / ELSD: RT=3.04min, MS(ES):m / z(MH + ) C 47 H 93 769.313 for NO6 1H NMR(300MHz,CDCl3)δ:ppm4.89(p,1H);4.14(m,4H);3.54(bm,2H);2.66-2.37(m,6H);2.30(m,2H);1.77-1.17(m,66H);0.91(m,12H). AD. Compound 65: Heptadecane-9-yl 8-((6-((((3-hexylnonyl)oxy)carbonyl)oxy)hexyl)(3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)amino)octanoate Ethyl 3-hexylnon-2-enoate [ka]

[0327] To a suspension of sodium hydride (4.697 g, 117.4 mmol) in THF (294 mL) was added triethyl phosphonoacetate (26.33 g, 117.4 mmol) dropwise over 20 min and the mixture was stirred at room temperature until gas evolution ceased (approximately 30 min). The reaction mixture was cooled to 0° C. and 7-tridecanone (10 g, 58.7 mmol) was added. The reaction was allowed to warm gradually to room temperature and then heated to reflux and stirred overnight. The reaction was quenched with saturated aqueous sodium bicarbonate. The aqueous phase was extracted with diethyl ether and the organic extracts were washed with brine, dried over MgSO4, and concentrated. The crude material was purified by silica gel chromatography (0-20% EtOAc:hexanes) to give ethyl 3-hexylnon-2-enoate (6.7 g, 27.9 mmol, 47.5%) as a clear oil. 1 H NMR(300MHz,CDCl3)δ:ppm5.63(s,1H);4.15(q,2H);2.61(t,2H);2.15(t,2H);1.53-1.20(m,19H);0.91(m,6H). Ethyl 3-hexylnonanoate [ka]

[0328] To a flask containing a slurry of Pearlmans catalyst (0.73 g, 5.2 mmol) in ethanol (20 mL) under N2 was added a solution of ethyl 3-hexylnon-2-enoate (6.975 g, 25.9 mmol) in ethanol (5 mL). The reaction was stirred under H2 (balloon) for 16 h. The reaction was filtered through a plug of Celite and the filtrate was evaporated under vacuum to give ethyl 3-hexylnonanoate (6.7 g, 24.7 mmol, 95%). The residue was carried on to the next step without further purification. 1 H NMR(300MHz,CDCl3)δ:ppm4.16(q,2H);2.23(d,2H);1.86(bs,1H);1.28(m,23H);0.90(m,6H). 3-Hexylnonan-1-ol [ka]

[0329] To a solution of lithium aluminum hydride in THF (49.5 mL of a 1 M solution in THF, 49.5 mmol) was added a solution of ethyl 3-hexylnonanoate (6.7 g, 24.7 mmol) in THF (20 mL). The reaction was stirred at room temperature for 16 h. The reaction was quenched with a saturated solution of sodium sulfate decahydrate. The white solid was removed by filtration through a plug of Celite, and the filtrate was evaporated under vacuum. The residue was purified by flash chromatography (ISCO) with 0-100% ethyl acetate in hexanes to give 3-hexylnonan-1-ol (5.62 g, 24.6 mmol, 99%). 1 H NMR(300MHz,CDCl3)δ:ppm3.69(t,2H);1.61-1.19(m,24H);0.91(m,6H). Heptadecane-9-yl 8-((6-((((3-hexylnonyl)oxy)carbonyl)oxy)hexyl)(3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)amino)octanoate [ka]

[0330] Compound 65 was prepared similarly to compound 25, using 3-hexylnonan-1-ol instead of nonan-1-ol. UPLC / ELSD: RT=3.13 min, MS(ES): m / z(MH + ) C 55 H 103 919.429 for N3O7 1 H NMR(300MHz,CDCl3)δ:ppm4.87(p,1H);4.17(m,4H);3.68(bm,2H);3.30(m,3H);2.65-2.41(m,6H);2.31(m,2H);1.87-1.19(m,73H);0.90(m,12H). AE. Compound 66: Heptadecane-9-yl 8-((6-((((3-hexylnonyl)oxy)carbonyl)oxy)hexyl)(2-hydroxyethyl)amino)octanoate [ka]

[0331] UPLC / ELSD: RT=3.16 min, MS(ES):m / z(MH + ) C 49 H 97 797.683 for NO6 1 H NMR(300MHz,CDCl3)δ:ppm4.89(p,1H);4.14(m,4H);3.54(bm,2H);2.68-2.38(m,6H);2.30(m,2H);1.77-1.17(m,70H),0.90(m,12H). AF. Compound 67: Heptadecane-9-yl 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(6-((((3-pentyloctyl)oxy)carbonyl)oxy)hexyl))amino)octanoate [ka]

[0332] Compound 67 was prepared similarly to compound 65 using 6-undecanone instead of 7-tridecanone. UPLC / ELSD: RT=3.04 min, MS(ES): m / z(MH + ) C 53 H 99 891.552 for N3O7 1 H NMR(300MHz,CDCl3)δ:ppm4.87(p,1H);4.17(m,4H);3.67(bm,2H);3.28(m,3H);2.68-2.38(m,6H);2.31(m,2H);1.86-1.18(m,69H);0.90(m,12H).

[0333] Example 2: Expression of hEPO in mice and residual lipid levels in the liver induced by sample formulations To assess the efficacy and metabolic stability of the disclosed lipid expression, hepatocyte protein expression (hEPO) was measured following administration of the disclosed nanoparticles (eg, loaded LNPs) to mice.

[0334] Lipid nanoparticles (LNPs) containing DSPC as the phospholipid, cholesterol as the structural lipid, PEG-1 as the PEG lipid, a compound according to formula (A), (A1), (A2), (A3), (B), (I), (I'), (IX), (IY), (I-Ya) (IA), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), (IIa), or (IIb), and mRNA encoding hEPO were administered intravenously to CD-1 mice. The concentration of hEPO in serum was tested 6 hours after injection. The particles tested had a PDI of about 0.1-0.4, an encapsulation efficiency of about 82-99%, and a particle diameter of about 56-145 nm. All tested LNPs containing various amounts of lipid demonstrated effective delivery of mRNA to hepatocytes remaining in the liver of mice after 24 hours.

[0335] Table 2. hEPO expression and residual lipid levels in the liver in mice induced by administration of LNPs containing the disclosed lipids. [Table 2]

[0336] Enumeration of embodiments Embodiment 1. Formula (I1): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1 But, C 5-30 Alkyl, C 5-20 alkenyl, -R*YR*", -YR*", and -R"M'R'; R 2 and R 3 However, independently, H, C 1-14 Alkyl, C 2-14 alkenyl, -R*YR*", -YR*", and -R*OR*", or R 2 and R 3 together with the atoms to which they are attached form a heterocyclic or carbocyclic ring, R 4 But hydrogen, C 3-6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 12 )2(CH2) n-o Q, -CHQR, -CQ(R)2, -C(O)NQR, and unsubstituted C 1-6 alkyl, and Q is a carbocycle, a heterocycle, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -N(R)R 8 , -N(R)S(O)2R 8 , -O(CH2) n OR, -N(R)C(=NR 9)N(R)2, -N(R)C(=CHR 9 )N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR 9 )N(R)2, -N(OR)C(=CHR 9 )N(R)2, -C(=NR 9 )N(R)2, -C(=NR 9 )R, -C(O)N(R)OR, -(CH2) n N(R)2, -C(R)N(R)2C(O)OR, NC(R)=R 11 , N(C=NR 15 )R 11 , NRC(C(O)NR 14 R 14 ')2, -NRC(O)(CH2) p C(O)NR 14 R 14 ', and [ka] A is selected from C 6-10 is an aryl or heterocyclic ring; each o is independently selected from 1, 2, 3, and 4; p is 0, 1, 2, 3, or 4; q is 1, 2, 3, or 4; and each n is independently selected from 1, 2, 3, 4, and 5; or R 4 but, [ka] and X a and X b are each independently O or S; R 10is H, halo, -OH, R, -N(R)2, -CN, -N3, -C(O)OH, -C(O)OR, -OC(O)R, -OR, -SR, -S(O)R, -S(O)OR, -S(O)2OR, -NO2, -S(O)2N(R)2, -N(R)S(O)2R, -NH(CH2) t1 N(R)2, -NH(CH2) p1 O(CH2) q1 N(R)2, -NH(CH2) s1 OR, -N((CH2) s1 OR)2, -N(R)-carbocycle, -N(R)-heterocycle, -N(R)-aryl, -N(R)-heteroaryl, -N(R)(CH2) t1 -carbocycle, -N(R)(CH2) t1 -Heterocycle, -N(R)(CH2) t1 -Aryl, -N(R)(CH2) t1 - selected from the group consisting of heteroaryl, carbocycle, heterocycle, aryl, and heteroaryl; n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; r is 0 or 1; t 1 is selected from 1, 2, 3, 4, and 5; p 1 is selected from 1, 2, 3, 4, and 5; q 1 is selected from 1, 2, 3, 4, and 5; s 1 is selected from 1, 2, 3, 4, and 5; Each R 5 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R 6 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; M is -OC(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NRM C(O)NR M -,-ON=C(R M )-, SO-, -OS-, -S(R M )2O-, -OS(R M )2-, -S(O)O-, -OS(O)-, M" is a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; M' is -OC(O)O-, -C(O)O-, -OC(O)-, -OC(O)-M”-C(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -C(O)N(R M )-, -N(R M )C(O)-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR M )O-, -S(O)2-, -SS-, -SO-, -OS-, S(R M )2O-, -OS(R M )2-, -S(O)O-, -OS(O)-, an aryl group, and a heteroaryl group; M" is selected from a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; R 7 But, C 1-3 Alkyl, C 2-3 alkenyl, and H; R 8 But, C 3-6 selected from the group consisting of carbocycles and heterocycles; R 9H, CN, NO2, C 1-6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2-6 Alkenyl, C 3-6 selected from the group consisting of carbocycles and heterocycles; R 11 But, C 3-6 selected from the group consisting of carbocyclic and heterocyclic rings; 3-6 The carbocycle and heterocycle each optionally contain one or more R 13 is replaced by R 12 But H, OH, C 1-3 Alkyl, and C 2-3 alkenyl, Each R 13 OH, oxo, halo, C 1-6 Alkyl, C 1-6 Alkoxyl, C 2-6 Alkenyl, C 1-6 Alkylamino, di-(C 1-6 alkyl)amino, amino, amido, cyano, and nitro; Each R 14 However, independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, Each R 14 ' but independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, R 15 However, independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, Each R is independently C 1-6 Alkyl, C 1-3 Alkyl-aryl, C 2-3 alkenyl, and H; R N But H or C 1-3 is alkyl, Each R' is independently C 1-18 Alkyl, C 2-18Alkenyl, -R*YR*", -YR*", (CH2) q OR*, and H; each q is independently selected from 1, 2, and 3; Each R M However, independently, H, C 1-6 Alkyl, and C 2-6 alkenyl, Each R” is independently 3-15 Alkyl and C 3-15 alkenyl, Each R*” is C 1-15 Alkyl, and C 2-15 alkenyl, Each R* is independently 1-12 Alkyl and C 2-12 alkenyl, Each R** is independently H, OH, C 1-12 Alkyl, C 2-12 Alkenyl, (CH2) q OR*, and (CH2) q OH; Each Y is independently 3-6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; Compound (I1) of formula (I1), or an N-oxide thereof, or a salt or isomer thereof, wherein m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0337] Embodiment 2. Formula (I'1): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1 But, C 5-30 Alkyl, C 5-20 alkenyl, -R*YR*", -YR*", and -R"M'R'; R 2 and R 3 However, independently, H, C 1-14 Alkyl, C 2-14 alkenyl, -R*YR*", -YR*", and -R*OR*", or R 2 and R 3 together with the atoms to which they are attached form a heterocyclic or carbocyclic ring, R 4 But hydrogen, C 3-6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 12 )2(CH2) n-o Q, -CHQR, -CQ(R)2, -C(O)NQR, and unsubstituted C 1-6 alkyl, and Q is a carbocycle, a heterocycle, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -N(R)R 8 , -N(R)S(O)2R 8 , -O(CH2) n OR, -N(R)C(=NR 9 )N(R)2, -N(R)C(=CHR 9 )N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR 9 )N(R)2, -N(OR)C(=CHR 9 )N(R)2, -C(=NR 9 )N(R)2, -C(=NR 9 )R, -C(O)N(R)OR, -(CH2) n N(R)2, -C(R)N(R)2C(O)OR, NC(R)=R 11 , N(C=NR 15 )R 11 , NRC(C(O)NR14 R 14 ')2, -NRC(O)(CH2) p C(O)NR 14 R 14 ', and [ka] A is selected from C 6-10 is an aryl or heterocyclic ring; each o is independently selected from 1, 2, 3, and 4; p is 0, 1, 2, 3, or 4; q is 1, 2, 3, or 4; and each n is independently selected from 1, 2, 3, 4, and 5; or R 4 but, [ka] and X a and X b are each independently O or S; R 10 is H, halo, -OH, R, -N(R)2, -CN, -N3, -C(O)OH, -C(O)OR, -OC(O)R, -OR, -SR, -S(O)R, -S(O)OR, -S(O)2OR, -NO2, -S(O)2N(R)2, -N(R)S(O)2R, -NH(CH2) t1 N(R)2, -NH(CH2) p1 O(CH2) q1 N(R)2, -NH(CH2) s1 OR, -N((CH2) s1 OR)2, -N(R)-carbocycle, -N(R)-heterocycle, -N(R)-aryl, -N(R)-heteroaryl, -N(R)(CH2) t1 -carbocycle, -N(R)(CH2) t1 -Heterocycle, -N(R)(CH2) t1 -Aryl, -N(R)(CH2) t1 - selected from the group consisting of heteroaryl, carbocycle, heterocycle, aryl, and heteroaryl; n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; r is 0 or 1; t 1 is selected from 1, 2, 3, 4, and 5; p 1 is selected from 1, 2, 3, 4, and 5; q 1 is selected from 1, 2, 3, 4, and 5; s 1 is selected from 1, 2, 3, 4, and 5; Each R 5 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R 6 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; M is -OC(O)O-, -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -C(O)N(R M )-, -N(R M )C(O)-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR M )O-, -S(O)2-, -SS-, -SO-, -OS-, S(R M )2O-, -OS(R M )2-, -S(O)O-, -OS(O)-, an aryl group, and a heteroaryl group; M" is selected from a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; M' is -OC(O)O-, -OC(O)-NR M-C(O)O-, -OM''-O-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, SO-, -OS-, -S(R M )2O-, -OS(R M )2-, -S(O)O-, -OS(O)-, M" is a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; R 7 But, C 1-3 Alkyl, C 2-3 alkenyl, and H; R 8 is C 3-6 selected from the group consisting of carbocycles and heterocycles; R 9 H, CN, NO2, C 1-6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2-6 Alkenyl, C 3-6 selected from the group consisting of carbocycles and heterocycles; R 11 But, C 3-6 selected from the group consisting of carbocyclic and heterocyclic rings; 3-6 The carbocycle and heterocycle each optionally contain one or more R 13 is replaced by R 12 But H, OH, C 1-3 Alkyl, and C 2-3 alkenyl, Each R 13 OH, oxo, halo, C 1-6 Alkyl, C 1-6 Alkoxyl, C 2-6 Alkenyl, C 1-6 Alkylamino, di-(C 1-6 alkyl)amino, amino, amido, cyano, and nitro; Each R 14 However, independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, Each R 14 ' but independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, R 15 However, independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, Each R is independently C 1-6 Alkyl, C 1-3 Alkyl-aryl, C 2-3 alkenyl, and H; R N But H or C 1-3 is alkyl, Each R' is independently C 1-18 Alkyl, C 2-18 Alkenyl, -R*YR*", -YR*", (CH2) q OR*, and H; each q is independently selected from 1, 2, and 3; Each R M However, independently, H, C 1-6 Alkyl, and C 2-6 alkenyl, Each R” is independently 3-15 Alkyl and C 3-15 alkenyl, Each R*” is C 1-15 Alkyl, and C 2-15 alkenyl, Each R* is independently 1-12 Alkyl and C 2-12 alkenyl, Each R** is independently H, OH, C 1-12 Alkyl, C 2-12 Alkenyl, (CH2) q OR*, and (CH2) qOH; Each Y is independently C 3-6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; A compound of formula (I'1), or an N-oxide thereof, or a salt or isomer thereof, wherein m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0338] Embodiment 3. Formula (IX1): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1 But, C 5-30 Alkyl, C 5-20 alkenyl, -R*YR*", -YR*", and -R"M'R'; R 2 and R 3 However, independently, H, C 1-14 Alkyl, C 2-14 alkenyl, -R*YR*", -YR*", and -R*OR*", or R 2 and R 3 together with the atoms to which they are attached form a heterocyclic or carbocyclic ring, R 4 But hydrogen, C 3-6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 12 )2(CH2) n-o Q, -CHQR, -CQ(R)2, -C(O)NQR, and unsubstituted C 1-6 alkyl, and Q is a carbocycle, a heterocycle, -OR, -O(CH2) nN(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -N(R)R 8 , -N(R)S(O)2R 8 , -O(CH2) n OR, -N(R)C(=NR 9 )N(R)2, -N(R)C(=CHR 9 )N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR 9 )N(R)2, -N(OR)C(=CHR 9 )N(R)2, -C(=NR 9 )N(R)2, -C(=NR 9 )R, -C(O)N(R)OR, -(CH2) n N(R)2, -C(R)N(R)2C(O)OR, NC(R)=R 11 , N(C=NR 15 )R 11 , NRC(C(O)NR 14 R 14 ')2, -NRC(O)(CH2) p C(O)NR 14 R 14 ', and [ka] A is selected from C 6-10 is an aryl or heterocyclic ring; each o is independently selected from 1, 2, 3, and 4; p is 0, 1, 2, 3, or 4; q is 1, 2, 3, or 4; and each n is independently selected from 1, 2, 3, 4, and 5; or R 4 but, [ka] and X a and X b are each independently O or S; R 10 is H, halo, -OH, R, -N(R)2, -CN, -N3, -C(O)OH, -C(O)OR, -OC(O)R, -OR, -SR, -S(O)R, -S(O)OR, -S(O)2OR, -NO2, -S(O)2N(R)2, -N(R)S(O)2R, -NH(CH2) t1 N(R)2, -NH(CH2) p1 O(CH2) q1 N(R)2, -NH(CH2) s1 OR, -N((CH2) s1 OR)2, -N(R)-carbocycle, -N(R)-heterocycle, -N(R)-aryl, -N(R)-heteroaryl, -N(R)(CH2) t1 -carbocycle, -N(R)(CH2) t1 -Heterocycle, -N(R)(CH2) t1 -Aryl, -N(R)(CH2) t1 - selected from the group consisting of heteroaryl, carbocycle, heterocycle, aryl, and heteroaryl; n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; r is 0 or 1; t 1 is selected from 1, 2, 3, 4, and 5; p 1 is selected from 1, 2, 3, 4, and 5; q 1 is selected from 1, 2, 3, 4, and 5; s 1 is selected from 1, 2, 3, 4, and 5; Each R 5 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R 6 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; M' is -OC(O)O-, -C(O)O-, -OC(O)-, -OC(O)-M”-C(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -C(O)N(R M )-, -N(R M )C(O)-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR M )O-, -S(O)2-, -SS-, -SO-, -OS-, S(R M )2O-, -OS(R M )2-, -S(O)O-, -OS(O)-, an aryl group, and a heteroaryl group; M" is selected from a bond, -(CH2) z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; R 7 But, C 1-3 Alkyl, C 2-3 alkenyl, and H; R 8 is C 3-6 selected from the group consisting of carbocycles and heterocycles; R 9 H, CN, NO2, C 1-6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2-6 Alkenyl, C 3-6 selected from the group consisting of carbocycles and heterocycles; R 11 But, C 3-6 selected from the group consisting of carbocyclic and heterocyclic rings; 3-6 The carbocycle and heterocycle each optionally contain one or more R 13 is replaced by R 12 But H, OH, C 1-3Alkyl, and C 2-3 alkenyl, Each R 13 OH, oxo, halo, C 1-6 Alkyl, C 1-6 Alkoxyl, C 2-6 Alkenyl, C 1-6 Alkylamino, di-(C 1-6 alkyl)amino, amino, amido, cyano, and nitro; Each R 14 However, independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, Each R 14 ' but independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, R 15 However, independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, Each R is independently C 1-6 Alkyl, C 1-3 Alkyl-aryl, C 2-3 alkenyl, and H; R N But H or C 1-3 is alkyl, Each R' is independently C 1-18 Alkyl, C 2-18 Alkenyl, -R*YR*", -YR*", (CH2) q OR*, and H; each q is independently selected from 1, 2, and 3; Each R M However, independently, H, C 1-6 Alkyl, and C 2-6 alkenyl, Each R” is independently 3-15 Alkyl and C 3-15 alkenyl, Each R*” is C 1-15 Alkyl, and C2-15 alkenyl, Each R* is independently 1-12 Alkyl and C 2-12 alkenyl, Each R** is independently H, OH, C 1-12 Alkyl, C 2-12 Alkenyl, (CH2) q OR*, and (CH2) q OH; Each Y is independently C 3-6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; A compound of formula (IX1), or an N-oxide thereof, or a salt or isomer thereof, wherein m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0339] Embodiment 4. A compound according to any one of the preceding embodiments, wherein at least one of M and M' is -OC(O)O-.

[0340] At least one of M and M' is -OC(O)N(R M )-or-N(R M )C(O)O—.

[0341] Embodiment 6. At least one of M and M' is -NR M C(O)NR M The compound of any one of the preceding embodiments, wherein

[0342] At least one of M and M' is -ON=C(R M )-.

[0343] Embodiment 8. At least one of M and M' is -OM"-O-, and each M" is independently C 1-13 Alkyl, C 2-13The compound of any one of the preceding embodiments, wherein the compound is selected from alkenyl, -B(R**)-, and -Si(R**)2-.

[0344] Embodiment 9. At least one of M and M' is -OM"-O-, and M" is C 1-3 The compound of any one of the preceding embodiments, wherein is alkyl.

[0345] Embodiment 10. A compound according to any one of the preceding embodiments, wherein M″ is methyl.

[0346] In the embodiment 11.M" is a branched C 1-3 The compound of any one of the preceding embodiments, wherein is alkyl.

[0347] Embodiment 12. At least one of M and M' is -OM"-O-, and M" is -(CH2) z The compound of any one of the preceding embodiments, wherein C(O)—.

[0348] Embodiment 13. A compound according to any one of the preceding embodiments, wherein Z is 3.

[0349] Embodiment 14. At least one of M and M' is [ka] The compound of any one of the preceding embodiments,

[0350] Embodiment 15. At least one of M and M' is [ka] The compound of any one of the preceding embodiments,

[0351] Embodiment 16. The compound of any one of the preceding embodiments, wherein at least one of M and M' is -OM"-O-, and each M" is independently selected from -B(R**)- and -Si(R**)2-.

[0352] Embodiment 17. Each R** is C 1-3 The compound of any one of the preceding embodiments, wherein is alkyl.

[0353] Embodiment 18. A compound of any one of the preceding embodiments, wherein each R** is methyl.

[0354] Embodiment 19. One of M and M' is -NR M C(O)NR M The compound of any one of the preceding embodiments, wherein

[0355] Embodiment 20. Each R M The compound of any one of the preceding embodiments, wherein

[0356] Embodiment 21.R 1 The compound of any one of the preceding embodiments, wherein is R″M′R′, and R′ is branched alkyl.

[0357] Embodiment 22.R 1 The compound of any one of the preceding embodiments, wherein is R″M′R′, and R′ is alkenyl.

[0358] Embodiment 23.R 1 The compound of any one of the preceding embodiments, wherein is R″M′R′ and R″ is branched alkyl.

[0359] Embodiment 24.R 1 The compound of any one of the preceding embodiments, wherein is R″M′R′ and R″ is alkyl substituted with OH.

[0360] Embodiment 25. A compound according to any one of the preceding embodiments, wherein R' is R*YR*" and Y is cyclopropyl, cyclopentyl, or cyclohexyl.

[0361] Embodiment 26. A compound according to any one of the preceding embodiments, wherein R' is R*YR*", where R*" is C2 alkyl, C3-alkyl, or C4 alkyl.

[0362] Embodiment 27. The compound has the following structure: [ka] R″ is a linear or branched C3-C optionally substituted with OH 13 The compound of any one of the preceding embodiments, wherein m is alkyl and m is selected from 5, 6, 7, 8, and 9.

[0363] Embodiment 28. The compound has the following structure: [ka] R″ is a linear or branched C3-C optionally substituted with OH 13 The compound of any one of the preceding embodiments, wherein m is alkyl and m is selected from 5, 6, 7, 8, and 9.

[0364] Embodiment 29. The compound has the following structure: [ka] R″ is a linear or branched C3-C optionally substituted with OH 13 The compound of any one of the preceding embodiments, wherein m is alkyl and m is selected from 5, 6, 7, 8, and 9.

[0365] Embodiment 30. The compound has the following structure: [ka] R″ is a linear or branched C3-C optionally substituted with OH 13 The compound of any one of the preceding embodiments, wherein m is alkyl and m is selected from 5, 6, 7, 8, and 9.

[0366] Embodiment 31. The compound has the following structure: [ka] R″ is a linear or branched C3-C optionally substituted with OH 13 The compound of any one of the preceding embodiments, wherein m is alkyl and m is selected from 5, 6, 7, 8, and 9.

[0367] Embodiment 32. The compound has the following structure: [ka] R″ is a linear or branched C3-C optionally substituted with OH 13 The compound of any one of the preceding embodiments, wherein m is alkyl and m is selected from 5, 6, 7, 8, and 9.

[0368] Embodiment 33. The compound has the following structure: [ka] R″ is a linear or branched C3-C optionally substituted with OH 13 The compound of any one of the preceding embodiments, wherein m is alkyl and m is selected from 5, 6, 7, 8, and 9.

[0369] Embodiment 34. Formula (I-Y1): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1 But, C 5-30 Alkyl, C 5-20 alkenyl, -R*YR*", -YR*", and -R"M'R'; R 2 and R 3 However, independently, H, C 1-14 Alkyl, C 2-14 alkenyl, -R*YR*", -YR*", and -R*OR*", or R 2 and R 3 together with the atoms to which they are attached form a heterocyclic or carbocyclic ring, R 4 But hydrogen, C 3-6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 12 )2(CH2) n-o Q, -CHQR, -CQ(R)2, -C(O)NQR, and unsubstituted C 1-6 alkyl, and Q is a carbocycle, a heterocycle, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -N(R)R 8 , -N(R)S(O)2R 8 , -O(CH2) n OR, -N(R)C(=NR 9 )N(R)2, -N(R)C(=CHR 9 )N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR 9 )N(R)2, -N(OR)C(=CHR 9 )N(R)2, -C(=NR 9)N(R)2, -C(=NR 9 )R, -C(O)N(R)OR, -(CH2) n N(R)2, -C(R)N(R)2C(O)OR, NC(R)=R 11 , N(C=NR 15 )R 11 , NRC(C(O)NR 14 R 14 ')2, -NRC(O)(CH2) p C(O)NR 14 R 14 ', and [ka] A is selected from C 6-10 is an aryl or heterocyclic ring; each o is independently selected from 1, 2, 3, and 4; p is 0, 1, 2, 3, or 4; q is 1, 2, 3, or 4; and each n is independently selected from 1, 2, 3, 4, and 5; or R 4 but, [ka] and X a and X b are each independently O or S; R 10 is H, halo, -OH, R, -N(R)2, -CN, -N3, -C(O)OH, -C(O)OR, -OC(O)R, -OR, -SR, -S(O)R, -S(O)OR, -S(O)2OR, -NO2, -S(O)2N(R)2, -N(R)S(O)2R, -NH(CH2) t1 N(R)2, -NH(CH2) p1 O(CH2) q1 N(R)2, -NH(CH2) s1 OR, -N((CH2) s1 OR)2, -N(R)-carbocycle, -N(R)-heterocycle, -N(R)-aryl, -N(R)-heteroaryl, -N(R)(CH2) t1 -carbocycle, -N(R)(CH2)t1 -Heterocycle, -N(R)(CH2) t1 -Aryl, -N(R)(CH2) t1 - selected from the group consisting of heteroaryl, carbocycle, heterocycle, aryl, and heteroaryl; n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; r is 0 or 1, t 1 is selected from 1, 2, 3, 4, and 5; p 1 is selected from 1, 2, 3, 4, and 5; q 1 is selected from 1, 2, 3, 4, and 5; s 1 is selected from 1, 2, 3, 4, and 5; Each R 5 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R 6 However, independently, OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; M' is -OC(O)O-, -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -OC(O)-NR M -C(O)O-, -OM''-O-, -C(O)N(R M )-, -N(R M )C(O)-, -OC(O)N(R M )-, -N(R M )C(O)O-, -NR M C(O)NR M -,-ON=C(R M )-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR M )O-, -S(O)2-, -SS-, -SO-, -OS-, S(R M )2O-, -OS(R M )2-, -S(O)O-, -OS(O)-, an aryl group, and a heteroaryl group; M" is selected from a bond, -(CH2)z C(O)-, C 1-13 Alkyl, C 2-13 alkenyl, -B(R**)-, -Si(R**)2-, -S(R**)2-, or -S(O)-, where z is 1, 2, 3, or 4; R 7 But, C 1-3 Alkyl, C 2-3 alkenyl, and H; R 8 But, C 3-6 selected from the group consisting of carbocycles and heterocycles; R 9 H, CN, NO2, C 1-6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2-6 Alkenyl, C 3-6 selected from the group consisting of carbocycles and heterocycles; R 11 But, C 3-6 selected from the group consisting of carbocyclic and heterocyclic rings; 3-6 The carbocycle and heterocycle each optionally contain one or more R 13 is replaced by R 12 But H, OH, C 1-3 Alkyl, and C 2-3 alkenyl, Each R 13 OH, oxo, halo, C 1-6 Alkyl, C 1-6 Alkoxyl, C 2-6 Alkenyl, C 1-6 Alkylamino, di-(C 1-6 alkyl)amino, amino, amido, cyano, and nitro; Each R 14 However, independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, Each R 14 ' but independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, R 15However, independently, H, OH, C 1-6 Alkyl, and C 2-3 alkenyl, Each R is independently C 1-6 Alkyl, C 1-3 Alkyl-aryl, C 2-3 alkenyl, and H; R N But H or C 1-3 is alkyl, Each R' is independently C 1-18 Alkyl, C 2-18 Alkenyl, -R*YR*", -YR*", (CH2) q OR*, and H; each q is independently selected from 1, 2, and 3; Each R M However, independently, H, C 1-6 Alkyl, and C 2-6 alkenyl, Each R” is independently 3-15 Alkyl and C 3-15 alkenyl, Each R*” is C 1-15 Alkyl, and C 2-15 alkenyl, Each R* is independently 1-12 Alkyl and C 2-12 alkenyl, Each R** is independently H, OH, C 1-12 Alkyl, C 2-12 Alkenyl, (CH2) q OR*, and (CH2) q OH; Each Y is independently 3-6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; A compound of formula (I-Y1), or an N-oxide thereof, or a salt or isomer thereof, wherein m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0370] Embodiment 35. The compound has the following structure: [ka] wherein each R″ is independently selected from H, OH, and C 1-6 alkyl; l is selected from 2, 3, 4, 5, and 6; and m is selected from 5, 6, 7, 8, and 9.

[0371] Embodiment 36.R 4 But -(CH2) n OH, where n is selected from 1, 2, 3, 4, and 5; and [ka] (n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10); R 10 is -N(R)2, and each R is independently C 1-6 Alkyl, C 2-3 The compound of any one of the preceding embodiments, wherein the alkyl group is selected from the group consisting of alkenyl, and H.

[0372] Embodiment 37. Formula (A): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein m is selected from 5, 6, 7, 8, and 9; R 2 and R 3 However, each independently, H, C 1-14 Alkyl, and C 2-14 alkenyl, R 4 But -(CH2) n OH, where n is selected from 1, 2, 3, 4, and 5; and [ka] (n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10); R 10 is -N(R)2, and each R is independently C 1-6 Alkyl, C 2-3 alkenyl, and H; M and M' are each independently selected from -OC(O)O- and -C(O)O-; At least one of M and M' is -OC(O)O-; R' a But, C 1-18 Alkyl or C 2-18 alkenyl, R” is a C3-C optionally substituted with OH 13 or an N-oxide thereof, or a salt or isomer thereof, of formula (A),

[0373] In the embodiment 38.R" [ka] is selected from [ka] indicates the point of attachment to N, [ka] The compound of any one of the preceding embodiments, wherein indicates the point of attachment to M.

[0374] Embodiment 39. The compound of any one of the preceding embodiments, wherein the compound has one of the following structures: [ka]

[0375] Embodiment 40.R' a but, [ka] and [ka] indicates the attachment point, R aα , R aβ , and R aγ However, each independently, H, C 1-12 Alkyl, and C 2-12 alkenyl; R aα , R aβ , and R aγ At least one of the 1-12 Alkyl and C 2-12 alkenyl, R' is C 1-12 Alkyl or C 2-12 The compound according to any one of the preceding embodiments, wherein said compound is alkenyl.

[0376] Embodiment 41.R aβ and R aγ are H and R aα But, C 1-6 The compound of any one of the preceding embodiments, wherein is alkyl.

[0377] Embodiment 42.R aα and R aγ are H and R aβ But, C 1-6 The compound of any one of the preceding embodiments, wherein is alkyl.

[0378] Embodiment 43.R aβ The compound of any one of the preceding embodiments, wherein is C alkyl.

[0379] Embodiment 44.R aα and R aβ are H and R aγ But, C 1-6The compound of any one of the preceding embodiments, wherein is alkyl.

[0380] Embodiment 45.R aγ The compound of any one of the preceding embodiments, wherein is C5 or C6 alkyl.

[0381] Embodiment 46. A compound according to any one of the preceding embodiments, wherein R' is C5 or C6 alkyl.

[0382] Embodiment 47. The compound has the following structure: [ka] The compound of any one of the preceding embodiments, having the following structure:

[0383] Embodiment 48.R 4 But -(CH2) n The compound of any one of the preceding embodiments, wherein R is OH.

[0384] Embodiment 49.R 4 The compound of any one of the preceding embodiments, wherein is -(CH2)2OH.

[0385] Embodiment 50.R 4 but, [ka] The compound of any one of the preceding embodiments,

[0386] Embodiment 51.R 4 but, [ka] The compound of any one of the preceding embodiments,

[0387] Embodiment 52. A compound according to any one of the preceding embodiments, wherein n2 is 2 or 4.

[0388] Embodiment 53. A compound selected from: [ka] [ka] [ka]

[0389] Embodiment 54. An empty lipid nanoparticle (empty LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structured lipid, and a PEG lipid.

[0390] Embodiment 55. A loaded lipid nanoparticle (loaded LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structured lipid, a PEG lipid, and one or more therapeutic and / or prophylactic agents.

[0391] Embodiment 56 The empty or filled LNP of any one of the preceding embodiments, comprising the compound in an amount of about 40% to about 60%.

[0392] Embodiment 57. The empty or filled LNP of any one of the preceding embodiments, comprising the phospholipid in an amount of about 0% to about 20%.

[0393] Embodiment 58. The empty or filled LNP of any one of the preceding embodiments, comprising the structured lipids in an amount of about 30% to about 50%.

[0394] Embodiment 59. The empty or filled LNP of any one of the preceding embodiments, comprising the PEG-lipid in an amount of about 0% to about 5%.

[0395] Embodiment 60. An empty or filled LNP according to any one of the preceding embodiments, comprising about 40 mol% to about 60 mol% of a compound according to any one of the preceding embodiments, about 0 mol% to about 20 mol% of a phospholipid, about 30 mol% to about 50 mol% of a structured lipid, and about 0 mol% to about 5 mol% of a PEG lipid.

[0396] Embodiment 61. The empty or filled LNP of any one of the preceding embodiments, comprising about 30 mol% to about 60 mol% of a compound of any one of the preceding embodiments, about 0 mol% to about 30 mol% of a phospholipid, about 18.5 mol% to about 48.5 mol% of a structured lipid, and about 0 mol% to about 10 mol% of a PEG lipid.

[0397] Embodiment 62. The loaded LNP of any one of the preceding embodiments, wherein the one or more therapeutic and / or prophylactic agents is a polynucleotide or a polypeptide.

[0398] Embodiment 63. The loaded LNP of any one of the preceding embodiments, wherein the one or more therapeutic and / or prophylactic agents is a nucleic acid.

[0399] Embodiment 64. The loaded LNP of any one of the preceding embodiments, wherein the one or more therapeutic and / or prophylactic agents are selected from the group consisting of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA).

[0400] Embodiment 65. The loaded LNP of any one of the preceding embodiments, wherein the DNA is selected from the group consisting of double-stranded DNA, single-stranded DNA (ssDNA), partially double-stranded DNA, triple-stranded DNA, and partially triple-stranded DNA.

[0401] Embodiment 66 The loaded LNP of any one of the preceding embodiments, wherein the DNA is selected from the group consisting of circular DNA, linear DNA, and mixtures thereof.

[0402] Embodiment 67. The loaded LNP of any one of the preceding embodiments, wherein the one or more therapeutic and / or prophylactic agents are selected from the group consisting of a plasmid expression vector, a viral expression vector, and mixtures thereof.

[0403] Embodiment 68. The loaded LNP of any one of the preceding embodiments, wherein the one or more therapeutic and / or prophylactic agents is RNA.

[0404] Embodiment 69. The loaded LNP of any one of the preceding embodiments, wherein the RNA is selected from the group consisting of single-stranded RNA, double-stranded RNA (dsRNA), partially double-stranded RNA, and mixtures thereof.

[0405] Embodiment 70. The loaded LNP of any one of the preceding embodiments, wherein the RNA is selected from the group consisting of circular RNA, linear RNA, and mixtures thereof.

[0406] Embodiment 71. The loaded LNP of any one of the preceding embodiments, wherein the RNA is selected from the group consisting of short interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecule, microRNA (miRNA), antagomir, antisense RNA, ribozyme, dicer substrate RNA (dsRNA), small hairpin RNA (shRNA), messenger RNA (mRNA), and mixtures thereof.

[0407] Embodiment 72 The loaded LNP of any one of the preceding embodiments, wherein the RNA is mRNA.

[0408] Embodiment 73. The loaded LNP of any one of the preceding embodiments, wherein the mRNA is a modified mRNA (mmRNA).

[0409] Embodiment 74. The loaded LNP of any one of the preceding embodiments, wherein the mRNA incorporates a microRNA binding site (miR binding site).

[0410] Embodiment 75. The loaded LNP of any one of the preceding embodiments, wherein the mRNA comprises one or more of a stem loop, a chain terminating nucleoside, a polyA sequence, a polyadenylation signal, and / or a 5' cap structure.

[0411] Embodiment 76. The empty or filled LNPs of any one of the preceding embodiments, wherein the phospholipid is selected from the group consisting of: 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-Hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof.

[0412] Embodiment 77. The empty or filled LNPs of any one of the preceding embodiments, wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

[0413] Embodiment 78. The empty or filled LNPs of any one of the preceding embodiments, wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.

[0414] Embodiment 79. The structured lipid comprises: [ka] or a salt thereof.

[0415] Embodiment 80. The structural lipid is cholesterol: [ka] or a salt thereof.

[0416] Embodiment 81. The empty or filled LNP of any one of the preceding embodiments, wherein the PEG-lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol, and mixtures thereof.

[0417] Embodiment 82. The empty or filled LNP of any one of the preceding embodiments, wherein the PEG-lipid is selected from the group consisting of 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disterglycerol (PEG-DSG), PEG-dipalmetyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE), or PEG-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DMA).

[0418] Embodiment 83 The empty or filled LNP of any one of the preceding embodiments, wherein the PEG lipid is PEG-DMG.

[0419] Embodiment 84. The PEG lipid has the formula (PL-I): [ka] Compounds of or a salt thereof, wherein R 3PL1 But -OR OPL1 and R OPL1 is hydrogen, an optionally substituted alkyl, or an oxygen protecting group; r PL1 is an integer between 1 and 100 inclusive, L 1 But, with arbitrary substitutions C 1-10 alkylene, optionally substituted C 1-10 At least one methylene of the alkylene is independently selected from optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, O, N(R NPL1 ), S, C(O), C(O)N(R NPL1 ), N.R. NPL1 C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R NPL1 ), N.R. NPL1 C(O)O, or NR NPL1 C(O)N(R NPL1 ), D is a moiety obtained by click chemistry or a moiety cleavable under physiological conditions; m PL1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, A is of the formula: [ka] The L 2 each instance of 1-6 alkylene, optionally substituted C 1-6 One methylene unit of the alkylene is optionally O, N(R NPL1 ), S, C(O), C(O)N(R NPL1 ), N.R. NPL1 C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R NPL1 ), N.R. NPL1 C(O)O, or NR NPL1 C(O)N(R NPL1 ), R 2SL Each instance of is independently 1-30 Alkyl, optionally substituted C 1-30 alkenyl, or optionally substituted C 1-30 alkynyl, and optionally R2SL one or more methylene units of are independently selected from optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R NPL1 ), O, S, C(O), C(O)N(R NPL1 ), N.R. NPL1 C(O), NR NPL1 C(O)N(R NPL1 ), C(O)O, OC(O), OC(O)O, OC(O)N(R NPL1 ), N.R. NPL1 C(O)O, C(O)S, SC(O), C(=NR NPL1 ), C(=NR NPL1 )N(R NPL1 ), N.R. NPL1 C(=NR NPL1 ), N.R. NPL1 C(=NR NPL1 )N(R NPL1 ), C(S), C(S)N(R NPL1 ), N.R. NPL1 C(S), NR NPL1 C(S)N(R NPL1 ), S(O), OS(O), S(O)O, OS(O)O, OS(O)2, S(O)2O, OS(O)2O, N(R NPL1 )S(O), S(O)N(R NPL1 ), N(R NPL1 )S(O)N(R NPL1 ), OS(O)N(R NPL1 ), N(R NPL1 )S(O)O, S(O)2, N(R NPL1 )S(O)2, S(O)2N(R NPL1 ), N(R NPL1 )S(O)2N(R NPL1 ), OS(O)2N(R NPL1 ), or N(R NPL1 )S(O)2O, R NPL1 each instance of is independently hydrogen, an optionally substituted alkyl, or a nitrogen protecting group; Ring B is an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl; pSL The empty or filled LNP of any one of the preceding embodiments, wherein is 1 or 2.

[0420] Embodiment 85. The PEG lipid has the formula (PL-I-OH): [ka] or a salt thereof.

[0421] Embodiment 86. The PEG lipid has the formula (PL-II-OH): [ka] or a salt or isomer thereof, wherein R 3PEG But -OR O and R O But hydrogen, C 1-6 alkyl, or oxygen protecting group; r PEG is an integer from 1 to 100, R 5PEG But, C 10-40 Alkyl, C 10-40 Alkenyl, or C 10-40 alkynyl, and optionally R 5PEG one or more methylene groups are independently selected from the group consisting of C 3-10 Carbocyclylene, 4-10 membered heterocyclylene, C 6-10 Arylene, 4-10 membered heteroarylene, -N(R NPEG )-, -O-,-S-,-C(O)-, -C(O)N(R NPEG )-, -NR NPEG C(O)-, -NR NPEG C(O)N(R NPEG )-, -C(O)O-, -OC(O)-, -OC(O)O-, -OC(O)N(R NPEG )-, -NR NPEG C(O)O-, -C(O)S-,-SC(O)-, -C(=NRNPEG )-, -C(=NR NPEG )N(R NPEG )-, -NR NPEG C(=NR NPEG )-, -NR NPEG C(=NR NPEG )N(R NPEG )-, -C(S)-, -C(S)N(R NPEG )-, -NR NPEG C(S)-, -NR NPEG C(S)N(R NPEG )-, -S(O)-, -OS(O)-, -S(O)O-, -OS(O)O-, -OS(O)2-, -S(O)2O-, -OS(O)2O-, -N(R NPEG )S(O)-, -S(O)N(R NPEG )-, -N(R NPEG )S(O)N(R NPEG )-, -OS(O)N(R NPEG )-, -N(R NPEG )S(O)O-, -S(O)2-, -N(R NPEG )S(O)2-, -S(O)2N(R NPEG )-, -N(R NPEG )S(O)2N(R NPEG )-, -OS(O)2N(R NPEG )-, or -N(R NPEG )S(O)2O-, R NPEG Each instance of is independently hydrogen, C 1-6 The empty or filled LNP of any one of the preceding embodiments, wherein the LNP is an alkyl, or a nitrogen protecting group.

[0422] Embodiment 87. The empty or filled LNP of any one of the preceding embodiments, wherein in said PEG lipid of formula (PL-II-OH), r is an integer between 40 and 50.

[0423] Embodiment 88. The empty or filled LNP of any one of the preceding embodiments, wherein in said PEG lipid of formula (PL-II-OH), r is 45.

[0424] Embodiment 89. The PEG lipid of formula (PL-II-OH), R5 But, C 17 The empty or filled LNP of any one of the preceding embodiments, wherein the LNP is alkyl.

[0425] Embodiment 90. The PEG lipid has the formula (PL-II): [ka] wherein r PEG The empty or filled LNP of any one of the preceding embodiments, wherein is an integer between 1 and 100.

[0426] Embodiment 91. The PEG lipid has the formula (PEG-1): [ka] 3. The empty or filled LNP of any one of the preceding embodiments, wherein the LNP is a compound of formula:

[0427] Embodiment 92. The PEG lipid has the formula (PL-III): [ka] or a salt or isomer thereof, wherein PL1 The empty or filled LNP of any one of the preceding embodiments, wherein is an integer between 1 and 100.

[0428] Embodiment 93. The PEG lipid has the following formula: [ka] 3. The empty or filled LNP of any one of the preceding embodiments, wherein the LNP is a compound of formula:

[0429] Embodiment 94. An empty lipid nanoparticle (empty LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC and the structural lipid is cholesterol.

[0430] Embodiment 95. An empty lipid nanoparticle (empty LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structural lipid, and a PEG lipid, wherein the structural lipid is cholesterol and the PEG lipid is PEG. 2k -DMG, empty lipid nanoparticles.

[0431] Embodiment 96. An empty lipid nanoparticle (empty LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structural lipid, and a PEG lipid, wherein the structural lipid is cholesterol and the PEG lipid is PEG-1.

[0432] Embodiment 97. An empty lipid nanoparticle (empty LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC and the PEG lipid is PEG. 2k -DMG, empty lipid nanoparticles.

[0433] Embodiment 98. An empty lipid nanoparticle (empty LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC and the PEG lipid is PEG-1.

[0434] Embodiment 99. An empty lipid nanoparticle (empty LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structured lipid, and a PEG lipid, wherein the phospholipid is DSPC, the structured lipid is cholesterol, and the PEG lipid is PEG. 2k -DMG, empty lipid nanoparticles.

[0435] Embodiment 100. An empty lipid nanoparticle (empty LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structural lipid, and a PEG lipid, wherein the phospholipid is DSPC, the structural lipid is cholesterol, and the PEG lipid is PEG-1.

[0436] Embodiment 101. A loaded lipid nanoparticle (loaded LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structured lipid, a PEG lipid, wherein the phospholipid is DSPC and the structured lipid is cholesterol, and one or more therapeutic and / or prophylactic agents.

[0437] Embodiment 102. A compound according to any one of the preceding embodiments, a phospholipid, a structured lipid, and a PEG lipid, wherein the structured lipid is cholesterol and the PEG lipid is PEG. 2k -DMG), and one or more therapeutic and / or prophylactic agents.

[0438] Embodiment 103. A loaded lipid nanoparticle (loaded LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structured lipid, a PEG lipid, wherein the structured lipid is cholesterol and the PEG lipid is PEG-1, and one or more therapeutic and / or prophylactic agents.

[0439] Embodiment 104. A composition comprising a compound according to any one of the preceding embodiments, a phospholipid, a structured lipid, and a PEG lipid, wherein the phospholipid is DSPC and the PEG lipid is PEG. 2k -DMG), and one or more therapeutic and / or prophylactic agents.

[0440] Embodiment 105. A loaded lipid nanoparticle (loaded LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structured lipid, a PEG lipid, wherein the phospholipid is DSPC and the PEG lipid is PEG-1, and one or more therapeutic and / or prophylactic agents.

[0441] Embodiment 106. A composition comprising a compound according to any one of the preceding embodiments, a phospholipid, a structured lipid, and a PEG lipid, wherein the phospholipid is DSPC, the structured lipid is cholesterol, and the PEG lipid is PEG. 2k -DMG), and one or more therapeutic and / or prophylactic agents.

[0442] Embodiment 107. A loaded lipid nanoparticle (loaded LNP) comprising a compound according to any one of the preceding embodiments, a phospholipid, a structured lipid, a PEG lipid, wherein the phospholipid is DSPC, the structured lipid is cholesterol, and the PEG lipid is PEG-1, and one or more therapeutic and / or prophylactic agents.

[0443] Embodiment 108. The empty or filled LNP of any one of the preceding embodiments, comprising DSPC in an amount of about 0% to about 20%.

[0444] Embodiment 109. The empty or filled LNP of any one of the preceding embodiments, comprising cholesterol in an amount of about 30% to about 50%.

[0445] Embodiment 110. PEG 2k - The empty or filled LNP of any one of the preceding embodiments, comprising DMG in an amount of about 0% to about 5%.

[0446] Embodiment 111. The empty or filled LNP of any one of the preceding embodiments, comprising PEG-1 in an amount of about 0% to about 5%.

[0447] Embodiment 112. About 40 mol% to about 60 mol% of a compound according to any one of the preceding embodiments, about 0 mol% to about 20 mol% of DSPC, about 30 mol% to about 50 mol% of cholesterol, and about 0 mol% to about 5 mol% of PEG. 2k 3. The empty or filled LNP of any one of the preceding embodiments, comprising:

[0448] Embodiment 113. The empty or filled LNP of any one of the preceding embodiments, comprising about 40 mol% to about 60 mol% of a compound of any one of the preceding embodiments, about 0 mol% to about 20 mol% DSPC, about 30 mol% to about 50 mol% cholesterol, and about 0 mol% to about 5 mol% PEG-1.

[0449] Embodiment 114. The loaded LNP of any one of the preceding embodiments, wherein the encapsulation efficiency of the therapeutic and / or prophylactic agent is between 80% and 100%.

[0450] Embodiment 115. The loaded LNP of any one of the preceding embodiments, wherein the weight / weight ratio of the lipid component to the mRNA is from about 10:1 to about 60:1.

[0451] Embodiment 116 The loaded LNP of any one of the preceding embodiments, wherein the weight / weight ratio of the lipid component to the mRNA is about 20:1.

[0452] Embodiment 117. A loaded LNP according to any one of the preceding embodiments, wherein the N:P ratio is from about 5:1 to about 8:1.

[0453] Embodiment 118. A pharmaceutical composition comprising a loaded LNP according to any one of the preceding embodiments and a pharma- ceutically acceptable carrier.

[0454] Embodiment 119. A pharmaceutical composition according to any one of the preceding embodiments, further comprising a cryoprotectant, a buffer, or a combination thereof.

[0455] Embodiment 120. The pharmaceutical composition of any one of the preceding embodiments, wherein the cryoprotectant comprises sucrose.

[0456] Embodiment 121. The pharmaceutical composition of any one of the preceding embodiments, wherein the cryoprotectant comprises sodium acetate.

[0457] Embodiment 122. A pharmaceutical composition according to any one of the preceding embodiments, wherein the cryoprotectant comprises sucrose and sodium acetate.

[0458] Embodiment 123. A pharmaceutical composition according to any one of the preceding embodiments, wherein the buffer is selected from the group consisting of acetate buffer, citrate buffer, phosphate buffer, and Tris buffer.

[0459] Embodiment 124. A method for delivering a therapeutic and / or prophylactic agent to cells in a subject, the method comprising administering to the subject a loaded LNP described in any one of the preceding embodiments.

[0460] Embodiment 125. A method for specifically delivering a therapeutic and / or prophylactic agent to an organ of a subject, said method comprising administering to said subject a loaded LNP described in any one of the preceding embodiments.

[0461] Embodiment 126. A method for enhanced delivery of therapeutic and / or prophylactic agents to a target tissue of a subject, the method comprising administering to the subject a loaded LNP described in any one of the preceding embodiments.

[0462] Embodiment 127. A method for producing a polypeptide of interest in cells in a subject, the method comprising administering to the subject a loaded LNP according to any one of the preceding embodiments.

[0463] Embodiment 128. A method of treating a disease or disorder in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of a loaded LNP described in any one of the preceding embodiments.

[0464] Embodiment 129. Use of a loaded LNP according to any one of the preceding embodiments in the manufacture of a medicament for delivering a therapeutic and / or prophylactic agent to cells in a subject.

[0465] Embodiment 130. Use of a loaded LNP according to any one of the preceding embodiments in the manufacture of a medicament for specifically delivering a therapeutic and / or prophylactic agent to an organ of interest.

[0466] Embodiment 131. Use of a loaded LNP according to any one of the preceding embodiments in the manufacture of a medicament for enhanced delivery of a therapeutic and / or prophylactic agent to a target tissue of a subject.

[0467] Embodiment 132. Use of a loaded LNP according to any one of the preceding embodiments in the manufacture of a medicament for producing a polypeptide of interest in a cell in a subject.

[0468] Embodiment 133. Use of a loaded LNP according to any one of the preceding embodiments in the manufacture of a medicament for treating a disease or disorder in a subject in need of such treatment.

[0469] Embodiment 134. A loaded LNP as described in any one of the preceding embodiments for use in delivering a therapeutic and / or prophylactic agent to cells in a subject, wherein said delivering comprises administering a therapeutically effective amount of said loaded LNP to said subject.

[0470] Embodiment 135. A loaded LNP according to any one of the preceding embodiments for use in specific delivery of a therapeutic and / or prophylactic agent to an organ of a subject, wherein said delivery comprises administering a therapeutically effective amount of said loaded LNP to said subject.

[0471] ...

Claims

1. Formula (A): 【Chemistry 1】 or an N-oxide or salt thereof, wherein m is selected from 5, 6, 7, 8, and 9; R ２ and R ３ each independently represents H, unsubstituted C １－１４ Alkyl, and unsubstituted C ２－１４ alkenyl, R ４ But -(CH ２ ) ｎ OH, where n is selected from 1, 2, 3, 4, and 5; and 【Chemistry 2】 (n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10); R １０ But -N(R) ２ and each R is independently an unsubstituted C １－６ Alkyl, unsubstituted C ２－３ alkenyl, and H; M and M' are each independently selected from -OC(O)O- and -C(O)O-; At least one of M and M′ is —OC(O)O—; R' ａ is unsubstituted C １－１８ Alkyl or unsubstituted C ２－１８ alkenyl, R" is C3-C １３ or an N-oxide thereof, or a salt thereof, wherein:

2. R” is 【Chemistry 3】 is selected from 【Chemistry 4】 indicates the point of attachment to N, 【Chemistry 5】 The compound of claim 1 , wherein indicates the point of attachment to M.

3. The compound has the following structure: 【Chemistry 6】 3. The compound according to claim 1 or 2, having one of the following:

4. R' ａ but, 【Chemistry 7】 and 【Chemistry 8】 indicates the attachment point, R ａα , R ａβ , and R ａγ each independently represents H, unsubstituted C １－１２ Alkyl, and unsubstituted C ２－１２ alkenyl; R ａα , R ａβ , and R ａγ At least one of the groups is unsubstituted C １－１２ Alkyl and unsubstituted C ２－１２ alkenyl, R' is unsubstituted C １－１２ Alkyl or unsubstituted C ２－１２ 3. The compound of claim 1 or 2, which is alkenyl.

5. R ａβ and R ａγ are each H, and R ａα is unsubstituted C １－６ The compound of claim 4, which is alkyl.

6. R ａα and R ａγ are each H, and R ａβ is unsubstituted C １－６ The compound of claim 4, which is alkyl.

7. R ａβ is unsubstituted C ２ The compound of claim 6, which is alkyl.

8. R ａα and R ａβ are each H, and R ａγ is unsubstituted C １－６ The compound of claim 4, which is alkyl.

9. R ａγ is unsubstituted C ５ or unsubstituted C ６ The compound of claim 8 which is alkyl.

10. R' is unsubstituted C ５ or unsubstituted C ６ The compound of claim 4, which is alkyl.

11. The compound has the following structure: 【Chemistry 9】 5. The compound of claim 4 having the formula:

12. R ４ But -(CH ２ ) ｎ 3. The compound according to claim 1 or 2, wherein:

13. R ４ But -(CH ２ ) ２ 3. The compound according to claim 1 or 2, wherein:

14. R ４ but, 【Chemistry 10】 3. The compound according to claim 1 or 2,

15. R ４ but, 【Chemistry 11】 3. The compound according to claim 1 or 2,

16. 3. The compound according to claim 1 or 2, wherein n2 is 2 or 4.

17. 【Chemical 12-1】 【Chemistry 12-2】 【Chemistry 12-3】 A compound selected from:

18. 3. An empty lipid nanoparticle (empty LNP) comprising a compound according to claim 1 or 2, a phospholipid, a structured lipid, and a PEG lipid.

19. (a) about 40 mol% to about 60 mol% of the compound, about 0 mol% to about 20 mol% of a phospholipid, about 30 mol% to about 50 mol% of a structural lipid, and about 0 mol% to about 5 mol% of a PEG lipid; (b) the phospholipid is selected from the group consisting of: 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-Hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), Sphingomyelins and their mixtures is selected from the group consisting of (c) the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, and mixtures thereof; (d) the PEG lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof; and / or (e) the PEG lipid is ２ｋ -DMG and PEG-1: 【Chemistry 13】 20. The empty LNP of claim 18, selected from the group consisting of:

20. A loaded lipid nanoparticle (loaded LNP) comprising the empty LNP of claim 18 and one or more therapeutic and / or prophylactic agents.

21. 21. The loaded LNP of claim 20, wherein the one or more therapeutic and / or prophylactic agents are nucleic acids.

22. 22. The loaded LNP of claim 21, wherein the nucleic acid is RNA, and the RNA is selected from the group consisting of short interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecules, microRNA (miRNA), antagomir, antisense RNA, ribozymes, dicer substrate RNA (dsRNA), small hairpin RNA (shRNA), messenger RNA (mRNA), and mixtures thereof.

23. 23. The loaded LNP of claim 22, wherein the RNA is mRNA.

24. 21. A pharmaceutical composition comprising the loaded LNP of claim 20 and a pharma- ceutically acceptable carrier.

25. A pharmaceutical composition for delivering a therapeutic and / or prophylactic agent to cells within a subject and / or an organ of a subject, comprising the loaded LNPs of claim 20.

26. 21. A pharmaceutical composition for specifically delivering a therapeutic and / or prophylactic agent to an organ of a target, comprising the loaded LNPs of claim 20.

27. A pharmaceutical composition for producing a polypeptide of interest in cells in a subject, comprising the loaded LNPs of claim 20.

28. 21. A pharmaceutical composition for treating a disease or disorder in a subject in need thereof, comprising the loaded LNPs of claim 20.

Images